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ABSTRACT 
For more than four decades it has been observed that T cells can present major 
histocompatibility complex II (MHCII) and that this phenomenon increases upon 
activation. Currently, the human MHC class II isotype, human leukocyte antigen 
DR (HLA-DR) is a well-accepted marker for T cells activation. Nonetheless, an 
increasing amount of research points to a more pronounced role for HLA-DR than 
being an activation marker. The constitutive expression of HLA-DR is limited to 
professional antigen-presenting cells (APCs) and in this context the functions of 
HLA-DR are well described. These cells use HLA-DR to present antigenic peptides 
to CD4+ T cells and HLA-DR is involved in many facets of immune homeostasis, 
including T cell activation, peripheral tolerance, and induction of apoptosis. How-
ever, the functional consequences and physiological relevance of HLA-DR on T 
cells remain enigmatic. It has been demonstrated that mouse T cells cannot endoge-
nously express MHCII but rather acquire it from APCs and a similar protein trans-
fer has been observed for human T cells. Consequently, there is still no consensus 
of whether an endogenous protein expression or a molecular acquisition accounts 
for the presence of HLA-DR on human T cells. 
The aim of the present PhD study was to investigate the endogenous expression 
and/or acquisition of HLA-DR by human T cells. The key methods applied in this 
investigation included flow cytometry to determine cellular phenotypes, qPCR to 
quantify gene expression, and the EV Array, which is a novel technique for charac-
terizing the protein phenotype of cell-derived vesicles. The research presented in 
the thesis indicates that human T cells in peripheral blood do not express HLA-DR 
endogenously, based on investigations at both the protein and transcript level. Fur-
thermore, the functional phenotype of these HLA-DR presenting T cells points to a 
role in down-regulating the activity of other T cells. This has a major impact in 
understanding the regulation of the immune system, since a likely role of these 
HLA-DR presenting T cells is to be involved in the induction and maintenance of 
peripheral tolerance. Thus, the research presented in this thesis has implications for 
both fundamental immunology as well as several pathological conditions, including 





I mere end fire årtier er det blevet observeret, at T-celler kan præsentere vævstype-
proteinet MHCII (major histocompatibility complex) i deres cellemembran og at 
antallet af disse celler stiger ved en aktivering af immunforsvaret. Den humane 
udgave af MHCII proteinet, kaldet humant leukocytantigen DR (HLA-DR), benyt-
tes en markør for aktiverede T celler. Forskning peger dog i stigende grad på, at 
HLA-DR er mere en blot en aktiveringsmarkør. Den konstitutive udtrykkelse af 
HLA-DR er forbeholdt professionelle antigen-præsenterende celler (APC) og disse 
celler anvender HLA-DR til at præsentere antigener til CD4 + T-celler, som aktive-
res, hvis antigenet genkendes. Dette igangsætter et immunrespons og dermed er 
HLA-DR et protein med en meget vigtig funktion. Det er stadig uvist, hvilke funk-
tionelle konsekvenser, samt hvilken fysiologiske relevans, det har, at HLA-DR kan 
findes på T celler. Det er blevet vist, at T-celler fra mus ikke selv kan udtrykke 
MHCII proteinet, men i stedet erhverver det fra APC.  Desuden er en tilsvarende 
observation blevet gjort for humane T celler. Der er derfor stadig uenighed om-
kring, hvorvidt humane T celler har evnen til selv at udtrykke HLA-DR proteinet, 
dvs. en endogen udtrykkelse, eller om en proteinoverførsel forklarer tilstedeværel-
sen af HLA-DR på disse celler.  
Formålet med denne Ph.d. afhandling var at undersøge humane T cellers endogene 
udtrykkelse og / eller erhvervelse af HLA-DR. Til denne undersøgelse blev en ræk-
ke metoder anvendt, hvoraf de centrale inkluderede flowcytometri til bestemmelse 
af cellernes proteinudtryk, qPCR til kvantificering af genudtrykkelse, samt EV 
Arrayet, der er en ny teknik til at karakterisere tilstedeværelsen af proteiner på cel-
le-deriverede vesikler. Resultaterne, der præsenteres i afhandlingen, indikerer, at 
humane T celler, som findes i perifært blod, ikke selv udtrykker de HLA-DR prote-
iner, der findes i deres cellemembran. Endvidere tyder den samtidige tilstedeværel-
se af en række cellemembran-proteiner på, at T-celler, som præsenterer HLA-DR 
har en rolle i at nedregulere aktiviteten af andre T-celler. Dette har stor betydning 
for forståelsen af, hvordan immunsystemet reguleres, da disse HLA-DR præsente-
rende T-celler sandsynligvis kan være involveret i at skabe og opretholde perifær 
tolerance. Derfor har den præsenterede forskning i denne afhandling konsekvenser 
for både grundlæggende immunologi samt for flere patologiske tilstande, herunder 
autoimmune sygdomme og kræft. 
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CHAPTER 1. INTRODUCTION 
1.1. THE ANTIGEN-SPECIFIC IMMUNE SYSTEM 
The immune system of the human body has a fundamental role in protection against 
pathogenic challenges as well as defeating them. The immune system thus encom-
passes a complex array of barriers, cells, and processes, which are dedicated to 
defense. In general, the immune system can be divided into two parts, namely the 
innate immune system and the adaptive immune system. Though not completely 
separated, one very key feature distinguishing these two systems is their mechanism 
for pathogen recognition. Accordingly, the innate immune system utilizes a limited 
number of specificities, while the adaptive immune system is highly specialized and 
antigen-specific (1). Two different aspects account for this antigen specificity. The 
first aspect relates to the effector cells of the adaptive immune system, the T cells. 
Two separate lineages of T cells exist, the CD4+ T cells and the CD8+ T cells, and 
common for both is their activation upon recognition of their specific antigen 
through interaction of the T cell receptor (TCR) and the antigen bound to a major 
histocompatibility complex (MHC) molecules. The antigens are peptide fragments 
derived from degraded proteins of either endogenous or exogenous origin and can 
be presented on MHC class I (MHCI) or class II (MHCII) molecules, respectively. 
Whereas the TCR comprises one half of the antigen specificity, the antigen presen-
tation on the MHC molecules constitutes the other. In line with this, any given T 
cell is specific for the complex of a particular peptide bound to a particular MHC 
molecule, a phenomenon called MHC restriction (1). This is one of the intricate 
regulatory mechanisms used by the immune system that allows for initiation of 
finely tuned and precise immune responses.  
All nucleated cells in the body express MHCI, however, the constitutive expression 
of MHCII is limited to the professional antigen-presenting cells (APCs): Dendritic 
cells (DCs), B cells, and monocytes/macrophages (2, 3). Moreover, inducible 
MHCII expression is possible in a number of non-APCs, including endothelial cells 
and fibroblast (3, 4). T cells constantly monitor the body for infections and other 
abnormalities, such as cancers, and consequently T cells make many temporary 
interactions with other cells. At the interface between these the interacting cells, a 
supramolecular structure is created, termed the immunological synapse (IS) (Figure 
1A). The formation of the IS facilitates extensive reorganization of the receptors 
involved in adhesion and antigen recognition (5). Within the IS, a peptide and a 
MHCII molecule complex (pMHCII) interacts with the cognate TCR on CD4+ T 
cells, informing the T cells about the presence of an infection. This interaction pro-
vides stimulatory signals to the involved T cells, which consequently differentiate. 
Depending on the nature of the co-stimulatory signals also received, the T cell dif-
ferentiation can lead to the formation of activated effector cells, the creation of 
anergic cells, or even the induction of apoptosis (Figure 1B). Regardless of the 
outcome of the differentiation, it is apparent that MHCII molecules hold pivotal 
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roles in the initiation, advancement, and termination of an adaptive immune re-
sponse. 
 
Figure 1 The immunological synapse (IS) and the interaction between pMHCII and the 
cognate TCR is essential for T cell activation. AThe IS is organized in a central 
supramolecular activation complex (cSMAC) and a peripheral SMAC (pSMAC). While the 
cSMAC harbors clusters of TCR, MHC determinants, and co-stimulatory molecules, the 
pSMAC is rich in molecules, which facilitate a tight adhesion of the interacting cells (5, 6). 
An important protein interaction in the pSMAC is that between lymphocyte function-
associated antigen 1 (LFA-1) on the T cell and intercellular adhesion molecule 1 (ICAM-1) 
on the APC (7). BDepending on the co-stimulatory signals received alongside the 
TCR:pMHCII ligation, the resulting fate of the T cell is quite different. Top panel: If the 
TCR:pMHCII ligation is accompanied by co-stimulatory signal via CD28 (T cell) and a B7 
molecule (CD80/CD86, APC), the target T cell is activated. Once activated, the T cell under-
goes clonal expasion and differentiation, acquiring its effector functions, such as cytokine 
production. This is under the control of IL-2, which is produced by the T cell itself only after 
receiving both the antigen-specific and co-stimulatory signals. Middle panel: The 
TCR:pMHCII interaction can also be accompanied by a co-inhibitory signal, such as that 
mediated by cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) on the T cells and CD80 
or CD86. The co-inhibitory signal can in some cases outcompete the co-stimulatory signal. 
This is the case for CTLA-4 (CD152), which has a much higher affinity for B7 molecules 
than CD28. The result of the co-inhibition is functional unresponsiveness, called anergy, or 
apoptosis. Lower panel: When the TCR:pMHCII ligation is not accompanied by a co-
stimulatory signal, the target T cell becomes anergic or undergoes apoptosis. 
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1.2. THE EXPRESSION AND REGULATION OF HLA-DR 
1.2.1. HLA-D ANTIGENS 
In humans, MHC molecules are also known as human leukocyte antigens (HLA). 
This term was coined due to the observation that antibodies identifying MHC mole-
cules targeted antigens on leukocytes. There are three classical and highly polymor-
phic isotypes of MHCII molecules, called HLA-DP, HLA-DQ, and HLA-DR (8) 
and all isotypes are all involved in antigen presentation to CD4+ T cells (9, 10). 
Two non-classical and less polymorphic isotypes of MHCII molecules also exist 
and these are HLA-DM and HLA-DO (8). These isotypes are involved in the load-
ing of antigenic peptides to HLA-DP, HLA-DQ, and HLA-DR molecules (1). Sev-
eral similarities exist for all HLA-D molecules, related to both genetic sequence and 
protein structure. In line with this, all HLA-D molecules are heterodimeric, 
transmembrane glycoproteins (11), which consist of one -chain and one -chain 
(Figure 2A). For HLA-DP, HLA-DQ, and HLA-DR it is the extracellular domains 
of both chains that form the peptide-binding groove, enabling antigen presentation 
(Figure 2A). Both polypeptide chains are encoded by distinct set of genes located 
on the short arm of chromosome 6. These genes are part of a genetic cluster, which 
is involved in the expression of other proteins also involved in antigen processing 
and presentation (1, 9). The genetic diversity of HLA-D molecules arises from both 
the presence of numerous genes encoding the - and -chains and extensive allelic 
polymorphism. Though the extent of this diversity is not as great as that for 
immunoglobulins and TCRs, it has both functional and medical implications related 
to aspects such as disease susceptibility and transplantations (1, 8, 10).  
 
1.2.2. THE GENETIC BASIS OF HLA-DR 
Of the HLA-D antigens, HLA-DR is the most widely studied isotype (10). It is 
subject to the largest extent of allelic polymorphism and is characterized by having 
a monomorphic -chain and a highly polymorphic -chain (1). Consequently, the 
-chain makes by far the largest contribution to the diversity of HLA-DR (10). 
Only one gene exist for the -chain (HLA-DRA) whereas four different loci encode 
functional HLA-DR -chains (HLA-DRB). These comprise HLA-DRB1, HLA-
DRB3, HLADR-B4, and HLA-DRB5 (Figure 2A). Also five genes exist encoding 
non-functional -chains; HLA-DRB2, HLA-DRB6, HLA-DRB7, HLA-DRB8, and 
HLA-DRB9 (8). All humans carry HLA-DRB1 on their chromosome 6, while the 
presence of any of the three remaining functional genes varies from individual to 
individual. Furthermore, the HLA-DRB1 locus has the most identified alleles (Fig-
ure 2A). However, any of these functional HLA-DR -chains can pair up with an 
HLA-DR -chain to form a heterodimeric HLA-DR molecule. Despite the diversity 
of HLA-DRB, it is possible to divide individuals into five different HLA-DR haplo-
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types, which denote a particular combination of HLA-DR alleles (8)(Figure 2B). 
These groups are characterized by their sole expression of HLA-DRB1 or HLA-
DRB1 in combination with HLA-DRB3, HLADR-B4, or HLA-DRB5. 
 
Figure 2 AStructure and expression of HLA-D molecules, as exemplified by HLA-DR. 
Top panel: HLA-DR is a type I membrane protein consisting of an / heterodimer (12). The 
-chain and -chain are approximately 35 kDa and 27 kDa, respectively (12). In the extracel-
lular part of HLA-DR, each of these chains consists of two domains of which one contributes 
to the peptide binding groove (-1 and a -1) and one to the immunoglobulin-like support 
(-2 and a -2). The latter provides a binding site for the CD4 co-receptor. HLA-DR is an-
chored to the cell surface by a transmembrane domain and has a C-terminal cytoplasmic tail, 
which can transmit intracellular signals (13). Lower panel: One gene encodes the -chain 
(HLA-DRA), whereas four genes encode functional - chains (HLA-DRB) of the HLA-DR 
protein. For each of these loci, a varying number of alleles and protein products exist (14). 
BThe five major HLA-DR haplogroups (DR1, DR8, DR51, DR52, and DR53). Each 
haplotype has been defined by the presence of a varying number of functional genes (black 
boxes) and pseudogenes (grey boxes) on chromosome 6. The DRB1 alleles can also be di-
vided into five families, which relate to the haplogroups. For each haplogroup, the corre-
sponding DRB1 allelic lineage is noted in red text, as exemplified by the DR1 haplogroup 
containing the HLA-DRB1*01 and HLA-DRB1*10 alleles (8). 
 
1.2.3. MODULATION OF HLA-DR EXPRESSION 
The expression of HLA-DR is subject to intricate regulation, consistent with the 
essential role in determining the specificity of the adaptive immune system. Ac-
cordingly, defects in this regulation have severe immunopathological consequences 
(8). A great number of biochemical and genetic mechanisms control the modulation 
of HLA-DR expression and new aspects continues to be unraveled.  
The modulation of HLA-DR expression occurs mainly at the transcriptional level 
(8, 11). The majority of the knowledge about this modulation is based on studies of 
the bare lymphocyte syndrome (BLS), a severe combined immunodeficiency char-
acterized by the lack of HLA-D gene expression (8, 11, 15). The transcriptional 
CHAPTER 1. INTRODUCTION 
5 
control involves several highly conserved sequences located in the proximal pro-
moter region upstream of both classical and non-classical HLA-D genes (8). The 
sequences are called the SXY module and four different bindings factors coopera-
tively bind to these sequences, forming a complex called the MHC class II 
enhanceosome. It is the result of multiple protein-protein and protein-DNA interac-
tions and, when assembled, it serves as a scaffold to which the class II trans-
activator (CIITA) can be recruited. It is CIITA, which then directs the subsequent 
transcription (8, 15). In effect, CIITA has been named the master regulator of 
MHCII gene expression, controlling both the constitutive and inducible HLA-DR 
expression (11, 15). Accordingly, out of all the trans-acting elements required for 
HLA-DR gene expression, CIITA is the only element that is not expressed ubiqui-
tously (15). Hence, the protein synthesis of HLA-DR correlates with the presence of 
CIITA. Adding another level of complexity, the expression of the gene encoding 
CIITA, called MHC2TA, is also complex and involves the engagement of at least 
three different promoters (CIITA-pI,- pIII, and -pIV), which each transcribe a 
unique first exon (16). The employment of the different promoters depends on both 
the cell type and the particular stimuli (3, 8, 17). Furthermore, CIITA requires sev-
eral post-translational modifications before it acquires its functional form (18-20). 
Interestingly, also several examples of CIITA-independent MHCII expression can 
be found for both professional APCs and non-APCs. Accordingly, the expression of 
MHCII was observed for both mouse B cells and DCs in the absence of CIITA, 
although the levels were five-fold reduced as compared to cells co-expression of 
CIITA and MHCII (21). Moreover, mouse corneal endothelium has been shown to 
express MHCII in a CIITA-independent manner and the resulting MHCII molecules 
were found to present antigens primarily of endogenous origin (4). Finally, it has 
been recognized that parameters such as epigenetic modifications and non-coding 
RNAs, e.g. miRNAs, are also important aspects of gene regulation (8, 22, 23). 
However, for the expression of HLA-DR genes the importance of these parameters 
remains to be investigated. 
Several biochemical mechanisms also modulate the expression of HLA-DR mole-
cules, although they are interdependent with those directly related to the genetics. 
These biochemical mediators also encompass a quite complex system of stimuli, 
where one mediator can exhibit different effects on two cell types, which impedes 
simple categorization. Nonetheless, the effects on the HLA-DR expression can be 
divided into two overall parts: An effect on the basal, constitutive expression or an 
effect on the induction or the enhancement the HLA-DR expression.  
It is known that the basal expression can be enhanced or down-regulated by a num-
ber of immune and neuroendocrine mediators. As examples of the former, granulo-
cyte-macrophage colony-stimulating factor (GM-CSF) can stimulate HLA-DR gene 
expression in DCs (24, 25), whereas glucocorticoids and prostaglandins down-
regulate HLA-DR expression in B cells (11, 26). Related to the effects of biochemi-
cal mediators on the inducible HLA-DR expression, interferon- (IFN-) is reported 
as a potent inducer of this expression in non-APCs, including endothelial cells, 
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epithelial cells, and fibroblasts (11, 22, 27-29). It is believed that these HLA-DR 
expressing non-APCs are involved in maintaining peripheral tolerance, when co-
stimulatory molecules are not concomitantly present (30), which can be related 
back to the same effect exerted by APCs on T cells (Figure 1B).   
1.2.4. THE MHCII ANTIGEN PRESENTATION PATHWAY 
Of great relevance to the function of HLA-DR is the entire pathway that directs its 
trafficking to intracellular compartments associated with antigen processing, load-
ing of antigenic peptides, and ultimately transport to the cell surface. The molecular 
mechanisms involved in this pathway have been comprehensively investigated with 
the majority of the work focusing on HLA-DR or mouse MHCII (I-A and I-E)(2).  
After synthesis, the HLA-DR heterodimer assembles in the endoplasmic reticulum 
(ER) together with the invariant chain (Ii, CD74) (Figure 3). The Ii protein forms a 
heterotrimer and acts as a chaperone for three HLA-DR heterodimers by carrying 
out a number of important tasks. First, Ii enhances the formation of stable HLA-DR 
heterodimers and also prevents premature binding of peptides by blocking the pep-
tide-binding groove of the HLA-DR molecule. Moreover, Ii directs HLA-DR to and 
within the endosomal pathway (12, 31). From the ER, the HLA-DR:Ii complex is 
transported from the Golgi to the MHC class II compartment (MIIC). The MIIC is a 
late endosomal compartment, which contains a high density of MHCII molecules, 
HLA-DM, and proteolytic enzymes, called cathepsins, as the minimal prerequisite 
for loading of antigenic peptides to HLA-DR (32). The transport of the HLA-DR:Ii 
complex to the MIIC occurs either directly or via the cell surface (Figure 3)(2, 12, 
31). Upon entry into the endosomal pathway, Ii is degraded by resident proteases, 
leaving only a small peptide fragment, called the class II-associated invariant chain 
peptide (CLIP), in the peptide-binding groove of HLA-DR (32, 33). Within the 
MIIC, CLIP is exchanged for antigenic peptides, which is a process supported by 
HLA-DM, and in some cells also HLA-DO (2). Subsequently, the antigen-loaded 
HLA-DR molecule is transported to the plasma membrane where if functions to 
present antigens to CD4+ T cells (Figure 3). A fraction of the cell surface HLA-DR 
molecules may yet again enter the endosomal pathway for re-loading and recycling 
back to the plasma membrane (34). However, the exact mechanism by which the 
complex is targeted for degradation or recycling and how these processes are regu-
lated still remains elusive (2, 32). As a final point, HLA-DR is internalized and 
degraded, most likely following ubiquitination (2, 35). 
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Figure 3 The MHCII antigen presentation pathway. The HLA-DR / heterodimer as-
sembles in the ER, forming a stable complex Ii. The complex enters the endocytotic pathway 
either directly or via the cell surface. In the MIIC, Ii is degraded, leaving only the small 
peptide fragment CLIP in the peptide-binding groove of HLA-DR. The chaperone HLA-DM 
assists the exchange of CLIP for antigenic peptides, thus creating the mature HLA-DR, 
which is ultimately transported to the plasma membrane to exert its function in antigen 
presentation to CD4+ T cells.  
1.2.5. HLA-DR ANTIGENS ON T CELLS 
For more than four decades it has been observed that T cells in peripheral blood can 
present HLA-DR molecules on their cell surface. In addition, the number of these 
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cells increases upon activation (36). Accordingly, HLA-DR is often used as a mark-
er for T cell activation, along with other molecules, such as CD69 and CD25 (37, 
38). While the expression of HLA-DR is well described in the context of profes-
sional APCs, the expressional features of HLA-DR in T cells are still a topic of 
discussion. Furthermore, the possible functional implications of HLA-DR antigens 
on T cells remain poorly understood.  
The first observation of MHCII molecules on T cells was made in the late 1970’s 
(36, 39-41) and since then, several aspects pertaining to this observation have been 
investigated. It is widely accepted that HLA-DR marks activated T cell subsets. 
Moreover, both the percent-wise and the density of HLA-DR molecules on T cells 
increase following both mitogenic and antigenic stimulation (37). Commonly used 
mitogens, i.e. inducers of proliferation (mitosis), include phytohemagglutinin 
(PHA) and phorbol 12-myristate acetatate (PMA) in the combination with 
ionomycin. These two mitogenic stimulators activate T cells in a TCR-dependent or 
TCR-independent manner, respectively (37, 42). In terms of antigenic/antigen-like 
stimulation, either a combination of anti-CD3 and anti-CD28 antibodies or irradiat-
ed allogeneic peripheral blood mononuclear cells (PBMC) are often used (37, 43). 
When using the latter, the cellular assay is denoted a mixed lymphocyte culture 
(MLC) or reaction (MLR). This cellular assay has been employed for over four 
decades to investigate the proliferation and activation of responder PBMCs to al-
logeneic stimulator PBMCs. This has often been used to test the tissue compatibil-
ity of two individuals for the purpose of transplantation. The allospecific responder 
T cells, which constitute approximately 5% (44), recognize allogeneic pMHC com-
plexes on the stimulator cells and become activated. The stimulator cells are typi-
cally irradiated, leaving them incapable of dividing, so that the read-out of the assay 
only relates to the responder cells.  
HLA-DR is considered to be a late activation marker because its presence on T cells 
is detected approximately 3 to 5 days after activation (3, 37, 45). In contrast, CD69 
is an early activation marker, detectable within hours or few days after T cell acti-
vation (3, 37). Despite somewhat contrasting results, the presence of the HLA-DR 
protein on T cells can be caused by the occurrence of either of two events. In the 
first event, an inducible de novo endogenous synthesis is reported, sharing several 
similarities to that found in APCs. In contrast, the second event involves an acquisi-
tion of HLA-DR from adjacent cells by mechanisms that are yet to be resolved. In 
the following, each of these two events will be elaborated. 
1.2.6. CHARACTERISTICS OF ENDOGENOUS DE NOVO SYNTHESIS 
OF HLA-DR MOLECULES BY T CELLS 
Studies supporting the endogenous expression of HLA-DR molecules in T cells 
often highlight the role of CIITA as the master regulator of HLA-DR expression 
(see section 1.2.3). Thus, the regulation and expression of CIITA in T cells has 
received particular attention. It has been demonstrated that isolated and activated 
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human T cells use the CIITA-pIII for the expression of MHC2TA, following PHA 
stimulation either with (46) or without (47) simultaneous stimulation with allogene-
ic, irradiated PBMCs, i.e. with or without an MLC. Furthermore, unstimulated T 
cells investigated in the same studies lacked CIITA expression (46, 47). The ex-
pression of MHCII molecules has been reported for T cells in several other species 
than humans, including bovine, (48) equine, (49) guinea pig, (50), and rat (51, 52). 
Interestingly, mouse T cells are not able to synthesize MHCII molecules, even upon 
in vitro activation (53). This has been explained by a failure to express MHC2TA 
(33, 54), of which a contributing factor is methylation at the CIITA-pIII region (22). 
However, contradictory results also exist. As an example, it has been demonstrated 
that mouse T cells can present MHCII antigens following both mitogenic and anti-
gen-like (anti-CD3/anti-CD28) stimulation (55). Furthermore, a study noted that the 
preponderance of isolated primary CD4+ T cells do not express CIITA ex vivo (33).  
1.2.7. CHARACTERISTICS OF A MOLECULAR ACQUISITION OF HLA-
DR BY T CELL 
The phenomenon of intercellular transfer of molecules has received increasing 
attention within the last decades. In relation to the immune system, the current un-
derstanding of this cellular event is that it comprises a cell-to-cell communication of 
great importance in the orchestration and regulation of immune responses (56-58). 
The interacting cells can acquire cell surface proteins and other molecules, includ-
ing small RNAs, and entire membrane patches from each other. As a consequence 
of this, the recipient cell can acquire a new functional phenotype. Accordingly, this 
challenges the common perception of cellular autonomy, in the meaning that each 
cell is characterized by having a particular transcriptome and proteome (57, 59). In 
the context of HLA-DR, several investigations have shown that T cells from a 
number of species can acquire MHCII molecules from APCs (60-62). However, 
before elaborating on this particular process, the general features of intercellular 
exchange of molecules will be covered with regards to T cell:APCs interactions. 
Mechanisms of intercellular transfer of molecules 
It has been proposed that the transfer of proteins and other molecules between two 
cells can happen by either of four mechanisms. These include gap junctions, nano-
tubes, the process of trogocytosis, and the uptake of extracellular vesicles (Figure 4) 
(56, 57, 63). Gap junctions can be formed between cells in solid tissue, but also 
between immune cells (64). This creates a connection, which allows for the transfer 
of genetic material and other small molecules between cells (63). Nanotubes can be 
formed as membrane extensions between two interacting cells, thus creating a direct 
connection that facilitates a bi-directional exchange of vesicles, surface proteins, 
and small molecules (56). It is thought that the nanotubes may be formed either as 
membrane bridges upon termination of the IS, when the cells move apart, or by 
newly formed membrane outgrowths (56, 63). Trogocytosis (Greek trogo; 
gnaw/nibble) denotes the process in which entire membrane fragments are acquired 
by lymphocytes from the interacting APC (Figure 4) (65). Trogocytosis occurs at 
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the IS (section 1.1) and is triggered by signals conveyed through antigen receptors 
(65). The molecular transfer can be initiated only minutes after IS formation, after 
which the acquired molecules is either internalized, left in the membrane, or re-
turned to the cell surface in a functional form (56). Extracellular vesicles (EVs) 
comprise the final and most extensively studied transfer mechanism. Furthermore, 
one subgroup of these vesicles, termed exosomes, has received the most attention 
(Figure 4)(63, 66, 67). These membrane-enclosed entities have been shown to play 
important roles in cellular communication by virtue of their protein, RNA, and lipid 
content (66, 68-71). In relation to the immune system, EVs have well documented 
immunomodulatory effects (63). This can be accomplished either by direct recep-
tor-ligand signaling on the target cell or by being internalized or integrated into the 
plasma membrane, thus bestowing a new functional phenotype on the recipient cell. 
The vesicular transfer of molecules can occur either within the IS, in its close vicin-
ity, or by transport from more distant locations in the body, which means that direct 
cell contact is not a prerequisite (63, 67, 72, 73). 
T cells can aquire MHCII molecules from APCs 
Shortly after the first observation of MHCII proteins on T cells were made, it was 
described how APC-derived MHCII molecules could be acquired by T cell clones 
in vitro (74). Since then, several groups have investigated this cellular phenomenon 
for both primary cells and cell lines, demonstrating the transfer of a fully functional 
protein complex, occasionally accompanied by a simultaneous transfer of co-
stimulatory molecules (61, 75).  
As previously mentioned, it has been demonstrated that mouse T cells cannot ac-
tively synthesize MHCII molecules (section 1.3.1). This observation initiated the 
continued discussion about the physiological relevance of MHCII on T cells be-
cause the immune system of mice seemingly was not impaired by this significant 
difference. One explanation, which could account for this cellular variation, is that 
the mouse T cells acquire MHCII molecules from APCs. In effect, the first indica-
tions of such a transfer occurring in mice was made in the early 1980´s (74). Subse-
quent research has confirmed and elaborated on this event (62, 76-78). Also for 
both rat (60) and human T cells (61), the acquisition of functional pMHCII com-
plexes has been found. The requirements for the molecular transfer demonstrated in 
all species are currently not fully established and several contradictory results exist. 
A number of studies have reported that cell contact between T cell and APC is 
necessary for the molecular acquisition (61, 79). Furthermore, both trogocytosis 
(80) and vesicular transfer (60, 79, 81) has been indicated as the mechanisms re-
sponsible for the acquisition. While some studies report that the transfer is depend-
ent on TCR-ligation (81), other studies draw contradictory conclusions (61, 79). 
Nonetheless, the activation status of the T cells continues to be underlined for its 
importance and is has been demonstrated that the acquisition of pMHCII is en-
hanced, when the T cell is activated and also when the cognate interaction between 
TCR and pMHCII is involved (62, 77, 81). In line with this, it has been observed 
that only activated mouse T cells could acquire MHCII-containing vesicles from 
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APC and that the acquisition was dependent on the presence of LFA-1 on these T 
cells. Hence, this may indicate that a vesicle-mediated acquisition of MHCII could 
be regulated by means of only targeting activated T cells. Nonetheless, it may seem 
like there exist bimodal pathways for synthesis and acquisition of HLA-DR by 
human T cells. These may be complementary and account for distinct functionali-
ties, though this is currently unverified. 
 
Figure 4 Mechanisms of intercellular transfer of molecules. Upon interaction between 
two immune cells, the exchange of proteins and genetic material can occur. Currently, four 
mechanisms have been suggested to account for this molecular transfer. Nanotubes creates a 
direct passage, enabling a possible molecular transfer of proteins and vesicles. The formation 
of gap junctions facilitates the transfer of small molecules, including genetic material by 
directly connecting the cytoplasm of the interacting cells. Trogocytosis is the exchange of 
entire patches of plasma membrane occurring within the immunological synapse (IS). This 
can result in the transfer of several proteins to the recipient cell. Extracellular vesicles (EVs) 
can also enable intercellular communication and transfer of molecules. The EVs can be 
secreted either directly within the IS or into the extracellular space. 
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1.2.8. FUNCTION OF HLA-DR ON T CELLS 
In terms of functionality, it has been stated that MHCII characterizes the antigen-
presenting capacity of a cell (55). Hence, HLA-DR may be more than a mere acti-
vation marker for human T cells, regardless of whether the protein is acquired or 
synthesized endogenously. It could be reasonably assumed that some of the func-
tional features of HLA-DR on APCs could be directly extrapolated to T cells pre-
senting this protein. The finding of several co-stimulatory molecules on T cells (61) 
could further warrant a hypothesis of the existence and importance of antigen-
presenting T cells (T-APCs).  
Antigen-presentation by T-APCs has classically been associated with down-
regulatory signals (3, 82, 83). As such, T-APCs have been shown to induce either 
anergy (84-86) or apoptosis (87). Furthermore, in a study of mouse regulatory T 
cells (Tregs) it was described that the CD4+ CD25
hi
 MHCII+ phenotype identified 
a functionally distinct Treg population with the ability to suppress proliferation and 
cytokine production in responder T cells (83). Another study also connects the 
presence of HLA-DR on CD4+ CD25+ tumor necrosis factor 2 (TNFRII)+ with the 
strongest suppressive activity, as compared to CD4+ HLA-DR- subsets (88). Con-
versely, several studies report that T-APCs can activate responder T cells, (61, 62) 
thus indicating diversity in the possible functions of T-APCs. 
APC features of T cells 
If a T cell has the capacity of an APC, it is only natural to assume that it possesses a 
number of key features related to this function. Consequently, the central compo-
nents of the MHCII antigen presentation pathway would be expected to exist in T-
APCs, including the ability to express HLA-DR and also uptake, process, load, and 
present antigens (section 1.2.4). Finally, the simultaneous presence or absence of 
co-stimulatory molecules could provide indications of the functional capabilities of 
T-APCs.  
Related to the uptake of antigens, there are currently no unambiguous conclusions 
for T cells. While some state that T cells hold the ability to capture antigens (47), 
others claim that there is no known mechanism for this (33) and as a consequence 
of this, only present self-peptides, such as CLIP, or T cell tropic viruses (33, 89, 
90). The capacity to process and load peptides onto HLA-DR molecules requires 
the MIIC and its constituents (section 1.2.4). Accordingly, it has been demonstrated 
that T cells can express cathepsin S (CatS) (33), which is an enzyme that degrades 
Ii to CLIP (91, 92). The same study made the additional observation that T cells did 
not express the enzyme asparagine endopeptidase (AEP). This is relevant because 
AEP is the sole protease that, at the time of the study, had been proven necessary 
for the creation of antigenic peptides (33, 93). For a proper loading of antigenic 
peptides, within the peptide-binding groove of HLA-DR, the presence of HLA-DM 
is required. In line with this, HLA-DM has been detected within the CD3+ CD4+ 
HLA-DR+ T cells (33), however, no further studies on this expression are currently 
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available. A final requirement for the MIIC, and also for the entire MHCII antigen-
presenting pathway, is a high density of HLA-DR molecules. According to our own 
investigations, out of the CD3+ T cells in peripheral blood, which present HLA-DR 
on their cell surface, only a fraction of these also contain HLA-DR in the intracellu-
lar compartment (Manuscript 1, Figure 2, Appendix B1). Ultimately, the function of 
HLA-DR on T cells resides with its presence in the plasma membrane, where anti-
gen presentation can occur. However, the outcome of a potential antigen presenta-
tion is highly dependent on the co-stimulatory or co-inhibitory signals provided in 
parallel (Figure 1). The most well described co-stimulatory molecules are those 
belonging to the B7 family of which B7-1/CD80 and B7-2/CD86 are typical exam-
ples (94). They both interact with CD28, which is expressed by the majority of T 
cells in both human and mouse (95). Professional APCs express CD80 and CD86 
constitutively and this expression is increased upon activation of T cells (95). For 
the presence of co-stimulatory molecules on T cell, diverging reports have been put 
forward. On one hand, an active protein synthesis has been described (3). On the 
other hand, a molecular acquisition has been demonstrated by both human (61, 96) 
and mouse T cells (75, 97).  
Differences between T-APCs and APCs 
In order to delineate the possible functions of T-APCs, it seems reasonable to look 
for similarities between professional APCs and T-APCs. Even so, the differences 
observed between these two cellular subtypes might also provide relevant infor-
mation in that regard. The involvement of TCR, HLA-DR, and co-stimulatory mol-
ecules are present in both the case, where two T cells interact (T:T), and in the in-
teraction between T cells and APC (T:APC). However, the consequential produc-
tion of IL-2 is not induced following T:T interaction, while IL-4 production is in-
duced in both scenarios (98, 99). This reduced IL-2 synthesis is believed to be asso-
ciated with the reduced influx of Ca
2+
 observed after T:T interactions, when com-
pared to T:APC interactions (3, 98). Furthermore, the magnitude of TCR and CD3 
down-regulation was much greater after T:T interactions, as compared T:APC in-
teractions (84). This down-regulation has been proposed to correlate with the de-
gree of anergy induced in the responder cell (100). Finally, the up-regulation or 
presence of co-stimulatory molecules CD80 and CD86 on T cells could only be 
detected following T:APC interaction (84). Taken together, this suggests that the 
functions of APCs and T-APCs are dissimilar. 
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CHAPTER 2. AIMS OF THE PHD STUDY 
The overall aim of this PhD study is to investigate the endogenous expression 
and/or acquisition of HLA-DR by human T cells. In line with this, the study is 
based on the following hypotheses: 
Human T cells do not express HLA-DR endogenously 
HLA-DR is transferred to T cells from APCs, predominantly mediated by direct cell 
contact 
The main function of HLA-DR presenting T cells is to down-regulate the activity of 
other T cells 
 
The specific aims of each of the four manuscripts included in the thesis are as fol-
lows: 
MANUSCRIPT 1 
Revenfeld, A.L.S, Steffensen, R., Pugholm, L. H., Stensballe, A., Jørgensen, M.M, 
Varming, K. (2015): The existence of HLA-DR on circulating CD4+ T cells cannot 
be explained by a concurrent presence of HLA-DRB1 expression. BMC Immunolo-
gy. Accepted with revisions. 
The aim of the study in this manuscript is to evaluate the expression of HLA-DR 
at the transcriptional (mRNA) level and protein level in human T cells obtained 
from peripheral blood. If an endogenous protein expression occurs in human T 
cells, it can reasonably be expected that the corresponding mRNA also will be pre-
sent within this cell population. As a positive control, the simultaneous expression 
of HLA-DR mRNA and protein is evaluated in autologous B cells. Furthermore, the 
investigations are carried out with cells directly isolated from peripheral blood to 
approximate the in vivo conditions to the greatest extent.  
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MANUSCRIPT 2 
Revenfeld, A.L.S, Bæk, R., Varming, K., Jørgensen, M.M, Stensballe, A. (2015): 
Phenotypic characterization of extracellular vesicles and CD4+ HLA-DR+ re-
sponder T cells following contact-dependent and -independent allogeneic MLC. 
Journal of Leukocyte Biology. In preparation. 
This manuscript contains two aspects to further elucidate the presence of HLA-DR 
on T cells. Consequently, the first aim is to determine whether the expression of 
HLA-DR can be induced in monocultures of CD4+ T cells from peripheral blood 
as a measure of the possible endogenous HLA-DR expression. The obtained results 
should support those presented in Manuscript 1 (as described above). The second 
aim relates to the requirements of physical contact between T cells and APCs. 
Hence, the second aim is to investigate whether allogeneic cells can elicit any 
effects on each other without physical contact. In the applied experimental setup 
the responder and stimulator cells are separated by a membrane, which allows for 
the passage of molecules up to a particular size, including cytokines and small EVs, 
such as exosomes. Hence, the phenotype of the secreted EVs is determined to ob-
tain information about their role in the communication between responder and 
stimulator cells. Moreover, the cellular phenotype of the responder CD4+ HLA-
DR+ T cells is in focus in order to evaluate their possible functionality. As for the 
expression analysis described in Manuscript 1, the applied cells are primary, instead 
of clones or stable cell lines, to maximize the physiologic relevance.  
 
MANUSCRIPT 3 
Revenfeld, A.L.S., Bæk, R., Nielsen, M. H., Stensballe, A., Varming, K., 
Jørgensen, M. (2014): Diagnostic and prognostic potential of extracellular vesicles 
in peripheral blood. Clin Ther; 36, 6, pp. 830-46. 
This scientific review elaborates on the clinical potential of utilizing analyses of 
EVs from a blood sample. The aim of the review is to describe selected and useful 
techniques to create a platform for EV analysis of blood samples in a clinical 
setting. Among others, the review includes the description of an EV analysis meth-
od developed at the Department of Clinical Immunology, Aalborg University Hos-
pital, Aalborg, Denmark, called the EV Array. This technique can be used to pheno-
type EVs from a multitude of biological fluids, including blood and cell culture 
supernatant and has been used throughout the PhD study and in particular for the 
results presented in Manuscript 2. In addition, the review includes a section in 
which the role of EVs in the immune system is described, which is very relevant for 
the experimental work carried out in the present PhD study.  
 




Revenfeld, A.L.S., Søndergaard, E.K.L., Stensballe, A., Bæk, R., Jørgensen, M.M, 
Varming, K. (2015): Characterization of a cell culturing system for the study of 
contact-independent vesicle communication. Journal of Extracellular Vesicles. 
Submitted. 
The content of this manuscript, which is a technical report, should support the re-
sults presented in Manuscript 2. The aim of the study is to describe an experi-
mental system, where dynamic, vesicle-based communication between cells can 
be investigated. This is important since appropriate in vitro cell culturing systems 
are necessary to study the activity and biological function of EVs, not only in the 
context of HLA-DR, as was the focus of Manuscript 2. Many existing studies, 
which investigate aspects of contact-independent cell communication, do not justify 
the choice of the relative placement of the cells in the cell culturing setup. This may 
be relevant for the biological hypothesis being tested. Consequently, the study can 
serve to illustrate this importance for the design and validation of future studies. 
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2.1. METHODOLOGY 
A number of key methods and analyses have been employed to address the objec-
tives and aims in this thesis. For each original manuscript these methods are de-
scribed in the “Materials and Methods” section (Appendix B1, B2, and B4). How-
ever, additional background information not covered in the manuscripts, concerning 
methodological considerations and data interpretation, will be elaborated in the 
subsequent sections.   
2.1.1. CELLULAR PHENOTYPING BY FLOW CYTOMETRY 
Within the field of immunology, flow cytometry (FCM) is an indispensable tech-
nique. It facilitates rapid, multiparametric analysis of single particles, often cells, in 
a suspension. The particles are focused hydrodynamically, creating a flow of single 
particles, which subsequently pass a beam of light. The properties measured include 
the relative size, relative granularity (internal complexity), and relative fluorescence 
intensity. In terms of cellular analyses, the use of multiple fluorochrome-conjugated 
antibodies provides the opportunity for simultaneous measurements of several pro-
teins located at the cell surface and intracellularly of a single cell in a larger popula-
tion. The use of >10 different antibodies in a composite stain is used routinely (101) 
and the possibility to expand this number exists (102). Ultimately, the use of multi-
color FCM analysis allows for functionally distinct cellular subsets to be separated. 
In this thesis, FCM holds a central place. As such, this technique has been applied 
throughout the majority of the presented original work. Moreover, a new assay was 
developed and validated and applied to obtain the FCM results shown in Manu-
script 1. Several aspects of this new assay demanded a thorough investigation of 
features relating to technique, staining, and gating to ensure that proper conclusions 
could be made from the obtained results. The following components from the de-
velopment/ validation of the FCM assay were evaluated and are presented in more 
detail below: 
 Choice of anti-HLA-DR antibody (specificity and fluorophore conjugation) 
 Choice of fixation and permeabilization conditions 
 Choice of incubation temperature and time 
 Choice of gating strategy 
 Test of antibody saturation (+/- fixation, +/- permeabilization, antibody concen-
tration) 
 Test of reversing the two anti-HLA-DR-antibodies with different fluorophores 
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Development of a flow cytometric assay for the identification of mem-
brane-bound and intracellular HLA-DR in T and B cells 
As stated in the beginning of Chapter 2, the overall aim of this thesis is to investi-
gate the endogenous expression of HLA-DR by human T cells. To facilitate this, a 
FCM assay was developed in which the aim was to separate the plasma membrane-
bound HLA-DR (HLA-DR mem) from the intracellular HLA-DR (HLA-DR IC). 
As pointed out in Manuscript 1 (Appendix B1), the hypothesis driving such an 
assay design is that T cells would only present HLA-DR in both cellular compart-
ments if they possess the ability to express the HLA-DR protein endogenously. In 
line with this, the expression of HLA-DR mem and HLA-DR IC by autologous 
CD19+ B cells was used as a positive control, due to the constitutive HLA-DR 
expression by these cells. 
The starting point was to choose a monospecific antibody, which would identify 
mature and functional HLA-DR, since the presence of this protein on the T cells 
could also provide possible functional clues, aside from those related to expression. 
Accordingly, the monoclonal mouse anti-human HLA-DR antibody L243 was se-
lected. L243 recognizes mature and non-Ii associated HLA-DR (12) by binding to a 
conformational epitope on the -chain of HLA-DR (section 1.2.2). The binding 
requires the correct assembly of the HLA-DR -heterodimer (103-105). Further-
more, L243 selectively targets HLA-DR and not other MHCII molecules, including 
HLA-DP and HLA-DQ (section 1.2.1) (105). The L243 antibody was chosen con-
jugated to two different fluorophores (explained in a subsequent section) and the 
staining setup included a primary targeting of the HLA-DR mem with one antibody 
followed by fixation and a subsequent permeabilization of the plasma membrane 
and identification of HLA-DR IC with the second antibody.  
To facilitate the access to the intracellular target, a cell fixation/permeabilization kit 
from Invitrogen was chosen, since it had previously been used successfully in our 
laboratories. Though Invitrogen does not provide the constituents of the included 
solutions, the kit supposedly provides mild fixation and permeabilization of cells. 
This preserves their side (SSC) and forward scatter (FSC) properties, which is rele-
vant from a flow cytometric point-of-view, since these two properties often are used 
as an initial identification of the cell populations of interest. Moreover, the 
autofluorescence of the cells has been reported as low after using the kit (106). This 
is a desirable trade, because the increased autofluorescence, which is often associat-
ed with cellular fixation, can lead to overlap with the emission spectra in the green 
region of the spectrum, affecting the use of fluorophores such as fluorescein 
isothiocyanate (FITC) and Alexa Fluor 488 (AF488) (107). The manufacturer of the 
kit provided the incubation temperature and time and these were used only with 
minor changes (see final protocol after Figure 10), since they had previously been 
applied successfully for other applications in our laboratories.  
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Identification of positive events with the Fluoresence Minus One 
method 
The use of several different fluorophore in a multiparametric FCM analysis calls for 
the need to estimate and correct the amount of spectral overlaps, also called fluores-
cence compensation. The overlaps occur since the light emitted from one 
fluorophore may be detected within the wavelength range assigned to another 
fluorophore (108, 109). Compensation is usually an obligate step performed as the 
instrument is started. It is carried out with compensation control samples stained 
with only one of the fluorochromes used in the composite stain (109). With more 
complex stain sets, the inclusion of a Fluorescence Minus One (FMO) sample is 
very useful, especially when there is a need to distinguish weakly positive events 
from the negative events. The FMO control includes all the staining reagents but 
one and in some cases replacing it with an isotype control antibody (109). Thereby, 
it is possible to estimate the cumulative contribution of all other fluorophore into 
the channel of the one omitted and the threshold for non-stained cells can conse-
quently be determined (108). When a cell is unstained or has no cell-associated 
fluorescence for a particular dye, the compensation results in a population distribut-
ed symmetrically around zero in the corresponding channel (109). This is termed 
autofluorescence. The width of this distribution can vary considerably depending on 
the fluorescence compensation, making it difficult to establish whether a cell is 
weakly positive or unstained. Hence, an FMO control should always be included, 
when this is an issue.  
In this PhD study, the FMO is an essential control in the FCM analysis of HLA-DR 
on T cells, as presented in Manuscript 1 (Figure 1, Appendix B1). This is the case, 
since the distribution of HLA-DR+ events across a T cell population is heterogene-
ous with no clear separation to the HLA-DR- population. Therefore, the FMO is 
necessary for a more unbiased determination of the threshold defining the HLA-
DR+ and HLA-DR- populations than by merely using isotype antibody controls. 
These controls are otherwise commonly used to evaluate non-specific binding by 
the target antibodies and are applied to set the threshold, which defines when a 
population stains positively with a target antibody (109). However, the isotype 
control antibodies are often used in a composite stain, thus considerably underesti-
mating the background staining in each channel (101). A subsequent placing of the 
staining boundaries for the antigen specific antibodies, based only on the isotype 
controls, would thus erroneously indentify false-positive events. For the data pre-
sented in Manuscript 1, the FMO sample was used to set the gate for HLA-DR mem 
and HLA-DR IC so that the positive gate for these markers did not contain more 
than 1% of the negative events (Figure 1, Manuscript 1). Consequently, this bound-
ary level is placed between two and three standard deviations (SD) from the mean 
value of the negative population. This is based in the principles of normal distribu-
tion and standard deviation in which 0.1% of the events in a distribution are over 
three SD above the mean of the population, while approximately 2% of the data are 
two SD above.  
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Choice of fluorophores for the anti-HLA-DR antibody 
Initially, FITC- and phycoerythrin (PE)-conjugated L243 (L243-FITC and L243-
PE) were applied to target HLA-DR mem and HLA-DR IC, respectively. Of the 
two fluorophores, PE has the highest intrinsic brightness (110), which is useful, 
when a low density of the target antigen is expected, such as HLA-DR on T cells. 
Although PE is a bulky molecule (240 kDa), compared to FITC (390 Da), it has 
been used successfully for intracellular staining (111). The combination of L243-
FITC for staining HLA-DR mem and L243-PE for staining DR IC, identified 18% 
CD3+ HLA-DR mem+ and >1% CD3+ HLA-DR mem+ DR IC+ T cells (n=3) 
(Figure 5, left panel). All CD19+ B cells stained positive for HLA-DR mem. None-
theless, >1% of the B cells from one donor were also HLA-DR IC+, while this 
number was 45% for a second donor (Figure 5, left panel).  
 
Figure 5 Staining of HLA-DR in the membrane and cytoplasm of T and B cells with two 
different anti-HLA-DR antibodies. A flow cytometric assay was developed to separate the 
membrane-bound (HLA-DR mem) HLA-DR from the HLA-DR found in the intracellular 
compartment (HLA-DR IC) of human T and B cells. The setup included staining PBMCs 
with anti-CD3, anti-CD19, and two different anti-HLA-DR antibodies of the same clone 
(L243) but with different fluorophores. As described in Manuscript 1 and the sections above, 
one L243 antibody was used initially along with the antibodies against the cell-specific sur-
face markers. Subsequently, the cells were permeabilized and the second L243 antibody was 
applied. In the subsequent flow cytometric analysis, the number of CD3+ T cells and CD19+ 
B cells presenting HLA-DR were determined using the FMO gating strategy described in the 
previous section and in Manuscript 1. Left panel: The histograms show the results obtained 
with the combination of L243-FITC to stain HLA-DR mem and L243-PE to stain HLA-DR 
IC. Note, that no permeabilization control (i.e. entire staining procedure with 
permeabilization omitted) is included in this panel. n = 3 (T cells), n = 2 (B cells). Right 
panel: The histograms show the results of switching the two antibodies used in the top panel 
with cells from the same donor. n = 3. 
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The observations found for the latter donor were confirmed several times and an 
increase in the amount of antibody for HLA-DR IC did not increase the amount of 
B cells staining positive (data not shown). It was unexpected not to identify more B 
cells presenting HLA-DR IC and to further investigate this observation, the two 
L243 antibodies were switched (Figure 5, right panel). With this combination, 5% 
CD3+ HLA-DR mem+ and 69% CD3+ HLA-DR mem+ DR IC+ T cells were iden-
tified, while all CD19+ B cells were double positive (n=3). However, in the sample, 
where no permeabilization agent was added, an equal sized HLA-DR IC signal was 
also found for both CD3+ T cells and CD19+ B cells (Figure 5, right panel, histo-
grams with dashed lines). This permeabilization control was only included for one 
of the three donors in the first L243-FITC HLA-DR mem/L243-PE HLA-DR IC 
combination presented in Figure 5, left panel (though not for the donor included in 
the figure). Yet, it demonstrated that the HLA-DR IC signal in the permeabilization 
control for that combination was not greater than the signal from the FMO control 
(data not shown). Hence, this indicated that the increased HLA-DR IC signal ob-
served in the permeabilization control for the second antibody combination (L243-
PE for HLA-DR mem/ L243-FITC for HLA-DR IC) could be fluorophore-specific. 
Subsequently, two new antibodies, L243-AF488 and L243-AF647, were tested to 
further investigate this phenomenon. The AF conjugates are reported to be chemi-
cally resistant and very photostable, making them useful for both staining of intra-
cellular targets and for microscopy. Similar to the initial choice of antibodies, the 
brighter of the two fluorophores was chosen for the staining of HLA-DR IC. Here, 
this was the L243-AF647 antibody. An additional advantage of AF647 over PE is 
its relatively low molecular weight of 1250 Da, making it more suitable for intracel-
lular staining than PE. Finally, the emission spectra of AF488 and AF647 
fluorophores are very different (107), providing optimal conditions for non-
overlapping signals from the staining of HLA-DR mem and HLA-DR IC. The 
combination of L243-AF488 for staining HLA-DR mem and L243-AF647 for stain-
ing of HLA-DR IC resulted in the identification of approximately 18% CD3+ HLA-
DR mem+ and 3% CD3+ HLA-DR IC+ (Table 2, Manuscript 1, n = 10). A positive 
correlation between HLA-DR mem and HLA-DR IC was observed for CD3+T cells 
(Figure 2, Manuscript 1). Accordingly, the T cells presenting HLA-DR IC were all 
HLA-DR mem+, but not vice versa (Figure 13). This yielded 18% double positive 
CD3+ T cells (i.e. HLA-DR mem+ HLA-DR IC+). The subsequent focus on HLA-
DR IC in T cells was therefore placed on the T cells also presenting the membrane-
bound protein (i.e. CD3+ HLA-DR mem+ HLA-DR IC+ T cells). The analysis of 
the CD19+ B cells showed that these cells expressed both markers. Representative 
results of this analysis can be seen in Figure 6, left panel. 
When switching the two antibodies, approximately 19% CD3+ HLA-DR mem+ and 
10% CD3+ HLA-DR IC+ T cells were identified for cells from the 2 included do-
nors (Figure 6, right panel). This corresponded to roughly 45% of the CD3+ HLA-
DR mem+ T cells also being HLA-DR IC+. All B cells were double positive. As 
can be deduced, a higher number of T cells presenting HLA-DR IC were observed 
with combination 2 of the L243 antibodies, when compared to combination 1 (Fig-
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ure 6). However, the HLA-DR IC signal from the permeabilization control also 
increased, when switching the two antibodies (Figure 6, histograms with dashed 
lines). Nonetheless, the specific HLA-DR IC signals did not increase by the same 
magnitude (Figure 6, filled histograms). For combination 1, the specific HLA-DR 
IC signal for the CD3+ HLA-DR mem+ T cells was  seven times higher than the 
signal in the permeabilization control. The corresponding increase was only two-
fold higher, when using combination 2, yielding a lower resolution between the two 
signals from combination 2. The difference was even more pronounced for the B 
cells. Here, the specific HLA-DR IC signal obtained with combination 1 was ap-
proximately 10-15 times higher than the permeabilization control, while the incre-
ment was five times higher for combination 2. 
 
 
Figure 6 New fluorophores for staining of HLA-DR in the membrane and cytoplasm of 
T and B cells. PBMCs were stained with antibodies against CD3, CD19, and HLA-DR 
(L243) to target HLA-DR mem. The cells were permeabilized and a second L243 antibody 
was applied to identify HLA-DR IC. In contrast to the results presented in Figure 5, two new 
conjugates for the HLA-DR antibody were applied (AF488 and AF647). In the subsequent 
flow cytometric analysis, the number of CD3+ T cells and CD19+ B cells presenting HLA-
DR were determined using the FMO gating strategy described in the previous section and in 
Manuscript 1. Left panel: The histograms are representative examples of results obtained 
with the combination of the two L243 antibodies described in Manuscript 1 (Appendix B1). 
Here, L243-AF488 was used to target HLA-DR mem and L243-AF647 was applied to stain 
HLA-DR IC. n = 10. Right panel: The histograms show the results of switching the two 
antibodies used in the top panel with cells from the same donor. Similar results were ob-
tained with cells from another individual (see Figure 7, left panel). n = 2.  
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Next, a blocking step was tested in order to investigate, whether the HLA-DR IC 
signal observed in the permeabilization control was due to non-specific binding. 
Accordingly, blocking was performed with 20% heat-inactivated human serum after 
the initial HLA-DR mem targeting with L243-AF647. The blocking step was intro-
duced at this stage, and not before the initial staining step, because the issue with 
the increased background seemingly originated from the second antibody incuba-
tion step. Nonetheless, the blocking of the cells did not decrease the HLA-DR IC 
(L243-AF488) signal in the permeabilization control. In effect, the median fluores-
cence intensity (MFI) value of the HLA-DR IC signals in this sample increased 
approximately 50% for both T and B cells, as compared to the scenario, where no 
blocking agent was used (Figure 7, histograms with dashed lines). The blocking 
agent was not included in the final and optimized staining protocol and no other 
blocking agents and setups were tested.  
 
Figure 7 Effect of blocking with human serum to reduce any non-specific antibody 
binding. PBMCs were stained with antibodies against CD3, CD19, and L243-AF647 for 30 
min. Subsequently, the cells were blocked in 20% heat-inactivated human Ab serum for 20 
min at room temperature, followed by two washes in PBS. Next, fixation, permeabilization, 
and incubation with L243-AF488 were carried out, as previously described. In the subse-
quent flow cytometric analysis, the number of CD3+ T cells and CD19+ B cells presenting 
HLA-DR were determined using the FMO gating strategy described in the previous section 
and in Manuscript 1. Left panel: The histograms represent the observed signals from HLA-
DR mem and HLA-DR IC on T and B cells without any blocking step added to the staining 
procedure. Right panel: The histograms represent the corresponding signals to those in the 
top panel, when adding a blocking step after the initial HLA-DR staining. n = 1. 
Due to the results obtained for the L243-AF488 and L243-AF647 antibodies pre-
sented above, and the knowledge about the fluorophore properties, the optimal 
combination for the assay was chosen to be L243-AF488 for targeting HLA-DR 
mem and L243-AF647 for HLA-DR IC. This decision was primarily based on the 
lowest degree of binding in the permeabilization control for L243-AF647 (Figure 
6). The highest degree of background binding was present, when using either L243-
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AF488 or L243-FITC to target HLA-DR IC, indicating a possible link between the 
non-specific binding and the any shared properties of these two fluorophores that 
have similar structure and emission spectra. However, this link was not further 
investigated. The remaining optimization of the assay was carried out only for the 
selected antibody combination.  
Validation to ensure saturation of membrane-bound HLA-DR with the 
applied antibody 
The ultimate condition, which must be fulfilled to validate the presented flow 
cytometric assay, is that the primarily used anti-HLA-DR antibody must saturate 
HLA-DR mem. Otherwise, the subsequent staining with a second antibody against 
HLA-DR would result in a detection of a fraction of false-positive HLA-DR IC+ 
cells. In addition, the number of HLA-DR mem+ cells may be underestimated. 
Several controls were included to investigate, if the saturation of HLA-DR mem 
was present. First, one control was included in most optimization and all final ex-
periments (presented in Manuscript 1 and in the section above). In this control, the 
entire staining procedure was performed, only omitting the permeabilization agent. 
Typical results of this permeabilization control can be seen in Figure 3 (Manuscript 
1) and in Figure 6. With the applied combination 1 of the L243 antibodies (Figure 
6, left panel), the HLA-DR IC signal (L243-AF647) in the permeabilization control 
was negligible for the T cells. For the B cells, the signal for HLA-DR IC in the 
control was slightly elevated, when compared to the FMO sample. This was a gen-
eral feature for all donors. However, the intensity of the signals recorded for HLA-
DR IC in the permeabilization control and in the full stain sample was always sepa-
rated by at least a decade in the resulting histograms for the B cells, as depicted in 
Figure 6. Moreover, the permeabilization control was included as a part of validat-
ing confocal microscopy experiments. These experiments were performed to visual-
ize HLA-DR in the two cellular compartments and to validate the staining setup 
used for FCM. The results of the microscopy are depicted in Figure 4 (Manuscript 
1) and in Figure 8, where all the controls are included. As can be seen in this figure, 
no HLA-DR IC signal could be detected in the permeabilization control and no 
non-specific binding from the secondary antibody used for CD3 was detected. 
Hence, the microscopy validated the staining procedure used in the flow cytometric 
analysis. 
However, to address the signal present in the FCM analysis, it was investigated 
whether this unexpected HLA-DR IC signal was present due to non-saturated HLA-
DR mem from the first antibody incubation. Consequently, the amount of both 
L243 antibodies was doubled from 1 g/ 1 million cells to 2 g/ 1 million cells. The 
former was the amount recommended by the vendor of the antibodies and the 
amount used in the final protocol in Manuscript 1. In addition, the effect of an in-
creased incubation time of the initial HLA-DR mem staining from 15 to 30 min was 
also tested. 
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Figure 8 Confocal microscopy of membrane-bound and intracellular HLA-DR. Isolated 
CD4+ T cells and CD19+ B cells were stained with L243-AF488 (green) and L243-AF647 
(red) to target HLA-DR mem and HLA-IC, respectively. Anti-CD3 was also used in the T 
cell samples (turquoise) A) Full stain of the CD4+ T and CD19+ B cells (also found in Fig-
ure 4, Manuscript 1). B) The secondary antibody control (towards anti-CD3) and 
permeabilization controls. For the T cell permeabilization control, pictures of both a CD3+ 
HLA-DR mem+ and a contaminating CD3- HLA-DR mem+ has been included to illustrate 
the absence of a HLA-DR IC signal. The pictures are representative examples from one of 
the two donors included. The size bar is 10 m. 
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The results of increasing the antibody amount are presented in Figure 9. A doubling 
of the amount of applied HLA-DR antibodies did neither reduce nor increase the 
specific L243-AF488 and L243-AF647 signals. Accordingly, the number identified 
HLA-DR mem+ and HLA-DR IC+ T and B cells were similar for the two experi-
mental conditions, as were the corresponding MFI values. Furthermore, the HLA-
DR IC signal observed in the permeabilization control did not decrease with an 
increasing amount of L243 antibodies. In fact, the signal was marginally increased, 
when using 2 g of the two antibodies (Figure 9, right panel). For the experiment, 
which produced the results presented in Figure 9, an increased incubation time of 
30 min was applied in the initial HLA-DR mem staining. Only very subtle changes 
could be observed, when comparing the results obtained with 1 g of each L243 
antibody (Figure 9, left panel) to those previously acquired with a shorter 15 min of 
incubation time and with the same amount of antibody used. Consequently, a simi-
lar amount of HLA-DR mem and HLA-DR IC presenting T and B cells were identi-
fied with the two incubation times and the MFI values for these were also compara-
ble (data not shown). However, the MFI values of the HLA-DR IC signal in the 
permeabilization controls were identical for the B cells but slightly decreased for 
the T cells, when using an incubation time of 30 min (data not shown). Therefore, 
an incubation time of 30 min was used in the subsequent analyses and in the final 
protocol.
 
Figure 9 Effect of increasing the amount of anti-HLA-DR antibodies on specific and 
non-specific signals. PBMCs were stained with anit-CD3, -CD19, and either 1 g or 2 g of 
L243-AF488, as described in Manuscript 1 and in the sections above. For this experiment, an 
increased incubation time of 30 min (compared 15 min in previous experiments) was used 
for the initial staining step. The cells were fixed and permeabilized and the L243-AF647 
antibody was applied to stain HLA-DR IC. In the subsequent flow cytometric analysis, the 
number of CD3+ T cells and CD19+ B cells presenting HLA-DR were determined using the 
FMO gating strategy described in the previous section and in Manuscript 1. Left panel: The 
histograms show the observed signals from HLA-DR mem and HLA-DR IC for T and B 
cells when using 1 g of both L243 antibodies per 1 million cells, as was applied in Manu-
script 1. Right panel: The histograms represent the corresponding signals to those in the left 
panel, when doubling the amount of both L243 antibodies to 2 g per 1 million cells. n = 1.  
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The final control experiment evaluated the effect of the fixation step after the stain-
ing of HLA-DR mem. In this experiment, the entire staining procedure was applied, 
however, the fixation of the cells was omitted (Figure 10). In the subsequent FCM 
analysis, no events could be detected in the samples, where the cells had been 
permeabilized but not fixed, indicating that these cells had undergone lysis. Hence, 
the fixation step seemingly stabilized the cells prior to permeabilization, which has 
also been observed in other intracellular staining protocols (107). Consequently, the 
only sample providing any information from the non-fixed cells was the 
permeabilization control, i.e. no fixation and no permeabilization added (Figure 10, 
solid black line). With this sample, it was possible to see that fixation of the cells 
seemingly also had an impact on the detected HLA-DR mem signal. As a consistent 
observation done across many experiments, the HLA-DR mem signal in the fully 
stained sample and the signal in the corresponding permeabilization control were 
very similar (data not shown). In contrast, a decreased HLA-DR mem signal was 
observed in the permeabilization control for the non-fixed cells, when compared to 
the fixed cells (Figure 10, L243-AF488 histograms).  
 
Figure 10 Effect of fixation to separate membrane and intracellular HLA-DR in the 
flow cytometric assay. The PBMCs were stained with antibodies against CD3, CD19, and 
L243-AF488 for 30 min. To evaluate the effect of the subsequent fixation step, the cells were 
either fixed for 15 min or resuspended in PBS. The cells were permeabilized and the L243-
AF647 antibody was applied to stain HLA-DR IC. In the subsequent flow cytometric analy-
sis, the number of CD3+ T cells and CD19+ B cells presenting HLA-DR were determined 
using the FMO gating strategy described in the previous section and in Manuscript 1. Since 
the cells underwent lysis if they were permeabilized without any prior fixation, the only 
results presented for the non-fixed cells are those obtained with the non-fixed 
permeabilization control (i.e.. no fixation and no permeabilization). n = 2 
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This was the case for both CD3+ T and CD19+ B cells, for which the MFI values of 
the HLA-DR mem signal decreased with approximately 45% and 30%, respective-
ly, when compared to the fully stained sample (n=2). In addition, the HLA-DR IC 
signal observed for the HLA-DR mem+ T and B cells increased in the 
permeabilization control for the non-fixed cells as compared to the corresponding 
fixed sample (Figure 10, L243-AF647 histograms). The increase observed for the T 
cells amounted to approximately 60%, while for the B cells it was 50% for one 
donor (data not shown) and as much as 300% for the second donor included (Figure 
10). Hence, it seems likely that the fixation increases the ability to retain the anti-
body bound to HLA-DR mem on the cells after the initial staining step. 
The optimization and validation experiments lead to the protocol for the FCM assay 
described in Manuscript 1, in which membrane HLA-DR can be separated from 
HLA-DR found in the intracellular compartment of human T and B cells. In short, 
the protocol is as follows: 
1. Peripheral blood mononuclear cells are isolated from heparinized blood with-
drawn from healthy blood donors. 
2. The cells incubate with antibodies against CD3, CD19, HLA-DR (L243-AF488, 
1 g/106 cells), or the corresponding isotype control antibodies (FMO; 1 g/106 
cells for HLA-DR control) for 30 min at room temperature. 
3. Fixation solution is added and the samples incubate for an additional 15 min at 
room temperature. 
4. Cells are washed with PBS. 
5. The second antibody against HLA-DR (L243-AF647, 1 g/106 cells) or the cor-
responding isotype control antibody (FMO; 1 g/106 cells) is added along with 
permeabilization solution. Incubate for 20 min at room temperature. 
6. Cells are washed with PBS, resuspended, and analyzed by flow cytometry on the 
same day as the staining procedure is carried out.  
7. The gates, defining if an event stains positive for HLA-DR mem or HLA-DR IC, 
are defined with the FMO control samples. 
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2.1.2. REAL TIME QUANTITATIVE POLYMERASE CHAIN REACTION 
Real-time quantitative polymerase chain reaction (PCR), or in short qPCR, is a 
technique that allows for simultaneous amplification and quantification of nucleic 
acid sequences (DNA, complementary DNA (cDNA), RNA). The method measures 
PCR product accumulation through a dual-labeled, fluorogenic probe (e.g. TaqMan 
probes) or from a non-specific, DNA-binding dye (e.g. SYBR Green) (112). Using 
TaqMan probes provides very accurate and reproducible quantitation of gene ex-
pression. Unlike other quantitative PCR methods, real-time PCR does generally not 
require post-PCR sample handling, preventing potential PCR-product carry-over 
contamination and resulting in much faster and higher throughput assays. The out-
put value of qPCR is the threshold cycle (Ct), which marks the cycle number of the 
PCR in which the fluorescent signal passes a defined threshold (113). In this PhD 
study, qPCR has been employed to investigate and compare the expression of HLA-
DRB1 mRNA (section 1.2.2) in human CD4+ T cells and CD19+ B cells. The re-
sults of this investigation are presented in Manuscript 1 (Appendix B1). 
Design of primers for HLA-DRB1*03 qPCR 
As a part of the investigation of HLA-DRB1 expression in human T and B cells, a 
new qPCR assay was created at the Department of Clinical Immunology, Aalborg 
University Hospital, Aalborg, Denmark. This assay is specific for the HLA-
DRB1*03 allele and consists of a set of primers and a TaqMan probe (Figure 11) 
with a FAM dye label and a minor groove binder (MGB). The MGB moiety stabi-
lizes the hybridized probe and effectively raises the melting temperature. It was 
expected that this custom designed assay would eliminate any potential detection of 
mRNA from other alleles by only targeting one specific HLA-DRB1 allele, thus 
simplifying the read-out. This is relevant because of the extensive homology be-
tween the different HLA-DRB1 transcripts, potentially creating false positive re-
sults. Also, an initial investigation using commercial primers and probe to HLA-
DRB1 yielded several non-specific results, which motivated the wish to design new 
primers and specific probes for qPCR of HLA-DRB1.  
The HLA-DRB1 protein is encoded by 6 exons (114). Exon 1 encodes the leader 
peptide, exons 2 and 3 encode the two extracellular domains, exon 4 encodes the 
transmembrane domain, and exon 5 encodes the cytoplasmic tail. In order to make 
allele-specific primers, it is necessary to target the polymorphic part of the tran-
script, which is constituted by the extracellular domains. Consequently, the speci-
ficity of the assay is based on the design of the forward primer, which targets a 
sequence of exon 2 in the DRB1*03:01:01:01 mRNA sequence from the 
IMGT/HLA database (Figure 11). In contrast, the reverse primer targets a generic 
sequence of HLA-DRB1 mRNA. The applied probe was chosen, since it targets the 
exon-exon boundary of exon 2 and 3  (Figure 11), which also ensures that only 
mRNA and not genomic DNA is amplified. The newly designed assay was tested 
on a broad panel of donors representing the five major HLA-DR haplogroups (Fig-
ure 2B). These experiments, and subsequent sequence homology analyses, demon-
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strated that the assay, aside from HLA-DRB1*03 mRNA, also amplified transcripts 
from a number of other HLA-DRB1 alleles. Consequently, these alleles were ex-
cluded from further analyses and only alleles, which did not produce any detectable 
PCR products, were included as negative controls (Manuscript 1). 
Analysis of qPCR data 
Two commonly used methods can be applied to analyze data from qPCR experi-
ments. These are absolute quantification and relative quantification, yielding either 
an exact copy number of the input material or a relative change in gene expression 
as compared to that of another sample, respectively (115). For the qPCR experi-
ments carried out in this PhD study, the relative quantification method has been 
employed. In relative quantification, data is often analyzed using the comparative 
Ct method, also called the 2
-Ct
 method (113). By using this method of analysis, 
the relative changes in gene expression between two samples, i.e. before and after a 
treatment, can be shown. Ct is calculated as (Ct target gene – Ct reference 
gene)Time X – (Ct target gene – Ct reference gene)Time 0. As a note, the use of endoge-
nous reference genes to normalize data provides a way to correct for differences in 
the amount of template input (113). If equal amounts of nucleic acid are analyzed 
for each sample, and if amplification efficiency before the quantitative analysis is 
equal for each sample, the gene expression of the reference gene(s) should yield 
equal signals for all samples. Since the purpose of the qPCR investigation included 
in this PhD study is to detect expression levels and not expression changes, a deriv-
ative of the 2
-Ct
 method is applied for the data analysis. This is simply denoted 2
-
Ct
 and it should be used, when qPCR data is presented as individual data points 
(115). Here, Ct is calculated as (Ct target gene – Ct reference). 
 
 
Figure 11 Target sequences of the forward primer, reverse primer, and Taqman probe 
of the HLA-DRB1*03 specific qPCR assay. A section of the relevant sequence (exon 2 and 
3) of the mRNA of HLA-DRB1*03 is shown along with the specific target sequences of the 
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2.1.3. VESICLE PHENOTYPING USING THE EV ARRAY 
The characterization of EVs can comprise analyses of their biochemical and bio-
physical features, including size, cargo, and protein phenotype (66). The results of 
such analyses can be used to extract important information about their origin, 
amount and possible function, which are useful for both clinical and research pur-
poses. In the present PhD study, extensive phenotyping of the proteins found on 
EVs has been carried out using a newly developed technique, the EV Array (116), 
from the Department of Clinical Immunology, Aalborg University Hospital, Aal-
borg, Denmark. As such, the EV phenotypes presented in Manuscript 2 and 4 were 
determined using this technique. The EV Array is an antibody-based protein micro-
array for multiplexed phenotyping of EVs using unpurified starting material (116), 
including plasma, saliva, urine, and cell culture supernatants (Figure 12). It is an 
open platform, but the current setup detects the vesicles, which contain CD9, CD63, 
and/or CD81, which are all accepted exosome markers (66). Furthermore, more 
than 60 protein markers can be detected simultaneously in the present setup (117). 
 
Figure 12 Principle of phenotyping EVs using the EV Array. The EVs are produced by 
cells from a multitude of biological systems and released into the extracellular space such as 
culture medium used for in vitro cellular assays. From here, the only preparation of the sam-
ple prior to analysis is removal of the cellular components. Capture antibodies against target 
protein are printed onto microarray glass slides after which EVs displaying these target pro-
teins are captured onto the surface of the glass slide. In the current setup, a cocktail of 
biotinylated antibodies against CD9, CD63, and CD81 are used for the detection of the sur-
face-bound EVs. Fluorescent streptavidin is finally applied to create a detectable signal, 
which can be used to determine the relative amount of the target protein present on the EVs.  
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CHAPTER 3. MAIN FINDINGS OF THE 
PHD STUDY 
The research presented in this PhD thesis has focused on delineating some of the 
yet unknown aspects of HLA-DR in the context of T cells. In the following section, 
the original work of the thesis will be summarized and additional results not includ-
ed in Manuscript 1, 2, and 4 are presented (Appendix B1, B2, and B4). 
3.1. ENDOGENOUS EXPRESSION OF HLA-DR BY HUMAN T 
CELLS 
Before deriving any functional information about the presence of HLA-DR on hu-
man T cells, it was important to establish whether these cells express HLA-DR 
antigens endogenously. To investigate this, a correlation between the presence of 
the functional molecule, i.e. the HLA-DR protein, and the transcription of the HLA-
DR gene, determined by its mRNA, was performed (Manuscript 1). As a reference 
point/ positive control to the T cells, a simultaneous investigation of autologous B 
cells was included, due to their constitutive expression of HLA-DR. For the protein 
investigation, a subcellular distribution of HLA-DR was determined for CD3+ T 
and CD19+ B cells, distinguishing the HLA-DR found in the plasma membrane 
from that found in the intracellular compartment by using an optimized protocol for 
FCM (Manuscript 1 and section 2.1.1). The staining setup applied in this protocol 
was confirmed by confocal microscopy. The FCM investigation demonstrated that 
HLA-DR could be detected both at the cell surface and intracellularly in all CD19+ 
B cells, whereas only a fraction of the CD3+ T cells presented HLA-DR in the cell 
membrane and an even smaller part of these also contained HLA-DR in the cyto-
plasm (Table II, Manuscript 1 and Figure 13A). Moreover, the densities of HLA-
DR molecules found it these two cellular compartments were considerably higher 
for the B cells, as compared to the T cell levels. To relate the amount of HLA-DR 
presenting CD3+ T cells in peripheral blood to the two T cell lineages CD4+ and 
CD8+, it was demonstrated that these two populations each contribute with roughly 
50% to the total number of CD3+ HLA-DR mem+ cells (Figure 13B). Of the HLA-
DR mem+ CD4+ and CD8+, 23% and 1% also presented another T cell activation 
marker CD25, respectively. 
The transcriptional analysis of HLA-DRB1 expression was carried out with a novel 
qPCR assay targeting only one HLA-DRB1 allele; HLA-DRB1*03. The analyzed 
cells included CD4+ T cells and CD19+ B cells, isolated from peripheral blood. 
This analysis revealed that the CD19+ B cells express HLA-DRB1 (Figure 5, Manu-
script 1), while only negligible amount of mRNA for HLA-DRB1 could be detected 
in the isolated CD4+ T cells, which was likely to be explained by a monocyte con-
tamination. 




Figure 13 Schematic illustrations of the FCM results presented in Manuscript 1 (Ap-
pendix B1). APresence of HLA-DR in the membrane (HLA-DR mem) and intracellular 
compartment (HLA-DR IC) in human CD3+ T cells and CD19+ B cells were determined by 
FCM. As presented in Table II in Manuscript 1, HLA-DR mem can be detected on approxi-
mately 18% of CD3+ T cells in peripheral blood. Out of these, HLA-DR IC can be found in 
an additional 18% (double positive). Of all CD3+ T cells, 3% present HLA-DR IC, while all 
of these are HLA-DR mem+. This is in concordance with the positive correlation found 
between HLA-DR mem and HLA-DR IC (dot plot; from Figure 2, Manuscript 1). The gates 
in the plots denote the FMO boundaries for HLA-DR mem and HLA-DR IC. BIn order to 
relate the presence of HLA-DR on CD3+ T cells to the two T cell lineages, CD4+ and CD8+ 
T cells, an additional flow cytometric analysis was made. These results are also presented in 
Manuscript 1. Here, it was determined that of all CD3+ CD4+ T cells, 9% presented HLA-
DR mem, while this number was 18% for the CD3+ CD8+. Moreover, of these HLA-DR 
mem+ cells, 23% and 1% also co-expressed CD25, respectively. However, since CD4+ T 
cells constitute a larger part of the total CD3+ T cell population than CD8+ cells (CD4/CD8 
ratio is approximately 2 in peripheral blood of adults (118, 119)), the two cell T cell lineages 
each contribute roughly equally to the total amount of CD3+ HLA-DR+ T cells. n = 6. 
3.2. THE ROLE OF APCS FOR THE PRESENCE OF HLA-DR ON 
T CELLS 
To further characterize the presence of HLA-DR on T cells, the role of APCs in this 
context was addressed. It was demonstrated by FCM that the presence of HLA-DR 
could not be increased in the plasma membrane after mitogenic or antigen-like 
stimulated monocultures of CD4+ T cells. However, when APCs and accessory 
cells were present, both types of stimuli increased the presence of HLA-DR on the 
T cells (Figure 1, Manuscript 2). Furthermore, it was demonstrated that physical 
contact between APC and T cells is required to induce proliferation and increase the 
number of CD4+ HLA-DR+ T cells following an alloresponse (Figure 2 and 3, 
Manuscript 2).  
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3.3. EXTRACELLULAR VESICLES IN PROTEIN TRANSFER AND 
CELLULAR COMMUNICATION INVOLVES HLA-DR 
The phenotype of extracellular vesicles produced during alloresponses was charac-
terized, since a vesicle-mediated acquisition of HLA-DR by T cells is a possible 
mechanism for explaining the presence of HLA-DR on these cells (60, 79, 81). The 
EV phenotype was also determined to derive functional clues of the vesicle-
mediated cell communication and possible transfer of other proteins (Figure 5, 
Manuscript 2). A summary of the main findings for the EV phenotype is outlined in 
Table I below. Moreover, it was possible to demonstrate that the experimental de-
sign affects this EV phenotype (Figure 4, Manuscript 4). Hence, when studying 
contact-independent cell communication any effects of this should be determined. 
In addition to the EV phenotyping results from Manuscript 2, phenotyping of EVs 
from allogeneic MLCs of isolated CD4+ T cells and immature (iDC) or lipopoly-
saccharide (LPS)-matured DCs (mDC) derived from monocyte are also included. 
Furthermore, it was established that it is possible to detect a sufficient signal on the 
EV Array from only 20.000 DCs (data not shown). 
Table I Summary of the EV phenotype following contact-dependent and contact-
independent allogeneic MLCs (Manuscript 2). The EV Array was applied to phenotype 
EVs from the cell supernatants from the classic MLC and TW MLC. For the classic MLC, 
one value exists for each marker, since only one cell supernatant could be harvested. For the 
TW MLC, two values exist for each marker, since both stimulator cells (S) and responder 
cells (R) produced supernatants. Furthermore, observations from a similar analysis from 
MLCs of CD4+ T cells and immature or LPS-matured monocyte-derived dendritic (MDDCs; 
here denoted iDCs and mDCs) are also included. The values, which are being referred to, are 
the intensity of the log2 signals from the EV Array. (+) : minimal expression (0-1; 0 not 
included); + : low expression (value 1-2); + + : intermediate expression (value 3-4); + + +: 







Additional results: EVs 
from DC/CD4+ T cell MLC 
CD9 + + S & R: + + + 
Detected in all DC-containing 
cultures 
CD63  S: + ; R: (+) Detected only in co-cultures 
CD81 + + S: + + + ; R: + + Detected in all cell cultures 
CD82 + + S: + + + ; R: + + 
Detected in co-cultures and 
mDC monoculture 
CD3 + S: (+) Detected only in co-cultures 
CD11a + S & R: + Detected in all cell cultures 
ICAM-1 + S & R: (+) 
Detected in co-cultures and 
mDC monoculture 
HLA-DR + S: + ; R: (+) 
Detected in co-cultures and 
mDC monoculture 
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In addition to the EV phenotype, a cellular phenotyping of the included cells in the 
DC/CD4+ T cell MLCs was also performed. In Figure 14, the results of a selected 
panel of this cellular phenotyping can be seen. The markers included the tetraspanin 
family members CD9, CD63, and CD81, being key exosomal markers, along with a 
cell-specific marker; ICAM-1. For the CD4+ T cells, CD63 and in particular CD81 
was detected in these cells in both the mono- and co-cultures. For the DCs, while all 
three of the exosomal markers were present on DCs, regardless of their maturation 
state. As an interesting observation, the CD4+ T cells co-cultured with allogeneic 
iDCs were phenotypically positive for ICAM-1 after the MLC, which was not the 
case for the CD4+ T cells co-cultured with the mDCs (Figure 14). 
<
 
Figure 14 Cellular expression of the exosomal markers CD9, CD63, CD81, and ICAM-1 
by CD4+ T cells, immature DCs, and LPS-matured DCs. Following 6 days of co-culture 
(MLC) between isolated CD4+ T cells and allogeneic DCs (iDCs and mDCs), derived from 
monocytes, the expression of CD9, CD63, CD81, and ICAM-1 was determined by FCM. For 
the monocultures, the expression of these markers was evaluated after 48h of culturing. For 
CD63, the expression was only determined for the co-cultures of T cells and DCs. The ex-
pression of ICAM-1 was determined for all cell cultures except for T cell monocultures. 
Unpublished data. n = 1. 
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3.4. FUNCTIONAL PHENOTYPE OF HLA-DR+ CD4+ T CELLS 
In order to derive information about the possible functionality of the CD4+ T cell 
that present HLA-DR antigens, the phenotype of these cells was characterized by 
FCM (Figure 3B, Manuscript 2). Consequently, the presence of seven different cell 
surface markers was determined for the CD4+ HLA-DR+ responder T cells follow-
ing a 6 day-allogeneic MLC with or without physical contact between the stimula-
tor cells and the responder cells. A summary of this cellular phenotyping is shown 
in Table II, while the background for the choice of these markers can be seen in 
Table III. Furthermore, when comparing the HLA-DR- and the HLA-DR+ CD4+ 
subsets in both types of MLCs, the HLA-DR+ population was enriched in five out 
of the eight investigated markers, encompassing CD11a, CD25, CTLA-4, pro-
grammed death-1 (PD-1; CD279), and TNFRII.  
Table II The phenotype of the CD4+ HLA-DR+ responder T cells following a 6-day 
allogeneic MLC. The presence of seven markers were determined for the CD4+ HLA-DR+ 
responder T cells from contact-dependent and contact-independent MLCs (Figure 3B and 
3C, Manuscript 2). These markers are related to activation and regulation of T cells and to 
various effector functions (Table III). Selected markers were also investigated for the re-
sponder cell control (i.e. responder cells cultured without the presence of stimulator cells) to 
account for any culture-induced protein expression. Also, the baseline expression was evalu-
ated for each responder cell donor. For each cellular condition, the % positive events of 
parent gate  SEM is given. n = 3. 
* The CD4+ HLA-DR+ T cell population was initially gated from lymphocytes as shown in 
Figure 3A (Manuscript 2) after which the HLA-DR+ cells were determined using an FMO 











CD4+HLA-DR+* 20.5  2.4 13.3  3.3 18.0  1.3 6.9  2.0 
            CD11a+ 99.0  0.1 97.3  1.5 N/A 99.7  0.0 
            CD25+ 28.8  5.6 15.3  3.8 9.0  0.3 18.6  4.1 
            CD62L+ 69.3  11.2 72.4  6.4 N/A 32.7  0.8 
            CD127neg/low 44.3  4.8 39.7  4.8 N/A 54.2  1.8 
            CTLA-4+ 40.5  3.3 26.6  4.6 6.8  0.3 2.6  0.4 
            PD-1+ 65.2  8.1 52.1  10.4 N/A 42.8  4.0 
            TNFRII+ 51.9  0.9 38.0  5.4 N/A 24.6  3.5 
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Table III Notes about the seven cell surface markers included in the phenotyping of 
CD4+ HLA-DR+ responder cells following a 6-day allogeneic MLC. As presented in 
Table II and Manuscript 2 (Appendix B2), the CD4+ HLA-DR+ respoder T cells from the 
contact-dependent and –independent MLCs were phenotyped to obtain functional infor-
mation. The choice of the seven included markers was based on their involvement in effector 
T cell (Teff) and Treg activation and function, which is described in this table along with 




General notes Relation to activation and/or regulation of T 
cells 
CD11a The -chain of the integrin and adhe-
sion molecule, LFA-1. CD18 consti-
tutes the -chain. Major ligand: 
ICAM-1 on APCs (Figure 1, section 
1.1) (120, 121).  
LFA-1 is constitutively expressed by T cells, 
switching to a high-affinity state upon T cell 
activation (120). Has been associated with the 
uptake of MHCII-enriched, DC-derived 
exosomes by activated T cells (76).  
CD25 The -chain of the IL-2 receptor (IL2-
R), which also comprise a - and a -
chain (45). T cells can also produce 
IL-2, working both in an autocrine 
and paracrine way to drive prolifera-
tion and onset of effector functions in 
activated T cells (122) (Figure 1B). 
Upregulated transiently on activated T cells 
and is called a T cell activation marker (37, 38, 
123). CD4+ CD25+ T cells are often used to 
define a population of Tregs with suppressive 
activity (83, 124). The expression of CD25 on 
Tregs is more stable than for other T cells 
(123). 
CD62L Adhesion molecule. Also called L-
selectin. A homing receptor and a 
marker of T-cell development. Lig-
ands: Peripheral node adressins (125).  
Upon TCR-engagement, the expression of 
CD62L is down-regulated in T cells. A sup-
pressive capacity has been demonstrated for 
CD4+ CD25+ CD62L+ Tregs (125). Also, a 
group of CD4+ CD25+ HLA-DR+ CD62L+ 
Tregs exist in peripheral blood (83).  
CD127 The -chain of the IL-7R, which also 
comprises a -chain (shared with IL-
2R). Binding of IL-7 to IL-7R induces 
the transcription of anti-apototic genes 
and initiates proliferation and IL-2 
production in activated T cells (126).  
CD127neg/low expression is often used as an 
additional identification marker of CD4+ 
CD25+ FoxP3+ Tregs. However, for in vitro 
activated Tregs a higher CD127 expression has 
been observed (127). 
CTLA-
4 
Co-inhibitory molecule. Part of the 
CD28-family of proteins. Ligands: B7 
molecules (CD80, CD86) on APCs. 
Competes with the co-stimulatory 
molecule CD28 for their shared 
ligands (128). 
CTLA-4 is expressed shortly after T cell 
activation (94). For Teffs, CTLA-4 facilitates 
down-regulation of these cells. For Tregs, 
CTLA-4 is an important molecule related to 
the suppressive function of Tregs (129) (Man-
uscript 2, Discussion). 
PD-1 Co-inhibitory molecule. Part of the 
CD28 family. Ligands (PD-Ls): PD-
L1 and PD-L2 (similarity to B7 
molecules). PD-L1 is expressed in T 
cells, B cells, macrophages and DC. 
PD-L2 is expressed by activated 
macrophages and DCs (130). 
While T cells exclusively express CTLA-4, 
PD-1 expression can be induced in T cells, B 
cells, and myeloid cells (130). T cells can 
express both PD-1 and PD-L1. The PD-1-PD-
L1 pathway has been associated with both 
induction and maintenance of immunological 
tolerance (129, 130).  
TNFRII Co-stimulatory molecule. Mediates 
the function of the cytokine TNF 
(124).  
The expression of TNFRII is limited to lym-
phocytes. It enhances TCR-mediated signaling 
in T cells (131). TNFRII enriched in Tregs 
marks a highly suppressive cell population 
(124). 
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CHAPTER 4. DISCUSSION 
The overall aim of this PhD thesis was to elucidate the endogenous expression 
and/or acquisition of HLA-DR by human T cells. The incentive for such an investi-
gation is based on two factors; 1) It still remains unclear whether human T cells 
possess a HLA-DR expression machinery similar to that found in APCs and 2) if 
the functions of HLA-DR on APCs can be directly extrapolated to HLA-DR on T 
cells. The subsequent discussion of the theory and data included in this thesis is 
divided into three sections, which overall relates to the result sections found in 
Chapter 3, where the main findings of the PhD study are presented. 
4.1. FUNCTIONAL PHENOTYPE OF CD4+ HLA-DR+ T CELLS 
4.1.1. PRESENCE OF THE FUNCTIONAL HLA-DR PROTEIN 
Preceding any functional investigation, it was important to study the endogenous 
expression of HLA-DR by human T cells. To elucidate this matter from several 
angles, the presence of HLA-DR at the protein level was compared to the presence 
of HLA-DRB1 transcripts in human T and B cells, of which the latter served as a 
positive reference. The protein-based FCM analysis distinguished between the pres-
ence of HLA-DR in the membrane and in the intracellular compartment. This sepa-
ration was interesting, since it was hypothesized that if the cell contained the pro-
tein in both compartments it was likely that it possessed the ability to endogenously 
express HLA-DR antigens. Even though the reported percentages of HLA-DR+ T 
cells in peripheral blood vary somewhat from less than 5% (118, 119) to more than 
15% (132), it was expected to observe that only a part of the T cells present HLA-
DR in the cell membrane. The expectations correlated with the actual observations, 
however, it was also demonstrated that only a fraction of the CD3+ T cells with 
membrane-associated HLA-DR also contained HLA-DR in the intracellular com-
partment. In contrast, all CD19+ B cells were double positive for HLA-DR in the 
membrane and intracellular. Supposing that the aforementioned hypothesis is true, 
these collected results served as the first line of evidence indicating that human T 
cells in peripheral blood do not possess the same endogenous expression machinery 
of HLA-DR antigens as APCs. 
4.1.2. VALIDATION OF FLOW CYTOMETRIC ANALYSIS OF HLA-DR 
Before drawing any conclusions, it was important to validate the applied FCM 
analysis. The assay was based on targeting HLA-DR mem with one anti-HLA-DR 
followed by permeabilization of the cells and targeting HLA-DR IC with a second 
anti-HLA-DR. The assay was developed and evaluated through a number of steps, 
as demonstrated in section 2.1.1. First of all, the selected anti-HLA-DR antibody, 
L243, was chosen based on the fact that it selectively recognizes all mature and 
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correctly assembled HLA-DR molecules (12, 103-105). Several other anti-HLA-DR 
antibodies exist, although with different specificities. However, with L243, the 
HLA-DR identified on both types of lymphocytes would be a functional molecule, 
which in the context of T cells is very interesting, since it provides possible func-
tional clues aside from those related to expression.  
The entire setup also relied on the ability to separate between two HLA-DR signals; 
One originating from the membrane-associated protein and one originating from the 
intracellular compartment. This entailed two aspects. The first was to access the 
proteins in both cellular compartments, while the other was to have reliable signals 
from each compartment. Consequently, this demanded that the cells could be suffi-
ciently permeabilized without changing the relevant HLA-DR epitope. Moreover, 
the fluorophore-conjugated antibodies should also both be resilient to the fixation/ 
permeabilization process and be able to pass the permeabilized plasma membrane. 
The last and most important requirement was, however, that the membrane-
associated HLA-DR should be saturated with antibodies prior to targeting of the 
intracellular HLA-DR. Otherwise the HLA-DR mem would be underestimated, 
while HLA-DR IC would be overestimated. 
The intracellular compartment was accessed using a commercially available fixa-
tion and permeabilization kit, which had previously been used successfully for other 
applications in our laboratories. In addition, a simultaneous conservation of FSC 
and SSC properties of the cells was achieved, which was a desirable trait. In terms 
of fluorophores, FITC- and PE-conjugated L243 were initially tested in the staining 
setup. However, the results were non-optimal, most likely related to both size and 
chemical properties of these fluorophores (Figure 5, section 2.1.1). The results lead 
to the search for another fluorophore-combination, ending up with AF488 and 
AF647. Some of the attributes accounting for their choice included a high degree of 
photostability, their brightness, and their recommendation for intracellular staining. 
In addition, the emission spectra of the two fluorophores do not overlap, creating 
favorable conditions for separating the signals from HLA-DR in the two cellular 
compartments. The results presented in Manuscript 1 are based on using L243-
AF488 to target HLA-DR mem and L243-AF647 to stain HLA-DR IC (Table II, 
Manuscript 1; Figure 6, section 2.1.1). The validity of these results were tested from 
several angles with the main goal of ensuring that HLA-DR mem was saturated 
with antibody prior to targeting of HLA-DR IC. Accordingly, the most important 
control sample for this was the one in which the entire staining procedure was car-
ried out, only omitting the permeabilization of the cells. Hence, in this 
permeabilization control, no signal from the HLA-DR IC-targeting antibody should 
be the present if the HLA-DR mem molecules were saturated with the initially 
applied L243 antibody. As can be seen in Figure 6 (left panel), the HLA-DR IC 
signal in the permeabilization control (dashed line) separated from the specific 
HLA-DR IC signal for both CD3+ T cells and CD19+ B cells, when using the anti-
body combination presented in Manuscript 1. However, it was noted for the B cells 
that the HLA-DR IC signal in the permeabilization control was slightly elevated, 
when compared to the FMO control, though with no major overlap to the specific 
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HLA-DR IC signal. When switching the two antibodies, equal sized HLA-DR 
mem+ populations were identified, while more CD3+ HLA-DR IC+ T cells were 
found with the second combination of antibodies (Figure 6, right panel). Neverthe-
less, also a higher HLA-DR IC signal was detected in the permeabilization control 
with this antibody combination. In fact, the resolution between the specific HLA-
DR IC signal and that from the permeabilization control was reduced to 1/3 of that 
obtained with the antibody combination from Manuscript 1. Introducing a blocking 
step after the initial HLA-DR mem staining and increasing the incubation time did 
not reduce the HLA-DR IC signal in the permeabilization control (Figure 7). This 
was expected for the B cells, due to their Fc receptor expression (133); a protein, 
which is not expressed by T cells (134). Moreover, an increase in the amount of 
applied antibodies did not reduce the HLA-DR IC signal in the permeabilization 
control (Figure 9), thus indicating that this signal in the control sample was not due 
to HLA-DR mem antibody shortage. Also, the specific HLA-DR mem and HLA-
DR IC signals in the fully stained sample did not increase, when a larger amount of 
antibodies was applied. It was also demonstrated that fixation of the cells was re-
quired for maintaining the structural integrity of the cells prior to permeabilization 
and also to retain the antibody, which initially targeted HLA-DR mem (Figure 10). 
Finally, the staining procedure used in the FCM assay was validated using confocal 
microscopy (Figure 8). No HLA-DR IC signal was observed for the 
permeabilization control with this assay. Taken together, the results from the vali-
dation of the FCM assay indicates that the HLA-DR mem molecules were saturated 
prior to the staining for HLA-DR IC. Consequently, the supposed non-specific 
HLA-DR IC signal observed in the permeabilization control could either originate 
from fluorophores-related features or from cross-reactivity of the L243 antibody. It 
can be deduced from Figure 6 that the HLA-DR IC signal in the permeabilization 
control was greatest, when L243-AF488 was applied to target HLA-DR IC, as 
compared to the situation when L243-AF647 was used (as in Manuscript 1). When 
comparing this to the HLA-DR IC signal observed in the permeabilization control 
with L243-FITC (Figure 5, right panel), there is a similarity to the L243-AF488 
results. The FITC and AF488 molecules are similar in structure and have nearly 
identical emission spectra, so they are likely to share some properties. It has been 
demonstrated that FITC molecules under some conditions can bind non-specifically 
to intracellular components, making them very difficult to remove by washing 
(133). This may also be the case for AF488, however, in this study, this feature was 
not tested further. In relation to the specificity of L243, it has been shown that L243 
only recognizes a conformational epitope on the native HLA-DR protein (105). 
However, it has also been demonstrated that it recognizes a linear epitope on the N-
terminal of denatured HLA-DP (135), though not on the native HLA-DP molecule 
(105, 136). Both the fixation and permeabilization procedure applied to the cells in 
the presented FCM analysis may unintentionally have created some of these linear 
epitopes. Consequently, a low degree of cross-reactivity cannot be excluded. The 
application of an HLA-DP-specific antibody or a pre-incubation with the relevant 
peptide could be interesting additional tests not already included in the present PhD 
study. Also, the inclusion of an anti-HLA-DR of a different clone than L243 could 
also have been performed. Nevertheless, for the results presented in Manuscript 1, 
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the combination of L243-AF488 to stain HLA-DR mem and L243-AF647 to target 
HLA-DR IC yielded the best resolution of the specific and non-specific signals 
(Figure 6). Based on the validation tests carried out and with the stringent gating 
protocol applied, this antibody combination provides reliable results for a flow 
cytometric evaluation of HLA-DR mem and HLA-DR IC in CD3+ T cells and 
CD19+ B cells from peripheral blood. 
4.1.3. TRANSCRIPTION OF HLA-DR MRNA 
The presence of the HLA-DR protein on the surface of human T cells has been 
observed for many decades and has also been evaluated in this PhD study, as de-
scribed above. However, in the context of this thesis, the presence of the protein 
was correlated to the transcription of its mRNA, as a way of further investigating 
the endogenous expression of HLA-DR by T cells. In essence, the transcriptional 
analysis was performed to confirm or deny that the protein found on the surface of 
T cells could be explained by an active protein synthesis. A novel qPCR assay tar-
geting the HLA-DRB1*03 allele was developed for this purpose. While the main 
focus of the protein analysis was the CD3+ T cells, the qPCR analysis was centered 
on CD4 lineage of the CD3+ T cells. Consequently, the basis of this analysis was a 
T cell population in which approximately 9% presented HLA-DR in the membrane 
(Figure 13B and Manuscript 1). In terms of correlating the results from the protein 
analysis of HLA-DR mem and HLA-DR IC and those from the qPCR assay, it is 
important to remember one aspect. While the applied L243 antibody targeted all 
functional HLA-DR -heterodimers (HLA-DRA in complex with either HLA-
DRB1, -DRB3, DRB4, or DRB5; Figure 2A, section 1.2.2), the qPCR assay fo-
cused on the expression of only one of the functional -chains; HLA-DRB1. All 
humans carry the HLA-DRB1 gene on their chromosome 6, while the genes encod-
ing the remaining three functional -chains are found in a varying degree, depend-
ing on the haplotype (section 1.2.2). With the applied FCM analysis it was not pos-
sible to determine which -chain(s) was present on the HLA-DR+ T cells. Howev-
er, if the T cells can express HLA-DR endogenously, it would be very unlikely that 
they exclusively expressed all other -chain genes than HLA-DRB1, since one 
haplogroup (DR8) only contain the HLA-DRB1 gene (Figure 2B, section 1.2.2). 
Therefore, it can be reasonably expected that HLA-DRB1 mRNA would be detected 
in T cells if these cells express the HLA-DR proteins found on their surface. With 
the applied transcriptional analysis it was found that B cells clearly encompassed an 
active transcription of HLA-DRB1, while this did not seem to be the case for the 
CD4+ T cells (Figure 6A, Manuscript 1). The minimal amounts of mRNA for HLA-
DRB1*03 detected in the isolated CD4+ T cells was very likely to be caused by a 
contamination of monocytes, which are known to express HLA-DR (137) and to 
some extent CD4 (138). Therefore, these cells would be isolated with the applied 
isolation kit, which positively selected CD4 expressing cells. It was confirmed by 
FCM, that approximately 1% of CD14+ monocytes was present in the isolated 
CD4+ T cell population. Similar to the evaluation of contaminating B cells by 
qPCR of CD19 mRNA (Figure 6B, Manuscript 1), a quantification of CD14 mRNA 
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could further estimate the extent of this problem. Furthermore, including an incuba-
tion step between the cell isolation and the qPCR could minimize the monocyte 
contamination, since these cells adhere to cell culture plastic (139), thus removing 
them from the non-adherent CD4+ T cells. 
4.1.4. INDUCTION OF HLA-DR EXPRESSION IN HUMAN T CELLS 
As a third investigation of the endogenous expression of HLA-DR antigens by 
human T cells, it was observed that isolated CD4+ T cells does not possess the 
ability to up-regulate the presence of HLA-DR antigens upon stimulation with ei-
ther PHA or anti-CD3/anti-CD28 (Figure 1, Manuscript 2). In contrast, the presence 
of HLA-DR increased on stimulated CD4+ T cells while being a part of a PBMC 
population. Even though, this latter investigation does not provide direct proof of a 
non-existing endogenous expression of HLA-DR antigens by human T cells, it 
underlines the apparent differences in the underlying mechanisms explaining the 
presence of HLA-DR on T cell, when compared to APCs. This further implies that 
it is difficult to draw any immediate conclusions of HLA-DR on T cells, as we 
know it from APCs. Nonetheless, the observations about the induction of HLA-DR 
protein expression indicate an important role of APCs, and perhaps accessory cells, 
in this context (further addressed in section 4.2). The observed differences between 
T cells and APC, in the context of HLA-DR, were also apparent from both the FCM 
analysis of HLA-DR mem and HLA-DR IC and from the transcriptional analysis of 
HLA-DRB1 mRNA (Manuscript 1).  
With the collected investigation about the presence of HLA-DR on human T cells 
presented in this PhD thesis, it has been made very probable that human CD4+ T 
cells in peripheral blood do not express HLA-DR endogenously. As a natural next 
step, this trend should be investigated with similar protein and transcript analyses in 
T cells, which have been activated in vitro, like the isolated CD4+ T cells subjected 
to PHA or anti-CD3/anti-CD28 stimulation. Also an investigation of T cells from 
other relevant tissues, such as the palatine tonsils (140), could improve the under-
standing of HLA-DR on T cells. 
4.2. ROLE OF APC AND VESICLES IN T CELL ACTIVATION 
AND FUNCTION 
To investigate the role of APCs in relation to HLA-DR on T cells, a number of 
experiments were carried out. Here, the proliferation and functional phenotype of 
the HLA-DR+ CD4+ T cells was characterized following an allogeneic MLC in 
which the responder and stimulator cells were co-cultured with or without physical 
contact. Furthermore, the phenotype of the EVs produced during the MLCs was 
characterized, in order to derive information of the importance of vesicle-mediated 
communication and possible transfer of HLA-DR from APCs to T cells. It was 
demonstrated and confirmed (61, 79) that physical contact is required to observe an 
increase in the presence of HLA-DR on CD4+ T cells following an alloresponse. In 
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addition, the proliferation of responder cells was contact-dependent. The two types 
of MLCs produced distinct vesicle populations, indicating a potential difference in 
the functionality of intercellular communication facilitated by vesicles. Although 
the overall EV phenotypes were quite heterogeneous, there were contact-dependent 
differences in the levels of the detected HLA-DR bearing EVs. Interestingly, the 
majority of these EVs were detected in the transwell chamber holding the irradiated 
stimulator cells. Additionally, EVs from this chamber also contained high levels of 
CD9 and CD81, thereby indicating that the stimulator cells are capable of produc-
ing EVs and that these vesicles can contain HLA-DR. Moreover, it has been ob-
served that HLA-DR+ EVs are produced by DCs in monoculture and also during 
DC:T cells co-cultures, but not by isolated CD4+ T cells (Table I). This could indi-
cate that the HLA-DR-bearing vesicles observed from the stimulator cells in the 
transwell chamber are produced by the APCs in this cell population. Since it has 
been demonstrated that activated T cells can acquire such vesicles (76), a priming 
of the responder T cells prior to the MLC may change the entire outcome of such a 
contact-independent alloresponse. Nevertheless, this remains to be investigated. 
However, with the results presented in this thesis, it is not possible to unambiguous-
ly determine that vesicle-mediated cellular communication is important for the 
presence of HLA-DR on T cells.  
4.2.1. EV PHENOTYPE AS AN INDICATOR OF CELLULAR AND ENVI-
RONMENTAL STRESS 
In line with priming of T cells, an additional observation from this PhD study indi-
cates an importance of the inflammatory status of the T cell milieu. This relates to 
the adhesion molecule ICAM-1, which is normally expressed by APCs and has an 
important role in establishing the synapse formed between T cell and APC (Figure 
1, section 1.1). As noted in Table I (section 3.3), ICAM-1 was detected on EVs 
from co-cultures of both CD4+ T cells and iDCs and mDCs and also from the mon-
ocultures of mDCs. However, ICAM-1 was not detected on EVs from monocultures 
of either CD4+ T cell or iDCs, thus indicating both cell- and maturation-state-
specific differences for this protein on EVs. When relating these EV phenotypes to 
the cellular phenotypes, a different pattern occurred (Figure 14). Here, ICAM-1 was 
highly expressed by DCs in monoculture, which was interesting since no ICAM-1-
presenting EVs were detected for the iDC monoculture. Moreover, ICAM-1 was 
present on both CD4+ T cells and iDCs after co-culture, while ICAM-1 was down-
regulated on mDCs and absent on the co-cultured CD4+ T cells. Whether or not 
ICAM-1 was transferred from the iDCs to the CD4+ T cells can only be speculated 
at the moment. However, the phenomenon is interesting. To further characterize 
any vesicle-mediated transfer, an indirect way of measuring this is to investigate the 
possible transfer of APC-derived proteins, including HLA-DR, to T cells by 
trogocytosis. Such an investigation could be facilitated with a FCM analysis de-
scribed and employed in other studies (141-143). Nonetheless, the observations 
with ICAM-1 illustrates two points; First, different inflammatory milieus can create 
different cellular and EV phenotypes. This suggests that the cells are capable of 
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adapting and differentiating both the cellular and the vesicular response relative to 
the present situation. This is ultimately bound to have an impact of the functional 
outcomes. Second, EVs are not complete mirror images of the parent cell, which is 
otherwise a general assumption in the EV research field.  
Aside from the observation about ICAM-1, an interesting notion about CD3 can 
also be found. From Table I it can be deduced that CD3 was detected on EVs from 
the contact-dependent MLC and in the co-cultures of CD4+ T cells and both iDCs 
and mDCs. Also, a very weak signal was detected for the EVs from the stimulator 
cells in the contact-independent MLC. In contrast, CD3 was not detected on EVs 
from the responder cells of the contact-independent MLC and from the CD4+ T cell 
monocultures; a control cell sample from the CD4+ T-DC experiments. Hence, it 
could seem as though the T cells, which assumingly produce the CD3-presenting 
EVs, only produce these, when a physical interaction between T cells and APC can 
be formed and an activation of the T cells occurs. This can be correlated with the 
observation that T cells down-regulate CD3 (TCR) upon activation (144, 145) and 
that this process has been associated with the production of CD3-enriched EVs, as a 
tool of the down-regulation (73). This yet again correlates with the results found in 
Figure 2 in Manuscript 2, which demonstrates that cellular proliferation, which is an 
indication of activation, only occurs in the contact-dependent MLC. In summary, 
this once again demonstrates how the cells are able to adjust the vesicle-associated 
proteins according to a given situation and also points to EVs having numerous 
functionalities, which may not all be associated with communication.  
In relation to the more general EV/ exosome markers, here including CD9, CD63, 
CD81, and CD82 (Table I), all the included experiments indicate that these markers 
are ubiquitously present on the analyzed EVs, except for CD63. In general, CD63 is 
the most applied exosome marker, probably due to its initial discovery and descrip-
tion in the 1990s (66, 146). However, similar to the observation made here, the 
presence of CD63 on EVs from plasma has been found to be far more heterogene-
ous, when compared to CD9 and CD81 (116). Nevertheless, CD63 is still often 
found in relation to EVs, thus indicating a role in this context. This role could likely 
be more specific than the one for CD9 and CD81, thus making CD63 a poor general 
EV marker. The EV phenotyping presented in Manuscript 2 (Appendix B2) includ-
ed a panel of 25 markers, comprising both the general EV markers as well as a 
selection of cell-specific markers. With these markers, several contact-dependent 
differences were identified. However, only a fraction of these potential differences 
has probably been identified. Here, a total protein profile of the EV proteins, ob-
tained by proteomics, would aid in selecting new candidate antibodies for a second 
round of EV Array analysis and pinpoint interesting targets in an extended cellular 
phenotyping as well. Mass spectrometry has been deemed a powerful method for 
such a profiling of EV proteins and has demonstrated the heterogeneity of EV pro-
teins, even though particular protein subsets also seem to be enriched in these vesi-
cles (66, 147, 148). This underlines the complexity of EV-based cellular communi-
cation and unraveling its roles in physiological and pathophysiological scenarios are 
still in its infancy. 
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4.3. FUNCTIONALITY OF HLA-DR ON T CELLS 
An essential aspect of HLA-DR on T cells is the functional consequences of this 
phenomenon. It is becoming increasingly evident that HLA-DR is probably more 
than an activation marker for T cells and may provide the T cell with APC-like 
functions. Currently, the role of such T-APCs has mainly been associated with 
down-regulating the activity of the responder T cell (3, 82, 83). However, it is also 
possible that T-APCs can activate other T cells (61, 62) (Figure 15). In the present 
PhD study, it was attempted to add information to the functionality of HLA-DR-
presenting CD4+ T cells by characterizing the phenotype of these cells following 
contact-dependent and -independent allogeneic MLCs. The phenotyping included 
seven cell surface markers related to T cell activation and regulation (Table II and 
III, section 3.4). With the obtained results it is obvious that the CD4+ HLA-DR+ T 
cells from each of the MLCs are quite heterogeneous cell populations. This was not 
unexpected since the CD4+ HLA-DR+ responder T cells were not a clearly defined 
population, but overlapped with the CD4+ HLA-DR- T cells. This feature was also 
observed for T cells in peripheral blood (both for the entire CD3+ population and 
within each T cell lineage; Figure 13 and Manuscript 1). However, two observa-
tions emerged from the phenotyping characterization of the responder T cells in the 
MLCs. First, practically all the investigated markers were enriched in the CD4+ 
HLA-DR+ responder T cells from the contact-dependent MLC, compared to the 
contact-independent counterpart (Figure 3C, Manuscript 2). Secondly, several of 
the markers were predominantly expressed in the HLA-DR-presenting CD3+ CD4+ 
subsets of the MLCs than in the corresponding HLA-DR- subsets (Figure 4, Manu-
script 4). Most noteworthy was the four differentially expressed markers, which 
separated the CD4+ HLA-DR+ T cells from the two types of MLCs; CD25, CTLA-
4, PD-1, and TNFRII (Table II, section 3.4; Figure 3B, Manuscript 2). As previous-
ly mentioned, all of these were present to the greatest extent in the contact-
dependent MLC. Both effector T cells (Teffs) and Tregs can express all of these 
proteins, though with different functional outcomes. Hence, it is difficult to make 
any immediate conclusions to determine if the CD4+ HLA-DR+ belongs to either 
of the two T cells subsets. A simultaneous expression analysis of the Treg-
associated FoxP3 transcription factor (88) could have aided to solve this issue, 
though some controversy about FoxP3 as Treg identifier also exists (149).  
4.3.1. POSSIBLE ROLES OF HLA-DR-PRESENTING T-APCS/TREGS 
It is, nevertheless, possible to deduce some functional clues about the CD4+ HLA-
DR+ T cells based on the results of the present study, particularly focusing on 
CTLA-4 and PD-1. Both CTLA-4 and PD-1 are co-inhibitory molecules involved in 
down-regulation of T cell activity, consequently involved in induction and mainte-
nance of immune tolerance and homeostasis (Table III, section 3.4) (129, 150). 
Moreover, it has been demonstrated that blocking HLA-DR on Treg impairs their 
suppressive activity (151), while blocking CTLA-4 and PD-1 reduces Treg activity 
in melanoma (152). This suggests a link between HLA-DR, CTLA-4, PD-1, and 
Tregs and indicates a probable role for these cells in tolerance induction. Addition-
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ally, a correlation between PD-1 and TNFRII was detected for the CD4+ HLA-DR+ 
T cells from both MLCs (Figure 4A, Manuscript 2). A suppressive activity of CD4+ 
CD25+ TNFRII+ HLA-DR+ T cells has previously been determined and these cells 
also presented high levels of CTLA-4 (88). Taken together, the simultaneous pres-
ence of HLA-DR, CD25, CTLA-4, PD-1, and TNFRII on CD4+ T cells could very 
likely identify a subset of cells with suppressive activity. T cells with such regulato-
ry functions are frequently known as Tregs and not T-APCs, since the investigated 
mechanisms of suppression most often do not include any related to antigen-
specificity. However, this does not exclude a possible role of antigen-specific sup-
pression by Tregs/T-APCs. The Treg subset is a heterogeneous group of cells, 
which can be quite difficult to categorize, since their functional phenotypes depend 
on several factors, including cell lineage (natural versus induced) and status of the 
surrounding environment (153-155). Hence, these cells can seemingly be tailored 
for the situation at hand. This feature correlates with the presented results from the 
contact-dependent and –independent MLCs, which produced different CD4+ HLA-
DR+ T cell subsets, though both with a suppressive molecular profile (Figure 3, 
Manuscript 2). However, any suppressive activity of the investigated CD4+ HLA-
DR+ responder T cells remains to be established. Moreover, an investigation of the 
co-stimulatory molecules CD80 and CD86, which are two APC-related co-
stimulatory molecules (section 1.3.3), would further elucidate their putative T-
APCs/Tregs function.  
4.4. IMPLICATIONS 
Delineating all aspects of HLA-DR is pivotal, since HLA-DR in essence controls 
the specificity of the adaptive immune system. Despite the longstanding observa-
tion, HLA-DR on T cells is still a topic of debate, containing several contradictory 
opinions and results. The results presented in this PhD thesis indicates that CD4+ T 
cells in peripheral blood do not possess an active, endogenous expression of the 
HLA-DR protein. Moreover, APCs have an important role in the presence of HLA-
DR on CD4+ T cells, since an increase in CD4+ HLA-DR+ cells can only be ob-
served, when T:APC interaction can occur. By combining the expression results 
with those from investigating the role of APCs, it is warranted to hypothesize that a 
major mechanism accounting for the HLA-DR on CD4+ T cells could be a molecu-
lar transfer from APCs. On a general note, this phenomenon of intercellular transfer 
of molecules adds another layer of complexity to the function of the immune sys-
tem and it could possibly necessitate a paradigm shift in relation to immune 
regulationterms of how this system is regulated. The work of this PhD thesis also 
points to a down-regulatory function of HLA-DR-presenting T cells. A likely role 
of these HLA-DR+ T cells is participating in the induction of peripheral tolerance, 
either to limit autoreactive T cells, with a consequent implication in autoimmunity, 
or to limit clonal expansion of Teffs, which could serve to terminate an ongoing 
immune response (Figure 15). Aside from the basic mechanisms of the immune 
system, understanding the function and dynamics of HLA-DR+ T cells could be 
used to expand the knowledge of how cancer cells escape immune recognition, 
which may identify targets of new therapeutic strategies.  
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Figure 15 Functional consequences of HLA-DR on T cells. As described with the existing 
literature and the experimental results of PhD thesis, HLA-DR on T cells may play a yet 
unknown role in regulating the immune system. The possible effects of such a role can be 
categorized as being either immunostimulatory (positive regulation) or immunosuppressive 
(negative regulation). The positive regulation involves HLA-DR+ T cells acting as T-APCs 
with a consequent possibility to activate other T cells upon interaction. This requires the 
simultaneous presence of the antigen-specific and co-stimulatory signals (also see Figure 1). 
The function of an HLA-DR+ T-APCs could be to expand the APC repertoire, thereby am-
plifying an immune response. Moreover, acquisition of HLA-DR from APCs may limit the 
amount of cognate peptide-HLA-DR complexes available in a secondary immune response, 
thus favoring the maturation of high-affinity memory T cells (156, 157). As previously men-
tioned, HLA-DR on T cells has mainly been associated with down-regulatory activity and the 
induction of tolerance or anergy in other T cells. Consequently, the proposed effects of such 
a negative regulation includes limiting clonal expansion by ligation of the TCR without a 
concurrent co-stimulatory signal (Figure 1). This could serve to terminate an ongoing im-
mune reaction. Moreover, a similar scenario could limit autoreactive T cells. In addition, the 
simultaneous presence of co-inhibitory molecules, such as PD-1, could also negatively regu-
late the responder T cell. Finally, an acquisition of HLA-DR by T cells from an APC could 
make HLA-DR inaccessible for another interaction between a naïve T cell and the APC, 
causing a limit to the degree of T cell activation. 
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CHAPTER 5. FUTURE WORK 
The work presented in this PhD thesis has investigated several aspects of HLA-DR 
on human T cells, indicating the absence of an endogenous HLA-DR expression 
and a down-regulatory function of HLA-DR+ CD4+ T cells. To support and elabo-
rate on these results, a number of additional investigations could be carried out: 
1. To investigate the transfer of HLA-DR from APCs to T cells, the use of antibod-
ies specific for the protein products of particular HLA-DR alleles could be applied. 
These antibodies are available at the Department of Clinical Immunology, Aalborg 
University Hospital, Denmark, and their specificities have already been tested. With 
the antibodies it will hopefully be possible to determine whether the HLA-DR 
found on responder cells following an allogeneic MLC is the HLA-DR type of the 
responder cell or that of the stimulator cell. This would be indicative of an endoge-
nous protein expression or a molecular acquisition, respectively. Subsequently, a 
proteomic analysis of the HLA-DR found on the responder cells, using mass spec-
trometry, could further validate the findings from this investigation. This setup is 
currently being optimized at the Laboratory for Medical Mass Spectrometry, Aal-
borg University, Denmark. 
2. Since proliferation is expected for the CD4+ T cells stimulated with PHA or anti-
CD3/anti-CD28 (Manuscript 2), it would be reasonable to include this experimental 
outcome in the future work. Moreover, it would be relevant to include an experi-
ment in which the cells were stimulated for at least three days in order to ensure that 
the observations presented in Manuscript 2 (Figure 1) is not caused by a delay in 
the expression of HLA-DR, since HLA-DR typically is used as a late activation 
marker (section 1.3). 
3. To further evaluate the similarities of APCs and T-APCs, it would be interesting 
to use flow cytometry and fluorescence microscopy to investigate the co-
expression/ co-localization of HLA-DR and Ii in T cells. Since Ii is an important 
chaperone for HLA-DR in APCs, a similar role could be expected in T cells if these 
cells possess the ability to process and present antigens. In addition, the investiga-
tion of a possible transfer/presence of the co-stimulatory molecules CD80 and 
CD86 would increase the knowledge of the APC function of HLA-DR+ T cells.  
4. An evaluation of the suppressive activity of HLA-DR+ T cells would expand the 
findings from the phenotyping of these cells into a functional context. Classically, 
this activity is measured by following the proliferation of the responder cells (158), 
as described in Manuscript 2. With the results presented in this thesis, it would be 
natural to investigate the possible role of PD-1 in this suppression. Interestingly, it 
has also been demonstrated vesicle-mediated suppression by Tregs can occur (159), 
warranting EV analysis in the context of a functional analysis of HLA-DR present-
ing T cells. 
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5. Since it was shown that CD4+ T cells in peripheral blood most likely do not 
express the HLA-DR protein found in their membrane, it would be interesting to 
see if this was also valid for both in vivo and in vitro activated T cells. Hence, the 
correlation between HLA-DR mem/HLA-DR IC and HLA-DRB1*03 mRNA (as in 
Manuscript 1) for activated T cells could considerably improve the understanding 
of HLA-DR on T cells and its validity as a T cell activation marker.  
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The human major histocompatibility complex class II (MHCII) isotype HLA-DR is 
an activation marker for T cells. However, whether an endogenous protein expres-
sion or a molecular acquisition accounts for the presence of HLA-DR on T cells 
remains undetermined and controversial. 
Results 
Using human T cells from peripheral blood, we compared several aspects of the 
presence of the HLA-DR protein to the presence of mRNA for HLA-DRB1. Using 
an optimized flow cytometry setup, we determined that the HLA-DR observed on 
CD4+ T cells is almost exclusively membrane-associated, while for autologous 
CD19+ B cells, the protein could be located in the membrane as well as in the cyto-
plasm. In addition, negligible expression levels of HLA-DRB1 were found in CD4+ 
T cells, using an allele-specific qPCR assay. Finally, the presence of HLA-DR was 
not confined to activated CD4+ and CD8+ T cells, as evaluated by the co-expression 
of CD25.  
Conclusions 
The functional role of the HLA-DR molecule on T cells remains enigmatic, howev-
er, this study presents evidence showing that HLA-DR on CD4+ T cells in peripher-
al blood could not be explained by the simultaneous presence of an endogenous 
protein synthesis. Although an inducible endogenous protein expression cannot be 
excluded, our findings suggest a more pronounced role for HLA-DR on T cells than 
simply as an activation marker.   
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Background 
It has been observed for more than four decades that T cells in peripheral blood can 
present MHC class II (MHCII) molecules on their surface and that the number of 
MHCII+ T cells increases upon activation [1-4]. In line with this, one of the three 
human MHCII isotypes, called HLA-DR, is frequently used as a T cell activation 
marker along with other molecules, such as CD69 and CD25 [5-8]. Nonetheless, the 
functional role and significance of HLA-DR on human T cells is not fully deter-
mined and the unequivocal confirmation of an endogenous expression or a protein 
acquisition from other immune cells is absent. The constitutive expression of HLA-
DR is limited to a few cell types, collectively called APCs [9, 10]. These cells use 
HLA-DR to present antigenic peptides to CD4+ T cells and consequently HLA-DR 
is involved in many facets of immune homeostasis such as T cell activation, periph-
eral tolerance, and induction of apoptosis [11]. 
Since the first observations of HLA-DR on T cells in the late 1970’s, a number of 
studies have investigated aspects of the HLA-DR molecule in this particular context. 
Though still a subject of discussion, the general understanding is that the presence of 
this protein complex can be explained by either of two scenarios. The first involves 
an inducible de novo, endogenous protein synthesis, while the other encompasses a 
molecular acquisition from adjacent cells by currently unverified mechanisms. The 
studies supporting the former explanation have investigated several of the compo-
nents involved in HLA-DR expression, transport, and function, including lysosomal 
proteases [12], antigen presentation [13, 14], and engagement of CIITA [9, 12, 15], 
which is reported as the master regulator of HLA-DR expression [16-19]. Mouse T 
cells do not produce MHCII, which has been explained by a lack of CIITA expres-
sion [20]. However, even when CIITA is absent, MHCII expression is still observed 
for several cell types [21, 22]. The second phenomenon explaining HLA-DR on T 
cells is investigated in several other studies, demonstrating a transfer of a fully func-
tional protein complex from APCs [23, 24]. In accordance with this, the MHCII 
observed on mouse T cells is a result of an acquisition from APCs [25-27]. In addi-
tion, a number of studies have found that activated rat T cells can both synthesize 
and absorb MHCII molecules from adjacent cells [28-30]. The transfer of HLA-DR 
to human T cells has also been reported [31, 32], but a possible link between this 
acquisition and a potential endogenous expression of HLA-DR remains to be inves-
tigated. 
Our study aimed to investigate the presence of HLA-DR in human T cells from two 
perspectives: At the protein level and at the transcriptional level. This was carried 
out to further elucidate whether an endogenous expression of HLA-DR is present in 
human CD4+ T cells in peripheral blood from healthy individuals. For the protein 
analysis, a stringent flow cytometry setup was applied to allow for unbiased identifi-
cation of HLA-DR+ cells. A novel qPCR assay was developed to investigate the 
mRNA expression of a specific HLA-DRB1 allele, thus minimizing the homology 
issues otherwise associated with analysis the HLA-DR genes. Though an inducible, 
endogenous expression cannot be excluded, the cumulative results show that HLA-
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DR on CD4+ T cell in peripheral blood could not be explained by a concurrent pres-




Identification of HLA-DR in the membrane and intracellular compartment of 
CD3+ T cells 
We initially wanted to investigate the cellular distribution of the HLA-DR antigen 
both in the membrane (HLA-DR mem) and in the intracellular space (HLA-DR IC) 
of CD3+ T cells by using flow cytometry. An initial staining of HLA-DR mem was 
followed by fixation, permeabilization of the cellular membrane, and a secondary 
staining of HLA-DR IC. To separate the two HLA-DR signals, two anti-HLA-DR 
antibodies of the same clone, but with different fluorophores-conjugations, were 
applied (anti-HLA-DR mem AF488; anti-HLA-DR IC AF647). The distribution of 
HLA-DR mem and HLA-DR IC in CD3+T cells was compared to the distribution in 
CD19+ B cells, since the HLA-DR expression pattern in this APC is well character-
ized. To identify the HLA-DR mem and HLA-DR IC positive events, the Fluores-
cence Minus One (FMO)[33] approach was applied (Figure 1). This approach is 
very useful for resolving weakly stained cells in multicolor panels in flow cytometry 
analyses [34, 35]. The applied FMO included a tube containing all markers and 
replacing the HLA-DR antibody of interest with an isotype control antibody. In this 
way, the HLA-DR single and double positive events could be determined, as exem-
plified in Figure 1. 
Dimorphic distribution of HLA-DR in the membrane and intracellular com-
partment of CD3+ T cells and CD19+ B cells 
Based on the abovementioned staining and gating strategy, we identified the fraction 
of CD3+ T cells from peripheral blood in which HLA-DR could be found in either 
the membrane or the intracellular compartment or in both. An identical procedure 
was carried out for autologous CD19+ B cells, to ensure a positive reference. A 
summary of these findings can be found in Table 2. From here it can be seen that the 
presence of HLA-DR mem on CD3+ T cells and CD19+ B cells differed significant-
ly in terms of the percent-wise distribution. Moreover, the corresponding median 
fluorescence intensity (MFI) values were also markedly different with a nearly 14 
times greater MFI value detected for the CD19+ B cells than the equivalent value for 
the CD3+ T cells. A similar tendency was also observed for the presence of HLA-
DR IC. Here, the MFI for HLA-DR IC in the CD19+ B cells was approximately 5.5-
fold higher compared to the MFI for the CD3+ T cells. To investigate whether the T 
cells, which presented membrane-associated HLA-DR to the greatest extent, also 
carried the largest amount of HLA-DR IC, a correlation for HLA-DR in the two 
compartments was made. This revealed that a positive correlation between these two 
proteins existed, both for CD3+ T cells and CD19+ B cells (Figure 2), with corre-
sponding Pearson correlation coefficients of 0.73  0.03 and 0.41  0.03, respective-
ly. 
To validate the findings for HLA-DR mem and HLA-DR IC it was important to 
ensure than an initial saturation of HLA-DR mem had been obtained with the ap-
plied antibody. Hence, a saturation control was included in which all antibodies and 
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staining conditions were applied, only omitting the permeabilization agent. Conse-
quently, the HLA-DR IC signal should be absent in this sample if both the HLA-DR 
mem staining had saturated all membrane-associated HLA-DR and no HLA-DR IC 
antibody entered the cell. As a general feature, a small HLA-DR IC signal could be 
detected in the saturation control for both the CD3+ HLA-DR mem+ T cells and 
CD19+ HLA-DR mem+ B cells (Figure 3). However, for the CD3+ T cells, this 
signal never surpassed the HLA-DR IC signal from the fully stained sample (Figure 
3B) or the one in the FMO control (Figure 3A). For the CD19+ B cells, the HLA-
DR IC signal in the saturation control was slightly greater than the one detected in 
the FMO control (Figure 3A), but was sufficiently separated from the HLA-DR IC 
signal observed for the fully stained sample (Figure 3A and 3B). A doubling of the 
applied amount of both HLA-DR antibodies did not increase or decrease the record-
ed intensities and cellular distributions of these markers (data not shown).  
As a final investigation, the antibody staining procedure applied in the flow 
cytometric analysis was tested in a confocal microscopy setting. The purpose of this 
qualitative analysis was to visualize the separation of the fluorescence signals ob-
tained, when targeting HLA-DR mem and HLA-DR IC with two different anti-
HLA-DR antibodies. In contrast to the flow cytometric analysis, in which CD3+ T 
cells and CD19+ B cells from peripheral blood were the target cells, isolated CD4+ 
T cells and CD19+ B cells were used for the confocal microscopy investigation. 
With these cells it was shown that CD4+ T cells presenting HLA-DR mem could be 
identified (Figure 4, top panel). In contrast, CD4+ T cells presenting both HLA-DR 
mem and HLA-DR IC were almost absent (Additional Figure 1). To ensure that the 
observed HLA-DR signals in the CD4+ T cell population were not due to contami-
nating APCs, such as monocytes, the identification of these T cells included a CD3 
antibody. For the CD19+ B cells, the HLA-DR proteins were present in both the 
membrane and intracellular compartment of the entire cell population (Figure 4, 
bottom panel). The purity of the isolated CD4+ T cells and CD19+ B cells was 
97.6%  2.2 and 96.6%  0.4, respectively, as determined by flow cytometry (n=2; 
data not shown).  
Relative contribution of CD4+ and CD8+ T cells to CD3+ HLA-DR mem+ T 
cell subset 
In addition to the results about the presence of HLA-DR mem and HLA-DR IC for 
CD3+ T cells, it was investigated to which extent CD4+ and CD8+ T cells each 
contribute to the CD3+ HLA-DR mem+ subset. Accordingly, CD3+ CD4+ HLA-
DR mem+ and CD3+ CD8+ HLA-DR mem+ T cells (hereafter referred to as CD4+ 
HLA-DR mem+ and CD8+ HLA-DR mem+ T cells) were identified in a flow 
cytometric analysis of PBMCs. The presence of HLA-DR mem was evaluated for 
these cells (Figure 5A, left panel) by using the FMO approach described in Figure 1. 
This resulted in the detection of 8.9%  1.6 CD4+ HLA-DR mem+ T cells and 
18.7%  3.1 CD8+ HLA-DR mem+ T cells (n=6). Since the CD4/CD8 ratio in pe-
ripheral blood is approximately 2 for adults [36, 37], the CD4+ and CD8+ T cells 
each contributed roughly equally to the entire CD3+ HLA-DR mem+ T cell popula-
tion.  
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To further characterize the HLA-DR mem-presenting CD4+ and CD8+ T cells, the 
co-expression of another T cell activation marker, CD25, was also investigated for 
these cells. Of the CD4+ HLA-DR mem+, 22.8%  2.3 co-expressed CD25 (Figure 
5A, right panel). Additionally, CD25 was enriched in the CD4+ HLA-DR mem+ 
population, when compared to the corresponding CD4+ HLA-DR mem- population, 
for which the expression of CD25 was 12.7%  1.2 (Figure 5B). In contrast, the 
CD25 expression was greatest in the HLA-DR mem- subset of the CD8+ T cells 
(3.5%  0.8) as compared to the CD8+ HLA-DR mem+ T cells (1.3%  0.3).  
Contrasting expression profiles of HLA-DRB1 mRNA in CD4+ T cells and 
CD19+ B cells 
In order to link the presence of the HLA-DR protein in T cells to its transcription, an 
investigation of the HLA-DRB1 mRNA expression was performed. For this investi-
gation, a set of primers for a qPCR assay were designed to target the transcripts of 
the HLA-DRB1*03 allele (Table 1). To ensure that only the desired target was am-
plified, the HLA-DRB1*03-specific assay was initially tested on a panel of PBMCs 
from 13 individuals with HLA-DRB1 alleles representative of the major DR haplo-
types [38](data not shown). Accordingly, the HLA-DRB1*03 positive individuals 
were selected, when they had either the homozygous HLA-DRB1*03 genotype or the 
heterozygous HLA-DRB1*03/*15 genotype. For the HLA-DRB1*03 negative sam-
ples, individuals with either the homozygous HLA-DRB1*15 genotype or the heter-
ozygous HLA-DRB1*01/*07 were selected.  
Subsequently, the expression pattern of HLA-DRB1*03 was determined for human, 
isolated CD4+ T cells and CD19+ B cells from peripheral blood. As for the flow 
cytometric analysis of HLA-DR mem and HLA-DR IC, the CD19+ B cells were 
included as a positive control. The qPCR analysis was performed with cells from 
individuals with either a positive or a negative HLA-DRB1*03 genotype, as indicat-
ed on the section above. The results of the expression analysis are displayed in Fig-
ure 6A. The difference, which was observed between CD4+ T cells and CD19+ B 
cells with an HLA-DRB1*03 positive genotype, corresponded to a 240-fold higher 
transcript quantity in the B cells. No detectable signal was obtained for the CD4+T 
cells with an HLA-DRB1*03 negative genotype. In contrast, two of the five corre-
sponding CD19+ B cell samples produced a detectable signal, yielding normalized 
expression values in a similar range as those for the CD4+ T cells from the HLA-
DRB1*03 positive individuals (Figure 6B). The corresponding Ct values were 37.18 
 0.17 (n=2) and 36.20  0.52 (n=5), respectively. 
As evaluated by flow cytometry, the purity of the isolated CD4+ T cells was 98.8% 
 0.37 (n=10; data not shown). Moreover, the presence of a cellular contamination, 
which could contribute to the detected mRNA signal in the CD4+ T cells from the 
HLA-DRB1*03 positive individuals, was also investigated. First, the amount of 
mRNA for CD19 was evaluated by qPCR (Figure 6C). This B cell differentiation 
marker was included since B cells constitute the largest HLA-DRB1-expressing 
population in PBMCs, thus encompassing the greatest source of a possible cellular 
contamination. The CD19 transcripts were approximately 1500 times more abundant 
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in the CD19+ B cell samples compared to the CD4+ T cell samples, regardless of 
HLA-DRB1*03 genotype. Secondly, the presence of CD14+ monocytes was also 
assessed by flow cytometry. For the investigated samples, 0.97%  0.10 CD4+ 




The presence of HLA-DR antigens on T cells has been observed for more than four 
decades. The expression pattern and functionality of HLA-DR is well described for 
APCs but in the context of T cells, many unidentified aspects still remain. With the 
use of a stringent staining and gating strategy for flow cytometry, this study investi-
gated the distribution of HLA-DR in the cellular membrane (HLA-DR mem) and 
intracellular compartment (HLA-DR IC) of human CD3+ T cells from peripheral 
blood. As a positive reference, this distribution was compared to that of autologous 
CD19+ B cells. We hypothesized that if the cell of question contained the functional 
protein in both the membrane and intracellular compartment it was likely that an 
endogenous protein expression existed. 
The flow cytometric analysis identified that approximately 18% of CD3+ T cells 
from peripheral blood contained HLA-DR mem (Table 2). Other studies, which 
investigate HLA-DR on T cells, generally report a smaller amount of HLA-DR 
mem+ T cells. However, these reports range widely from less than 5% [36, 37] to 
approximately 10% [5], but also above 15% [39, 40]. An inherent challenge of flow 
cytometry is to separate the true positive events from the background, especially for 
low-density markers. Such a case favors the use of an FMO-approach [41], thus 
minimizing user specific bias in the gating process. This approach was used in the 
present study with a consequent more accurate determination of the HLA-DR mem+ 
T cells than previously demonstrated. The identification of a uniformly HLA-DR 
mem-expressing, autologous B cell population validated the applied strategy. While 
only a few percent of all CD3+ T cells in peripheral blood contained HLA-DR IC, 
all the autologous CD19+ B cells were HLA-DR IC+ (Table 2), yet again confirm-
ing their constitutive HLA-DR expression. A positive correlation between HLA-DR 
mem and HLA-DR IC was observed for both CD3+ T cells and CD19+ B cells 
(Figure 2). However, not all CD3+ HLA-DR mem+ T cells were also HLA-DR IC+ 
(Table 2), which could be expected if an active protein synthesis was present. 
Additional analyses revealed that CD4+ and CD8+ T cells each account for approx-
imately 50% of the entire CD3+ HLA-DR mem+ subset in peripheral blood. Nota-
bly, HLA-DR mem was twice as enriched in the CD8+ T cells (19% of total CD8+ 
population), when compared to the CD4+ T cells (9% of total CD4+ population). 
Also, the presence of HLA-DR mem was seemingly not confined to activated CD4+ 
and CD8+ T cells, as evaluated by a co-expression CD25 (Figure 5). More than 20% 
of the CD4+ HLA-DR mem+ T cells co-expressed CD25, while the expression of 
CD25 by the CD8+ HLA-DR mem+ T cell was minimal, as observed by others [42]. 
In addition, the CD4+ T cells with the highest density of HLA-DR mem were also 
the cells with the greatest CD25 expression (Figure 5B). Although both CD4+ HLA-
DR mem+ [3, 43] and CD8+ HLA-DR mem+ T cells [42] found in peripheral blood 
have been associated with regulatory functions, the difference in the expression of 
CD25 presented in this study could indicate distinct functionalities of these two 
cellular subsets. This relates to the observation that CD25 expression is an essential 
feature for regulatory CD4+ T cells, which are often identified by a CD25high phe-
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notype [3, 43-45]. However, further investigations are required to substantiate this 
hypothesis.  
In order to investigate the link between the presence of the HLA-DR protein on T 
cells to an endogenous expression, a transcriptional analysis of HLA-DRB1 was 
performed, using a novel qPCR assay. The assay targeted a specific allele of the 
most prevalently expressed beta subunit of the heterodimeric HLA-DR protein, 
namely the beta 1 (B1) chain. For the specific allele, we chose HLA-DRB1*03, 
which is a part of the DR52 haplotype (HLA-DRB1*03, *11, *12, *13, and *14)[38]. 
The amount of HLA-DRB1 transcripts in this haplotype is the most abundant, com-
pared to other haplotypes [46], making it a plentiful and advantageous target. By 
choosing to target only one allele, it was intended to circumvent the issues associat-
ed with the extensive homology of the HLA-DR genes, thus providing unambiguous 
expression results. Whereas the protein analyses mainly focused on the entire CD3+ 
T cell population in peripheral blood, the qPCR centered on isolated CD4+ T cells. 
Hence, the basis of this investigation was a population of cells of which approxi-
mately 9% presented HLA-DR mem (Figure 5A).  
With the qPCR of HLA-DRB1*03 presented here, only minimal amounts of tran-
scripts could be detected in the CD4+ T cells from HLA-DRB1*03 positive individ-
uals, while autologous CD19+ B cells clearly possessed an active gene transcription 
of HLA-DRB1 (Figure 6A). To further assess the marginally positive HLA-DRB1*03 
mRNA signals for these CD4+ T cells, the results from the negative controls were 
evaluated. The CD4+ T cells from HLA-DRB1*03 negative individuals did not yield 
any detectable signals. In contrast, for two out of the five corresponding CD19+ B 
cell samples all triplicates produced detectable signals, which were very similar to 
the HLA-DRB1*03 positive CD4+ T cells (Figure 6B). Although much effort was 
put into ensuring the specificity of the applied qPCR assay, the signal from the HLA-
DRB1*03 negative CD19+ B cells illustrates that a small level of non-specificity is 
most likely inevitable. It was not expected that the HLA-DRB1*03 negative CD4+ T 
cells could yield a similar non-specific signal, as these cells would not produce B 
cell-comparable amounts of HLA-DRB1 transcripts, given the existence of such a 
production in the CD4+ T cells. Aside from these negative controls, it was imminent 
to assess the presence of a cellular contamination, which could have contributed 
with HLA-DRB1*03 mRNA in the CD4+ T cell sample. The most abundant APC in 
peripheral blood is B cells. It is unlikely that these cells were present in the isolated 
CD4+ T cells, as evaluated in Figure 6C. Monocytes, however, are also known to 
express both HLA-DR [47] and CD4 [48] and could consequently also be isolated 
with the applied CD4+ positive selection kit. Approximately 1% of monocytes could 
be detected in the CD4+ T cell samples. Hence, it is plausible that these cells could 
have made a contribution to the HLA-DRB1*03 mRNA in the relevant CD4+ T cell 
samples. In total, this suggests that the signal detected in the CD4+ T cells with an 
HLA-DRB1*03 positive genotype could be non-specific or ascribed to a possible 
cellular contamination from APCs. 
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When correlated with the flow cytometric analysis of HLA-DR, the results from the 
qPCR assay signifies that the presence of HLA-DR on the surface of a rather con-
stant-sized population of circulating CD4+ T cells in healthy individuals cannot be 
explained by a concomitant presence of an active gene expression. Even if the spe-
cific mRNA may have been partially degraded in the HLA-DR-presenting CD4+ T 
cells, it can be still be reasonably expected that these cells would give rise to a de-
tectable HLA-DRB1 mRNA signal, if an expression was present, as they constituted 
roughly 9% of the investigated cells. However, the results do not exclude the possi-
bility that an inducible, endogenous expression of HLA-DR is present in these T 
cells. Nevertheless, this study showed tendencies for circulating HLA-DR-
presenting CD4+ T cells in healthy individuals. These characteristics may be differ-
ent for CD4+ HLA-DR mem+ T cells found in others tissues, such as in the lymph 
nodes, where elevated levels of HLA-DR-presenting T cells have been observed 
[40]. To support these theories and to fully appreciate the presence and dynamics of 
HLA-DR on human T cells, further analyses are required. These could include acti-
vated CD4+ T cells in lymphoid tissue, such as the palatine tonsils, or in individuals 
with constantly activated T cells, such as HIV-infected patients [49].  
In terms of functionality, HLA-DR on T cells has mainly been associated with im-
munosuppressive signals, inducing either apoptosis or anergy in activated T cells [3, 
50, 51]. However, reports about T cell activation can also be found [26, 32]. None-
theless, it seems that the function of HLA-DR in APCs cannot simply be extrapolat-
ed to T cells. This is based on a number of observations from this and other studies. 
Here, clear differences were demonstrated for the presence of HLA-DR both at the 
protein and transcript level, when comparing CD4+ T cells to CD19+ B cells. Others 
describe how T cell-T cell and T cell-APC interactions have significantly different 
effects on the responder T cells. Although TCR involvement, and consequently also 
HLA-DR, and co-stimulatory molecules are present for both types of cellular inter-
action [50], the resulting cytokine production (IL-2 and IL-4) and Ca
2+
 influx differ 
[51-53]. Moreover, most T cell-T cell interactions seemingly result in the induction 
of anergy, further underlining these differences [50]. In relation to key features of 
APCs, the mechanism for antigen acquisition remains unidentified for T cells [12], 
while other studies have investigated other requirements of antigen presentation in 
these cells, including HLA-DM, CLIP, and proteolytic enzymes [12, 50]. Finally, 
the expression of essential co-stimulatory molecules, including CD80 and CD86, has 
been investigated. While some report an endogenous expression by T cells [50], 
others demonstrate an acquisition of functional molecules from APCs [32, 54, 55]. 
One of these studies demonstrated a simultaneous acquisition of HLA-DR by CD4+ 
T cells in a contact-dependent manner [32] but also a contact-independent transfer of 
HLA-DR has been shown [27]. Aside from underlining apparent differences be-
tween T cells and APC, related to HLA-DR and antigen-presentation, the phenome-
non of intercellular transfer is very interesting from immunological point of view. It 
has been recognized that immune cells are particularly prone to engage in such mo-
lecular exchange, bestowing new functional phenotypes on the recipient cells [56-
62]. This challenges the classical subdivision of immune cells, which is based on 
such functional phenotypes, and also expands the regulatory mechanisms of the 
immune system. In relation to HLA-DR, many studies have used allogeneic stimula-
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tor cells to activate T cells, as part of a mixed lymphocyte culture (MLC), thereby 
inducing the presence of HLA-DR. However, if acquisition of HLA-DR and other 
molecules can occur in such a cell culture, it will have a major impact on future 
study design and interpretation of data and possibly also explain some of the contra-
dictory results reported about HLA-DR in T cells to date [50]. Even though the 
results presented in this study could indicate that an intercellular protein transfer 
may account for the presence of HLA-DR on CD4+ T cells from peripheral blood, 
the exact mechanisms explaining HLA-DR on these T cells remain to be delineated. 
 
Conclusions 
In this study we further elucidated the presence of HLA-DR on human T cells. To 
the best of our knowledge, no study has to date investigated the direct HLA-DRB1 
expression in human CD4+ T and CD19+ B cells from peripheral blood and corre-
lated it to the concurrent presence of HLA-DR antigens in the cell membrane and 
intracellular compartment. By doing so, observations about the presence of HLA-
DR on T cells along with indications about its functionality can be obtained simulta-
neously. We observed that the HLA-DR present on CD4+ T cells from peripheral 
blood of healthy individuals is mainly membrane-associated. With the lack of HLA-
DRB1 mRNA expression in CD4+ T cells, it can reasonably be proposed that HLA-
DR on CD4+ T cells in peripheral blood cannot be explained by the simultaneous 
presence of an active, endogenous protein synthesis. Moreover, HLA-DR-
presentation by both CD4+ and CD8+ T cells was not confined to activated T cells. 
The collected data add more layers to the presence of HLA-DR on T cells, pointing 




The following conjugated antibodies were obtained from BD Biosciences 
(Mountainview, CA, USA): Anti-CD3-PE (SK7), anti-CD3-PerCP (SP34-2), anti-
CD4-APC-H7 (SK3), anti-CD4-PE (RPA-T4), anti-CD8-PerCP (SK1), anti-CD8-
PerCP-Cy5.5 (SK1), anti-CD14-PE-Cy7 (M5E2), anti-CD19-APC (HIB19), anti-
CD19-PE (4G7), anti-CD19-PerCP-Cy5.5 (SJ25C1), anti-CD25-FITC (2A3), anti-
HLA-DR-FITC (G46-6), mouse-IgG1-APC-H7 (X40), mouse-IgG1-FITC (MOPC-
21), mouse-IgG2a-FITC (27-35), mouse IgG1-PE (MOPC-21), mouse-IgG2a-PE 
(MOPC-173), mouse IgG1-PerCP (MOPC-21), mouse IgG1-PerCP-Cy5.5 (MOPC-
21), and mouse IgG1-PE-Cy7 (MOPC-21). From BD Biosciences, the unconjugated 
anti-CD3 (HIT3a) was also acquired. Anti-CD45-FITC (T29/33), anti-HLA-DR-PE 
(AB3), and mouse-IgG1-APC (DAK-GO1) were purchased from Dako A/S 
(Glostrup, DK). Anti-HLA-DR-Alexa Fluor (AF) 488 (L243), anti-HLA-DR-AF647 
(L243), mouse-IgG2a-AF488 (MOPC-173), and mouse-IgG2a-AF647 (MOPC-173) 
were purchased from BioLegend (San Diego, CA, USA). Mouse-IgG1-PerCP-Cy5.5 
(P3.6.2.8.1) was obtained from eBioscience (San Diego, CA, USA). The goat anti-
mouse IgG-AF555 was purchased from Invitrogen (Life Technologies, Carlsbad, 
CA, USA).  
Cells and isolation 
Venous peripheral blood was obtained from healthy donors with known HLA types. 
The blood was collected in heparinized tubes (Vacuette, Lithium Heparin, Greiner 
Bio One, DE). Isolation of PBMCs was accomplished by using Lymphoprep gra-
dient centrifugation (Axis-Shield, Oslo, NO). The PBMCs were either used directly 
after the isolation or stored at -140 C in a storage medium (RPMI 1640 (Gibco, Life 
Technologies), 40% heat-inactivated fetal calf serum (FCS) (Gibco), 10% DMSO 
(Merck Millipore, Darmstadt, Germany), 100 U/mL penicillin/10µg/mL streptomy-
cin (Ampliqon, Odense, DK)). The CD4+ T cells were isolated from PBMCs using 
the Dynabeads CD4 Positive Selection kit (Invitrogen) according to the manufac-
turer’s guidelines. As an additional purification step, any residual B cells were re-
moved from the isolated CD4+ T cells by positive selection, using Dynabeads® 
CD19 Pan B (Invitrogen). The purity of the isolated CD4+ T cells was evaluated by 
staining with fluorochrome-conjugated antibodies with subsequent flow cytometric 
analysis.  
From the CD4+ depleted PBMCs, CD19+ B cells were isolated using the Dyna-
beads Untouched Human B Cells kit (Invitrogen) according to the manufactur-
ers guidelines.  
Detection of membrane-bound and intracellular markers by flow cytometry 
For the detection of membrane-bound and intracellular HLA-DR, 1x10
6
 PBMCs 
were stained with antibodies against CD3, CD19, HLA-DR (L243-AF488), or the 
corresponding isotype control antibodies (30 min, room temperature (RT)). Subse-
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quently, 100 l of Fixation Medium (reagent A) from FIX & PERM® Cell Fixation 
and Permeabilization Kit (Invitrogen) was added (15 min, RT). Following one wash 
with PBS (Gibco), a second antibody against HLA-DR (L243-AF647), or the corre-
sponding isotype antibody, and 100 l of Permeabilization Medium (reagent B) 
were added to the cells (20 min, RT). Finally, the cells were washed once with PBS 
prior to flow cytometric analysis. For the detection of membrane-bound HLA-DR on 
CD4+ and CD8+ T cells, the procedure only included the primary surface staining, 
using antibodies against CD3, CD4, CD8, CD25, and HLA-DR (L243-AF647). 
The acquisition of stained cells was performed on a FACSCanto A using FACSDi-
va software (version 6.1.3, BD Biosciences). Calibration and compensation set-
tings for the cytometer were obtained each day by using the 7-Color Setup Beads 
(BD Biosciences) and once a week with the FACSDiva CS&T Research Beads 
(BD Biosciences). The analysis of the data was carried out with the FlowJo software 
(version 10.0.7, FlowJo LLC, Ashland, OR, USA). Negative isotype controls were 
utilized to identify the positive events. The controls were either combined in a single 
tube or part of a “fluorescence minus one” (FMO) tube [33]. The median fluores-
cence intensity (MFI) was the statistical value of choice.  
Detection of membrane-bound and intracellular HLA-DR by confocal micros-
copy 
For all experiments, 1.5x10
5
 isolated CD4+ T cells or CD19+ B cells were left to 
adhere to poly-L-lysine coated slides (Sigma-Aldrich, St. Louis, MO, USA)(20 min, 
RT). The T cells were initially stained with anti-CD3 (HIT3a)(1:250; 45 min, RT), 
followed by incubation with secondary antibody (goat-anti-mouse IgG-
AF555)(1:200; 45 min, RT). Slides were washed 3 times in PBS and cells were 
fixed in 2% paraformaldehyde (PFA)(Sigma-Aldrich)(15 min, RT). Both T and B 
cells were then stained with anti-HLA-DR-AF488 (L243)(1:100; 45 min, RT). 
Slides were washed 3 times in PBS and cells were fixed in 2% PFA (15 min, RT) 
followed by another round of washing and permeabilization with permeabilization 
buffer (1% bovine serum albumin (BSA)(Sigma-Aldrich), 0.1% saponin (Sigma-
Aldrich), PBS)(8 min, RT). To visualize cytosolic HLA-DR, cells were subsequent-
ly stained with anti-HLA-DR-AF647 (L243)(1:100 in permeabilization buffer; 45 
min, RT). Slides were washed 4 times in PBS and mounted with mounting medium 
(Sigma-Aldrich). Images were acquired on a Leica TCS SP5 confocal laser scanning 
microscope (Leica, Wetzlar, Germany). Images were processed using ImageJ (ver-
sion 1.48, NIH, USA).  
Total RNA extraction and cDNA synthesis 
Total RNA was extracted from the isolated CD4+ T cells and CD19+ B cells by 
using the TRIzol extraction method (Invitrogen). The A260/A280 ratio was deter-
mined using a NanoDrop 1000 Spectrophotometer (Thermo Scientific, Waltham, 
MA, USA). Total cDNA for the quantitative PCR (qPCR) were generated from 1 μg 
total RNA from all samples using a mixture of poly-T and random primers with 
SuperScript VILO cDNA Synthesis Kit (Invitrogen) at a temperature profile of 25°C 
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for 10 min, 42°C for 60 min, and 85°C for 5 min according to the manufacturers 
guidelines.  
Quantitative PCR 
PCR primers for amplification of 57-136 base pairs gene-specific PCR products 
were used from conserved regions of the four studied genes (HLA-DRB1*03, CD19, 
B2M, and GUSB). Primers and FAM-labeled minor groove binder (MGB) TaqMan 
probes were used to detect the RNA expression level of the reference genes B2M 
and GUSB [67] and the target gene HLA-DRB1*03 for which the HLA-
DRB1*03:01:01:01 mRNA sequence from the IMGT/HLA database was used as 
target sequence. Expression levels of CD19 were detected using 20x probe assays 
mix (Life Technologies, USA). The information about primer and probe sequences 
are given in Table 1. The qPCR assay was applied to evaluate the gene expression 
profiles of the four genes and the data was analyzed using the QuantStudio 12K Flex 
system (Life Technologies, USA). The real-time PCR reactions were performed in a 
final volume of 25 μl, containing 1 μl cDNA solution, 12 μl Master Mix (TaqMan 
Universal PCR Master Mix, ABI, Darmstadt, Germany), 0.05 µM probe and 0.9 µM 
of forward and reverse primers. The PCR reaction for TaqMan gene expression 
assays contained 1 μl cDNA solution, 12 μl Master Mix and 1.25 μl TaqMan gene 
expression assay. Reactions were made up to a final volume of 25 μl with sterile 
water. All experiments were performed in triplicate and the real-time PCR protocol 
was as following: Denaturation by a hot start at 95°C for 10 min, followed by 50 
cycles of a two-step program (denaturation at 95°C for 15 sec and anneal-
ing/extension at 60°C for 1 min). For all the included gene targets, only the thresh-
old cycle (Ct) values below 40 were included in the subsequent data analysis. Gene 
expression of the target gene was normalized to the mean Ct of B2M and GUSB 
applying the formula 2
-ΔCt
, where ΔCt = Ct target gene – Ct reference genes. 
Statistical analysis 
The statistical analysis of data from both qPCR and flow cytometry experiments was 
performed using SigmaPlot (version 11, Systat Software Inc, San Jose, CA, USA). 
A paired or unpaired t-test was applied to test for differences between the groups of 
cells from the same individual or between two individuals, respectively. For non-
normally distributed data, the corresponding non-parametric analysis was applied. 
Differences between groups were considered statistically significant, when p < 0.05. 
Unless otherwise specified, the data is presented as mean  SEM.
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List of abbreviations 
APC: Antigen-presenting cell 
CIITA: Class II trans-activator 
CLIP: Class II-associated invariant chain peptide 
Ct: Threshold cycle 
CTLA-4: Cytotoxic T-lymphocyte-associated protein 4 
FSC: Forward scatter 
FMO: Fluorescence Minus One 
HLA-DR: Human leukocyte antigen DR 
HLA-DR IC: Human leukocyte antigen DR, intracellular 
HLA-DR mem: Human leukocyte antigen DR, membrane-bound 
IL: Interleukin 
ICAM-1: Intercellular adhesion molecule 1 
LFA-1: Lymphocyte function-associated antigen 1 
MFI: Median fluorescence intensity 
MHC: Major histocompatibility complex 
MLC: Mixed lymphocyte culture 
PBMC: Peripheral blood mononuclear cell 
SSC: Side scatter 
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Figure 1. Improved flow cytometric gating strategy identifies HLA-DR in the 
membrane and intracellular compartment of CD3+ T cells and CD19+ B cells. 
Initially, the lymphocyte population was gated in a forward scatter (FSC)/side scat-
ter (SSC) plot. From the lymphocytes, the CD3+ T cells and CD19+ B cells were 
subsequently gated. Subsequently, the CD3+ HLA-DR mem+ (17%) and CD19+ 
HLA-DR mem+ (99.7%) populations were identified with pre-defined gates set 
using the FMO control for HLA-DR mem. In the last step, it was determined, which 
HLA-DR mem+ cells also carried the HLA-DR protein intracellularly. For this pur-
pose, gates set with the FMO controls were used, identifying the double positive 
CD3+ HLA-DR mem+ HLA-DR IC+ (15.6%) and CD19+ HLA-DR mem+ HLA-
DR IC+ (95.2%) populations. For all the FMO controls, the threshold was set so that 
a maximum of 1% of the events fell into the double positive quadrant. The plots are 
from one donor as a representative example of the 10 included donors. 
 
Figure 2. Correlation between HLA-DR mem and HLA-DR IC in CD3+ T cells 
and CD19+ B cells. The gating strategy presented in Figure 1 was employed to 
identify the HLA-DR mem+ and HLA-DR IC+ CD3+ T cells and CD19+ B cells in 
the presented dot plots. These plots were made to visualize a possible correlation 
between HLA-DR in the two cellular compartments. Moreover, a statistical correla-
tion (Pearson) was made, correlating the HLA-DR mem value with the HLA-DR IC 
value for each event included in the CD3+ and CD19+ populations. This revealed a 
positive correlation between HLA-DR mem and HLA-DR IC for both CD3+ T cells 
and CD19+ T cells. Both dot plots are representative examples of the included do-
nors (n=10). 
 
Figure 3. Comparison of HLA-DR IC signal in CD3+ T and CD19+ B cells 
with/without permeabilization. To test for saturation of HLA-DR mem with the 
initially applied anti-HLA-DR antibody, a saturation control was made for all the 
included donors. For the control, the entire staining setup was applied, only omitting 
the permeabilization agent. Subsequently, the gating strategy displayed in Figure 1 
was applied to identify the CD3+ HLA-DR mem+ T cells and CD19+ HLA-DR 
mem+ B cells. A) The histograms show the HLA-DR IC signals for the fully stained 
sample, the corresponding FMO control, and the saturation control. The histograms 
are a representative example of the 10 donors included in the study. B) For all the 10 
donors, there was a detectable HLA-DR IC signal present in the saturation control 
for both the CD3+ T cells and the CD19+ B cells. However, this signal was always 
lower than the specific HLA-DR IC signal detected in the fully stained sample.  
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Figure 4. Confocal microscopy analysis of HLA-DR mem and HLA-DR IC in 
CD4+ T cells and CD19+ B cells. To verify the double staining procedure applied 
in the flow cytometric evaluation of HLA-DR mem and HLA-DR IC, confocal mi-
croscopy was performed. Isolated CD4+ T cells and CD19+ B cells were stained 
with anti-HLA-DR mem and anti-HLA-DR IC, using a similar procedure as that for 
the equivalent flow cytometric analyses. For the CD4+ T cells, an additional staining 
with anti-CD3 was performed. As for the flow cytometric analysis, the saturation of 
HLA-DR mem was evaluated prior to targeting of HLA-DR IC (Figure 3). In this 
control no intracellular staining was detected (data not shown). In addition, the con-
trol of the secondary antibody, applied to target the anti-CD3 antibody, showed no 
non-specific binding (data not shown). The presented results are representative of 
two independent experiments (n=2).  
 
Figure 5. Contribution of CD4+ and CD8+ T cells to the CD3+ HLA-DR mem+ 
T cell population. The relative contribution of CD4+ and CD8+ T cells to the CD3+ 
HLA-DR mem+ T cell population was investigated by staining PBMCs with anti-
bodies against CD3, CD4, CD8, CD25, and HLA-DR mem. A) Using the gating 
strategy described in Figure 1, the HLA-DR mem-presenting CD4+ and CD8+ T 
cells were identified (left panel). Subsequently, the co-expression of CD25 was 
determined for these cells and compared to the CD25 expression in the correspond-
ing HLA-DR mem- cells. B) The highest degree of CD25 expression was observed 
for the CD4+ T cells, which presented the most HLA-DR mem (top panel). In con-
trast, CD25 was found to the greatest extent of the CD8+ T cells presenting no 
HLA-DR mem (bottom panel). n=6. 
 
Figure 6. Quantifying mRNA from target genes by qPCR. A) The expression of 
HLA-DRB1*03 mRNA was investigated in isolated CD4+ T cells and CD19+ B 
cells from donors with an HLA-DRB1*03 positive or negative genotype (n=5 for 
each genotype). The expression of the target gene was normalized to the mean of 
two reference genes (B2M and GUSB). Data is presented as mean  SEM. B) Nor-
malized expression of HLA-DRB1*03 for selected samples are depicted in this pan-
el. The values represent each of the five HLA-DRB1*03 positive CD4+ T cell sam-
ples and the two HLA-DRB1*03 negative B cell samples, which yielded a detectable 
signal in the qPCR analysis of HLA-DR B1*03. C) Expression of CD19 mRNA in T 
and B cells (n=10). The expression of the target gene was normalized to the mean of 
two reference genes (B2M and GUSB). Data are presented median and interquartile 
range. The bars denote the 5% and 95% percentiles. *, p<0.05; **, p>0.01; ND, Not 
detectable. 










Additional Figure 1. Confocal microscopy analyses of HLA-DR mem and HLA-
DR IC in CD4+ T cells. Cells presenting HLA-DR both in the membrane and intra-
cellular compartment were rarely found among the isolated CD4+ T cells. One dou-
ble positive T cell was detected in one of the two independent experiments.  
File name: Additional file 1 
File format: TIF 
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Although the observation of major histocompatibility complex II (MHCII) mole-
cules on T cells is longstanding, the explanation for this occurrence remains enig-
matic. As such, reports of an inducible, endogenous expression exist, as do studies 
demonstrating a protein acquisition from other cells by mechanisms including vesi-
cle transfer. Here, we further characterized some of the requirements for the pres-
ence of the human MHCII isotype, human leukocyte antigen DR (HLA-DR), on 
human CD3+ CD4+ T cells. This was accomplished with a combination of flow 
cytometry of cell surface markers and extensive phenotyping of cell-derived extra-
cellular vesicles (EVs). It was found that expression of HLA-DR could not be in-
duced in CD3+ CD4+ T cell monocultures after both mitogenic and antigen-like 
stimulation. In addition, contact-dependent differences were observed for both pro-
liferation and presence of HLA-DR on the responder CD3+ CD4+ T cells following 
an allogeneic mixed lymphocyte culture (MLC). The functional phenotype of the 
CD3+ CD4+ HLA-DR+ responder T cells indicated a possible regulatory role for 
these cells. Finally, the phenotype of the EVs produced during the MLCs was more 
heterogeneous than the investigated cellular phenotype. Nevertheless, the EV pheno-
type displayed contact-dependent differences, which may provides clues about their 
intended functionality in cellular communication. 




The expression of major histocompatibility complex II (MHCII) is essential for the 
specificity of the adaptive immune system. The T cell receptor (TCR) of CD4+ T 
cells interacts with the cognate peptide-MHCII complexes on antigen-presenting 
cells (APCs), thus activating the T cells. The constitutive expression of MHCII is 
limited to professional APCs, however, MHCII has for more than four decades also 
been observed on T cells [1-4]. In addition, the number of MHCII+ T cells increases 
upon activation [4, 5]. In line with this, the most frequently expressed MHCII mole-
cule in humans, the human leukocyte antigen DR (HLA-DR), is commonly used as a 
marker for T cell activation [5-7]. It remains a subject of discussion, whether the 
presence of MHCII on T cells is explained by an endogenous protein synthesis or by 
an acquisition from adjacent cells. Furthermore, the functional consequences of 
MHCII on T cells are still poorly understood. 
An inducible, endogenous protein synthesis of MHCII has been reported for T cells, 
similar to that described for APCs. The expression of MHCII has been observed for 
T cells from several species, including bovine [8], rat [9, 10], and human [11]. In 
addition, T cells can also acquire fully functional MHCII from neighboring cells by 
yet unconfirmed mechanisms. This molecular transfer was already observed in the 
1980’s [12] and since then several studies have demonstrated that the acquisition is 
possible for rat [13], mouse [14-16] and human T cells[17]. Moreover, it has been 
stated that an acquisition explains the presence of MHCII on mouse T cells [13, 15], 
which are known not to express MHCII endogenously even after in vitro stimulation 
[18]. The responsible mechanisms have been reported as either being a vesicle-
mediated transfer [13, 19, 20] or the acquisition of entire membrane patches [21], 
also known as trogocytosis [22]. Regardless of an endogenous expression or protein 
acquisition, MHCII on T cells has mainly been associated with induction of down 
regulatory signals in the responder T cell [11, 23-25]. However, several studies also 
demonstrate that the MHCII+ T cells can activate other T cells [15, 17]. Nonethe-
less, these functional findings collectively suggest a more pronounced role of 
MHCII on T cells than being an activation marker.  
The purpose of this study was to further elucidate the presence of HLA-DR on the 
surface of human CD3+ CD4+ T cells. In this context, the influence of APCs in this 
phenomenon was investigated. It was observed that the presence of HLA-DR in 
monocultures of primary CD3+ CD4+ T cells was not inducible following in vivo 
mitogenic and antigen-like stimulation. Moreover, contact-dependent differences 
were observed for both proliferation and presence of HLA-DR on CD3+ CD4+ T 
cells following an allogeneic mixed lymphocyte culture (MLC). Furthermore, a 
phenotypical characterization of the responder CD3+ CD4+ HLA-DR+ T cells also 
revealed contact-dependent differences as well as indicating a possible regulatory 
function of these T cells. The phenotype of the cell-derived extracellular vesicles 
(EVs) was much more heterogeneous than the cellular counterpart. However, con-
tact-dependent differences in the EV phenotype were observed, providing clues to 
the vesicular communication in allogeneic MLCs. 
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Materials and Methods 
Cells and isolation 
Venous peripheral blood was obtained from healthy donors with known HLA types. 
The blood was collected in heparinized tubes (Vacuette, Lithium Heparin, Greiner 
Bio One, DE). Isolation of peripheral blood mononuclear cells (PBMCs) was ac-
complished by using Lymphoprep gradient centrifugation (Axis-Shield, Oslo, 
NO). The PBMCs were either used directly after the isolation or stored at -140 C in 
a storage medium (RPMI 1640 (Gibco, Life Technologies, Carlsbad, USA), 40% 
heat-inactivated fetal bovine serum (FBS)(Gibco), 10% dimethyl sulfoxide (Merck 
Millipore, Darmstadt, Germany), 100 U/mL penicillin/10µg/mL streptomycin 
(Ampliqon, Odense, DK)). The CD4+ T cells were isolated from PBMCs using 
either a Dynabeads CD4 Positive Selection kit (Invitrogen, Life Technologies, 
Carlsbad, CA, USA) or a Dynabeads Regulatory CD4+ CD25+ T Cell Kit (Invi-
trogen), using only the CD4+ isolation part. The entire procedure was carried out 
according to the manufacturer’s guidelines. The purity of the isolated cells was 
evaluated by flow cytometry. 
Mitogenic and antigen-like stimulation 
The isolated CD4+ T cells or PBMCs were seeded in a concentration of 7x10
5
 
cells/mL in culture medium (RPMI 1640, 10% FBS, 100 U/mL penicillin/10µg/mL 
streptomycin) with or without mitogenic/antigen-like stimuli for 20h. 
Phytohaemagglutinin-P (PHA-P)(Sigma-Aldrich, St. Louis, MO, USA) was used in 
a final concentration of 3.3 µg/mL, while Dynabeads Human T-Activator 
CD3/CD28 for T Cell Expansion and Activation (Invitrogen) was used according to 
the manufacturers guidelines. 
Mixed lymphocyte culture 
A 6-day allogeneic mixed lymphocyte culture (MLC) was performed with PBMCs 
from two donors with complete HLA mismatch. Prior to the MLC, the stimulator 
cells were irradiated (1700 rad), while the responder cells were labeled with 15 M 
Cell Proliferation Dye eFluor 450 (eBioscience, San Diego, CA, USA) according 
to the manufacturers guidelines. For the contact-dependent MLC (classical), 5x10
4
 
of each responder and stimulator cells were mixed in a 96-well plate (Nunc, Thermo 
Scientific, Waltham, MA, USA) in a total volume of 150 µL culture medium (RPMI 
1640, 10% FBS, 100 U/mL penicillin/10µg/mL streptomycin). For the contact-
independent setup, stimulator cells and responder cells were separated by a Milli-
cell Hanging Cell Culture Insert with a pore size of 0.4 µm (Merck Milli-
pore)(hereafter termed transwell (TW)) in 24-well plates (Nunc). The upper chamber 
contained 2.5x10
5
 stimulator cells in 400 µL of culture medium, while the lower 
chamber contained 5x10
5
 responder cells in 800 uL of culture medium. For the 
stimulator and responder control samples, 5x10
4
 of either responder or stimulator 
cells were seeded in a 96-well plate, as described above. On day 5, 50 µL (1 µCi, 
96-well plate) or 400 µL (8 µCi, 24-well plate) of Thymidine-
3
H (Perkin Elmer, 
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Waltham, MA, USA) was added to the selected wells designated for measurements 
of proliferation. The Thymidine-
3
H labeled cells were harvested after 24h and radio-
active incorporation was detected in a scintillation counter (TopCount NXT, Perkin 
Elmer). On day 6 of the MLCs, the cell culture supernatants were removed and cen-
trifuged once at 500xg 10 min at room temperature (RT) to pellet cells. The cell-free 
supernatants were stored at -40 °C prior to vesicle phenotyping. The pelleted cells 
from the cell supernatant were pooled with those harvested from the MLCs and the 
cellular phenotyping was performed using flow cytometry.  
Cellular phenotyping with flow cytometry 
Antibodies for cellular phenotyping: Conjugated antibodies against the following 
targets were obtained from BD Biosciences (Mountainview, CA, USA): CD3-APC 
(UCHT1), CD3-FITC (UCHT1), CD3-PerCP (SP34-2), CD4-APC-H7 (SK3), CD4-
FITC (RPA-T4), CD4-PE (RPA-T4), CD11a-FITC (G43-25B), CD25-FITC (M-
A251), CD62L-FITC (DREG-56), CD127-PE (HIL-7R-M21), CD152 (CTLA-4)-PE 
(BNI3), CD279 (PD-1)-PE-Cy7 (EH12.1), HLA-DR-FITC (L243), HLA-DR-PE 
(L243), HLA-DR-PerCP-Cy5.5 (L243), mouse-IgG1-APC-H7 (X40), mouse-IgG1-
FITC (MOPC-21), mouse IgG1-PE (MOPC-21), mouse IgG1-PerCP (MOPC-21), 
and mouse IgG1-PE-Cy7 (MOPC-21). Antibodies against HLA-DR-Alexa Fluor 
647 (L243) and mouse-IgG2a-Alexa Fluor 647 (MOPC-173) were from BioLegend 
(San Diego, CA, USA). Mouse-IgG2a-FITC (eBM2a) and mouse-IgG2a-PE 
(eBM2a) were from eBioscience. Anti-TNFRII (CD120b)-PE (80M2) was from 
Immunotech (Beckman Coulter, Inc., Brea, CA, USA). Mouse-IgG1-APC (DAK-
GO1) was from Dako A/S (Glostrup, DK). 
Data acquisition and analysis: The acquisition of stained cells was performed on a 
FACSCanto A using FACSDiva software (version 6.1.3, BD Biosciences). Cali-
bration and compensation settings for the cytometer were obtained daily by using 
the 7-Color Setup Beads (BD Biosciences) and once a week with the FACSDiva 
CS&T Research Beads (BD Biosciences). The analysis of the data was carried out 
with the FlowJo software (version 10.0.7, FlowJo LLC, Ashland, OR, USA). Nega-
tive isotype controls or fluorescence minus one (FMO) controls [26, 27] were uti-
lized to identify the positive events. For all populations, the median fluorescence 
intensity (MFI) was the statistical value of choice.  
EV Array analysis 
Production of microarrays: Microarray printing was performed on a SpotBot
®
 Ex-
treme Protein Edition Microarray Printer as previously described [28].  
Antibodies and proteins for vesicle phenotyping: A total of 24 anti-human antibodies 
and one protein were used. They are listed in the following with the corresponding 
product number (#) or clone. From R&D Systems (Minneapolis, MN, USA): 
Annexin V (#AF399), CD4 (34930), CD19 (4G7-2E3), CD45 (2D1), CD80 (37711), 
CD82 (#423524), CD83 (H15e), LAMP-2 (H4A3), TNFRI (#DY225), and TNFRII 
(#DY726). From Biolegend: Alix (3A9), CD63 (MEM-259), HLA-ABC (W6/32), 
and HLA-DR (L243). From LifeSpan BioSciences, Inc. (Seattle, WA, USA): CD9 
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(#LS-C35418), CD81 (#LS-B7347), and CTLA-4 (ANC152.2/8H5). From BD Bio-
sciences: CD3 (Hit3a) and CD14 (M5E2). From Abcam (Cambridge, MA, USA): 
Flotilin-1 (#Ab41927) and TSG101 (5B7). From Santa Cruz Biotechnologies (Dal-
las, TX, USA): TLR-3 (TLR3.7). From Abbiotec (San Diego, CA, USA): CD11a 
(HI111). From eBioscience: ICAM-1 (R6.5). From Haematologic Technologies, Inc. 
(Essex Juncton,VT, USA): Lactadherin (protein) (#BLAC-1200). All antibodies and 
protein were printed in triplicates at 87.5 – 200 µg/mL diluted in PBS containing 5% 
glycerol.  
Antibodies for semi-quantification of vesicles: For the semi-quantification, only anti-
CD9, anti-CD63, and anti-CD81 were printed on the micro-array slides, as previous-
ly described [29]. In short, 18 repeated spots were printed with a cocktail of the 
three antibodies.  
Catching and visualization: Initially, the microarray slides were blocked (50 mM 
ethanolamine, 100 mM Tris, 0.1% SDS, pH 9.0) prior to incubation with 100 µl of 
undiluted cell culture supernatant. The incubation was performed in Multi-Well 
Hybridization Cassettes (ArrayIt) at RT for two hours followed by overnight incuba-
tion at 4 °C. Following a wash in wash buffer (0.05% Tween
 
20, PBS), the slides 
were incubated with biotinylated detection antibodies (diluted 1:1500, anti-human-
CD9, -CD63, -CD81, (Ancell Corporation, MN, USA)) in wash buffer. After a 
wash, a subsequent 30 minutes incubation step with Cy5-labelled streptavidin (dilut-
ed 1:1500, Life Technologies) in wash buffer, was carried out for detection. Prior to 
scanning at 635 nm, the slides were washed first in washing buffer and then in 
MilliQ water and dried using a Microarray High-Speed Centrifuge (ArrayIt). Scan-
ning and spot detection was performed as previously described [29]. 
Data analysis: Creation of graphs was carried out using GraphPad Prism (version 
6.04, GraphPad Software, Inc., San Diego, CA, USA) and Excel (version 2013, 
Microsoft, Redmond, WA, USA). Heat maps were produced using Genesis (version 
1.7.6, IGB TU Graz, Graz, Austria). For a given antibody spot, the signal intensity 
was calculated as the mean signal of triplicate spots in relation to the sample signal 
of the negative spot (PBS) in triplicate. For each spot, the signal intensity was calcu-
lated by subtracting the mean of the background (no sample/blank, washing buffer) 
from the mean of the foreground (spot signal). Before visualization and calculation 
of linearity, the antibody signal intensities were converted to log space by log2 
transformation. 
Statistical analysis 
The statistical analysis of data was performed using SigmaPlot (version 11, Systat 
Software Inc, San Jose, CA, USA). To test for differences between two groups, a 
paired or unpaired t-test was applied to test for differences between the two groups 
of cells from the same individual or between two individuals, respectively. To test 
for differences between more than two groups, a one-way repeated measures ANO-
VA, followed by Tukey’s post-hoc analysis, was applied. Differences between 
groups were considered statistically significant, when p < 0.05. 




Inducible expression of HLA-DR in isolated CD3+ CD4+ T cells 
To investigate if CD3+ CD4+ T cells from peripheral blood endogenously express 
the HLA-DR observed on their cell surface, we attempted to induce this expression 
in isolated CD3+ CD4+ T cells with PHA-P or anti-CD3/anti-CD28. For both types 
of stimuli, an increase in the presence of HLA-DR could not be detected after 20 h 
of stimulation (Figure 1, filled bars). In contrast, the number of CD3+ CD4+ HLA-
DR+ T cells increased when PBMCs were stimulated with either PHA-P (p = 0.008) 
or anti-CD3/anti-CD28 (p = 0.001), as compared to the unstimulated counterpart 
(Figure 1, hatched bars). Moreover, the amount of CD3+ CD4+ HLA-DR+ T cells 
was approximately 12 and 9 times greater in the PBMC population than in the mon-
ocultures stimulated with PHA-P (p=0.006) or anti-CD3/anti-CD28 (p=0.002), re-
spectively. The purity of the isolated CD3+ CD4+ T cells was 94.5%  5.2 (n=3), as 
evaluated by flow cytometry (data not shown). 
Requirements for MLC-induced cellular proliferation 
A 6-day allogeneic MLC assay was employed to investigate the importance of APCs 
for CD4+ T cell activation and a subsequent presence of HLA-DR on CD4+ T cells. 
As an additional feature, the importance of a physical interaction between the re-
sponder cells and the stimulator cells was also evaluated. As an initial outcome 
measure, the cell proliferation was determined for the two MLC combinations. A 
prominent proliferative response was detected from the cells from the contact-
dependent MLC (classic MLC), as compared to the responder control sample (Fig-
ure 2). Contrary to this observation, the responder cells from the contact-
independent MLC (transwell (TW) MLC) did not proliferate above the level detect-
ed for the responder control. 
Cellular phenotype of HLA-DR-presenting responder CD4+ T cells 
In addition to the proliferation, the cellular phenotype of the CD4+ HLA-DR+ re-
sponder cells was characterized by a flow cytometric evaluation of seven cell sur-
face markers related to the activity and function of both regulatory T cells (Tregs) 
and effector T cell (Teff). Initially, it was established that the number of HLA-DR-
presenting CD3+ CD4+ T cells was highest in the contact-dependent MLC, in which 
20.5%  2.4 CD3+ CD4+ HLA-DR+ T cells could be detected (Figure 3B), which 
was significantly different from the baseline measurements of 6.9%  2.0 (p = 
0.009). For the TW MLC and the responder control sample, these numbers were 
lower with 13.3%  3.3 and 18.0%  1.3 CD3+ CD4+ HLA-DR+ T cells identified, 
respectively. When comparing the phenotype of the HLA-DR presenting responder 
cells from the classic MLC and the TW MLC, four of the included markers exhibit-
ed the largest difference in expression an were all enriched in the classic MLC (Fig-
ure 3C). These markers were CD25, cytotoxic T-lymphocyte associated protein 4 
(CTLA-4, CD152), tumor necrosis factor receptor II (TNFRII, CD120b), and pro-
grammed cell death 1 (PD-1, CD279)(Figure 3B). The most differentially expressed 
marker was CD25, which exhibited almost a 2-fold increase in expression in the 
 103 
classic MLC, as compared to the TW MLC. In addition, the detected CD25 expres-
sion in the classic MLC was more than 3 times greater than the corresponding ex-
pression in the responder control (9.0%  0.4; p = 0.027) and 1.6 times greater than 
the baseline expression (18.6%  4.1). For the TW MLC, these numbers were 1.7 
and 0.8, respectively. For CTLA-4, the expression was approximately 50% in-
creased in the classic MLC, when compared to the observed expression in the TW 
MLC (40.5%  3.3 and 26.6%  4.6; p = 0.017). The expression of CTLA-4 in both 
MLCs was also significantly different from the responder control (6.8%  0.3), 
yielding a 4-6 times higher expression in the MLCs. Moreover, when compared to 
the baseline measurements (2.6%  0.4), the expression was 10- and 15-fold higher 
in the TW MLC and classic MLC, respectively. With regard to TNFRII, the expres-
sion was approximately 40% greater in the classic MLC as compared to the TW 
MLC (51.9%  0.9 and 38.0%  5.4)(Figure 3B). However, the CD3+ CD4+ HLA-
DR+ responder T cells had increased the expression of TNFRII almost 1.6 and 2 
times in the TW MLC and classic MLC, respectively, as compared to the baseline 
measurements (24.6%  3.5). Finally, the expression of PD-1 was on average 25% 
greater in the classic MLC than in the in the TW MLC (65.2%  8.1 and 52.1%  
10.4). In relation to the baseline measurements (42.8%  4.0), PD-1 expression was 
1.2 and 1.5 times greater in the TW MLC and classic MLC, respectively.  
Differential expression separates the HLA-DR- and HLA-DR+ responder T 
cells 
In order to further characterize the MLC responder cells, the phenotypical differ-
ences between the CD3+ CD4+ HLA-DR- and CD3+ CD4+ HLA-DR+ T cells were 
evaluated. As shown in the correlation plots in Figure 4A, four of the investigated 
markers were enriched in the HLA-DR+ subsets of both MLCs, as compared to the 
corresponding HLA-DR- subsets. These markers were CD25, CTLA-4, TNFRII, 
and PD-1. Moreover, it was consistently observed for both types of MLC that the 
expression of CD11a was upregulated on the CD3+ CD4+ HLA-DR+ responder T 
cells, as compared to the corresponding HLA-DR- subsets (n=3)(Figure 4B).  
Contact-dependent differences observed for the phenotype of extracellular 
vesicles following allogeneic MLC 
In addition to the cellular phenotype of the responder cells from the MLCs, the phe-
notype of the extracellular vesicles (EVs) found in the cell supernatants on day 6 of 
the MLCs was also characterized. For the characterization, we applied the EV Array 
to detect the EVs, which display CD9, CD63, and/or CD81, known to be present on 
exosomes [30]. A summary of the additional protein markers detected on these EVs 
is depicted in the heat maps in Figure 5A (two of three included biological repli-
cates; third replicate can be found in [31]). Of the three exosomal markers, only 
CD9 and CD81 could be detected in all samples. In addition, CD82 was also present 
in all EV samples. The relative distribution of these markers can be seen in the left 
bar plot in Figure 5B. The presence of the remaining markers included in the EV 
phenotyping was quite heterogeneous. However, tendencies were present for a num-
ber of these markers. As such, CD3 was predominantly detected in the EVs from the 
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classic MLC, while it was virtually absent in the TW MLC samples (Figure 5B, 
right bar plot). This trend was also applicable for the detection of CTLA-4. Never-
theless, the detectable signals for this marker were low. In the TW samples, EVs 
were more enriched in TNFRI, when compared to the classic MLC and the controls 
(Figure 5B). Apart from the heterogeneous presence of many of the included mark-
ers, several of these markers could not be detected or yielded barely detectable sig-
nals for EVs from the MLCs. These included lineage specific markers CD4 (T 
cells), CD19 (B cells), and CD83 (DCs)(data not shown). Moreover, the hematopoi-
etic marker CD45 and the class I equivalent of HLA-DR, HLA-ABC, were also 
included in this list (data not shown). Finally, it was observed that both non-
irradiated and irradiated PBMCs, such as the stimulator cells, had produced equal 
amounts of CD9, CD63, and CD81 on the EVs found in the cell supernatant after 6 
days of cell culture (Figure 5C). 
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Discussion 
For many years it has been believed that T cells from most species possess the abil-
ity to express HLA-DR/MHCII endogenously. However, this dogma has been chal-
lenged by several studies demonstrating that a protein acquisition either completely 
account for or contribute to the presence of HLA-DR on T cells. We initially ad-
dressed this discrepancy by inducing in vitro HLA-DR expression in CD3+ CD4+ T 
cells from peripheral blood, either as monoculture or part of a PBMC population. 
This was interesting since it has been demonstrated that HLA-DR found on the sur-
face of CD3+ CD4+ in peripheral blood cannot be explained by a simultaneous 
mRNA production [32]. In the current study, the presence of HLA-DR only in-
creased in the CD3+ CD4+ T cells in the PBMC population after mitogenic (PHA-
P) or antigen-like (anti-CD3/anti-CD28) stimulation (Figure 1). Although these 
results cannot indisputably exclude endogenous HLA-DR expression in CD3+ 
CD4+ T cells, they indicate an important role of APCs, and possibly also accessory 
cells, in this context.  
This role was addressed in more detail, focusing on the interaction between T cells 
and APCs. By employing an allogeneic MLC, the in vivo antigen-recognition by T 
cells was approximated to a great extent [33]. Furthermore, we investigated whether 
a physical interaction was required for the presence of HLA-DR on the responder 
CD3+ CD4+ T cells following the MLC. This was carried out to elucidate aspects of 
a possible transfer of HLA-DR from APCs to T cells by vesicles, as reported earlier 
[13, 19, 20]. Since the relative placement of the cells in the TW system can affect 
the vesicle phenotype [31], the cells exerting the major stimulatory function (the 
stimulator cells) were placed in the upper compartment of the TW system, while 
primary vesicle recipient (responder cells) was placed in the lower compartment. For 
both MLCs, three experimental outcomes were measured to evaluate the contact-
dependent effects on the responder CD3+ CD4+ HLA-DR+ T cells: The prolifera-
tive capacity, the functional phenotype of these cells, and the phenotype of the ex-
tracellular vesicles (EVs) shed into the cell culture medium.  
In relation to the first experimental outcome, a notable proliferative response was 
detected for the responder cells in the contact-dependent (classic) MLC (Figure 2). 
On the contrary, no proliferation could be observed for the responder cells from the 
contact-independent (transwell, TW) MLC. Hence, the proliferation observed in 
allogeneic MLCs required physical contact between T cell and APC.  
For the second experimental outcome, the CD3+ CD4+ HLA-DR+ T cells were 
characterized by investigating the presence of seven cell surface markers. These 
markers included general T cell activation markers, as well as markers associated 
with Tregs and T cell suppression. The latter category of cell surface markers was 
included since HLA-DR on T cells mainly has been associated with suppressive 
activity [23-25], as it has been observed for HLA-DR+ Tregs [11]. In addition, anti-
MHCII antibodies have been demonstrated to block the suppressive activity of acti-
vated human Tregs [34], suggesting an important role for HLA-DR on Tregs. Of the 
seven included markers, the differential expression was mostly pronounced for four 
INVESTIGATING ASPECTS OF HLA-DR ANTIGENS ON T CELLS 
106
 
of these, when comparing the classic MLC to the TW MLC after the six days of 
incubation. These included CD25, CTLA-4, PD-1, and TNFRII (Figure 3B and 3C) 
and all markers were mostly enriched in CD3+ CD4+ HLA-DR+ responder T cells 
from the classic MLC. Moreover, the expression these markers were enhanced in the 
CD3+ CD4+ HLA-DR+ T cells, when compared to the corresponding HLA-DR- 
subsets (Figure 4A). However, as can be appreciated from Figure 3B, the number 
the CD3+ CD4+ HLA-DR+ T cells were quite similar for the MLCs and the re-
sponder control, although a significant increase was observed from the baseline 
measurements. However, the phenotype of these cells from the MLCs was not 
artifactually induced by the culturing conditions, as the MLCs created notably dif-
ferent CD25 and CTLA-4 expression than the control. Most of the investigated 
markers can be found on both conventional Teffs and Tregs. Due to their dissimilar 
functionalities, it was important to look for expressional patterns differentiating 
these two cellular groups. CD25 is used as a T cell activation marker and also to 
identify naturally occurring CD4+ Treg [35] and those induced from CD4+ CD25- 
precursors [36]. The function of CTLA-4 depends on its expression by either Teff or 
Tregs [37, 38].  For Teff, CTLA-4 is up-regulated following activation, where it 
provides co-inhibitory signaling by competing for the shared ligands of the co-
stimulatory receptor CD28 [39]. In Tregs, expression of CTLA-4 has been linked to 
their suppressive activity [39, 40]. For a part of the CD3+ CD4+ HLA-DR+ cells, 
CD25 and CTLA-4 displayed a positive correlation (Figure 3A, top panel). Howev-
er, the non-uniform correlation demonstrates how the HLA-DR-presenting CD3+ 
CD4+ T cells are a heterogeneous cell population. Nevertheless, further investiga-
tions are required to link this correlation to either Teff or Tregs function. Like 
CTLA-4, PD-1 is part of the CD28 family of proteins [41] with an essential role in T 
cell inhibition and consequently also in peripheral tolerance [42]. While T cells 
exclusively express CTLA-4 [41], both activated T and B cells can express PD-1 
[42]. Moreover, T cells can express one of the two ligands for PD-1 (PD-Ls), which 
is also expressed by other lymphoid and non-lymphoid cells [41, 43]. A PD-1/PD-
L1 ligation in T cells can result in either activation of anergy, though it is mostly 
asscociated with the latter [37, 41, 43, 44]. Interestingly, the ligation between PD-1 
and PD-L has also been suggested to play a role in the interaction between T cells 
[45], though with currently unverified effects. Blocking CTLA-4 and PD-1 reduces 
Treg activity in melanoma patients [46] and, as previously mentioned, blocking of 
HLA-DR on activated Tregs has similar effects [34]. This could a suggest a link 
between HLA-DR, CTLA-4, PD-1, Tregs, and their suppresive capacity. However, 
such a relationship remains to be established. Finally, TNFRII was also enriched in 
the CD3+ CD4+ HLA-DR+ responder T cells in both MLCs, when compared to the 
HLA-DR- counterparts (Figure 4A, bottom panel). Moreover, it positively correlated 
with the expression of PD-1. Although TNFRII is involved in lymphocyte activation 
and proliferation [25], several studies have shown that TNFRII is primarily confined 
to Tregs in both human and mouse [47-49]. A suppressive activity of CD4+ CD25+ 
TNFRII+ HLA-DR+ T cells has been established with an observed co-expression of 
CTLA-4 [25]. Hence, a concurrent presence of HLA-DR, CD25, CTLA-4, PD-1, 
and TNFRII on CD4+ T cells could very likely identify a subset of cells with sup-
pressive activity. A delineation of the suppressive activity of the CD3+ CD4+ HLA-
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DR+ responder T cells observed in the present study would consequently be rele-
vant. With regards to the contact-dependent differences observed here, it is notable 
that the phenotype of the CD3+ CD4+ HLA-DR+ responder T cells in the TW MLC 
was almost identical to the corresponding phenotype in the classic MLC, although 
with a delayed onset or a less prominent expression. This was observed for all of the 
three included biological replicates, possibly pointing to a consistent trend. Howev-
er, the lack of proliferation in the TW MLC indicates functional differences. It 
would consequently be interesting to explore if the TW MLC response encompasses 
one component of the full T cell response observed in the contact-dependent, classic 
MLC or if it could represent an particular mechanism for immune regulation.  
For the third experimental outcome, we characterized the EVs in the cell superna-
tants from the MLCs. This was achieved by extensively phenotyping the EVs for 
both vesicle-specific and cell-specific protein surface markers using the EV Array 
[29, 30]. With this analysis, we detected EVs containing CD9, CD81, and CD82, 
from all MLCs and controls. Of these three tetraspanins, CD9 and CD81 are gener-
ally accepted as markers that identify a particular subset of EVs, called exosomes 
[50, 51]. Moreover, CD82 has also been associated with this type of EV [52]. 
Exosomes are known to be key players in cellular communication, both in maintain-
ing homeostasis and for the progression of pathological condition, including cancer 
[30]. Also, immunomodulatory effects of exosomes have been documented, involv-
ing transfer of proteins and other molecules, such as RNA, between cells, effectively 
changing the phenotype and function of the recipient cell [19, 53-55]. The detection 
of CD9, CD81, and CD82 in the current study indicated that production of such EVs 
were present in all of the cellular samples. This is relevant, since vesicle-based cellu-
lar communication has yet to be characterized in the context of allogeneic MLCs. 
However, the detected EV phenotypes were very heterogeneous across the biologi-
cal replicates (Figure 5B, right bar plot). It has been demonstrated that EV pheno-
type obtained in the applied TW setup is reproducible [31], thus pointing to other 
factors giving rise to this heterogeneity. Pronounced inter-individual variations in 
the EV phenotype have been observed for the vesicles found in plasma of healthy 
individuals [29]. The quite different EV phenotypes detected in the present study 
could be a consequence of such variations. This may signify that the EV phenotype 
can be individually adapted, which is unlike the cellular phenotype described above, 
for which there were consistent trends for all individuals. However, the heterogenei-
ty of the EV phenotypes complicates identification of their functionality. Neverthe-
less, there were a few contact-dependent differences, which could be detected for the 
EV phenotypes. Two T cell-associated proteins, CD3 and CTLA-4, were predomi-
nantly observed in the classic MLC, while TNFRI was mostly found on EVs from 
the TW system. Also, HLA-DR-bearing EVs were mostly observed in the TW com-
partment holding the stimulator cells. In terms of functionality, the down-regulation 
of CD3 following T cell activation [56, 57] has been associated with the production 
of CD3-enriched EVs, as a tool of this down-regulation [58]. Hence, EVs may be 
used for other purposes than intercellular communication. Though the contact-
dependent differences in the EV phenotypes were subtle, they could reflect distinct 
functions of these vesicles in each of the MLC systems. Nonetheless, this remains to 
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be delineated. In the context of HLA-DR, it has been noted that vesicles possibly 
mediate the demonstrated transfer of HLA-DR from APCs to T cells [15-17, 19, 20]. 
The levels of EV-associated HLA-DR detected for both MLCs were low, either 
signifying a modest production of HLA-DR bearing EVs or a high uptake rate, ren-
dering them inaccessible to analysis. With the data presented here, it is, however, 
not possible to support that vesicle-mediated cellular communication is important 
for the presence of HLA-DR on CD3+ CD4+ T cells without additional studies.  
In the current study we elucidated some of the aspects of HLA-DR on human CD3+ 
CD4+ T cells. We found that APCs play an important role in this context and con-
firmed that physical contact between these two cells influence the presence of HLA-
DR on T cells [17, 20]. Although the allospecific activation gave rise to a heteroge-
neous population of CD3+ CD4+ HLA-DR+ responder T cells, the phenotype of 
these cells indicated a regulatory role. We also showed that, in spite of a high degree 
of heterogeneity, distinct vesicle subsets are formed during alloresponses, which 
could mediate important cell-to-cell communication. The results of the present study 
show valid tendencies for the evaluated outcome measures and indicate possible 
interesting markers for further investigation. This may be used to gain further under-
standing of the mechanisms of immunologic tolerance with great importance to 
basic immunology as well as autoimmune diseases, transplantation, and cancer.
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Figure 1 Presence of HLA-DR on in vitro PHA or anti-CD3/anti-CD28 stimu-
lated CD4+ T cells. Isolated CD4+ T cells or PBMCs were stimulated with PHA-P 
or anti-CD3/anti-CD28 for 20h. Subsequently, the presence of HLA-DR was evalu-
ated by flow cytometry for the CD3+ CD4+ T cells in all samples. Initially, the 
lymphocytes were gated in a FSC/SSC plot, after which the CD3+ CD4+ cells were 
identified. Finally, the CD3+ CD4+ HLA-DR+ T cell population was determined. 
Data is presented as mean  SEM. **, p  0.01; n=2-6. 
Figure 2 Cellular proliferation after contact-dependent and -independent 
MLCs. After a 6-day MLC, either contact-dependent (classic) or contact-
independent (transwell; TW), the proliferation of the responder cells was deter-
mined. The proliferative response was evaluated by the incorporation of Thymidine-
3
H from day 5 to 6 of the MLCs and for the responder control sample. Data is pre-
sented as mean  SEM. n=3. Cpm: Counts per minute.  
Figure 3 Cellular phenotypes of HLA-DR+ responder CD3+ CD4+ T cells after 
contact-dependent and -independent MLC. A flow cytometric analysis was used 
to determine the presence of HLA-DR and other selected cell surface markers on the 
responder cells of the contact-dependent MLC (classic) and contact-independent 
MLC (transwell, TW). A) Gating of the responder T cells. Initially, a lymphocyte 
gate was created in a forward scatter (FSC)/side scatter (SSC) plot. Next, the re-
sponder cells were identified from their eFluor 420 labeling after which the CD3+ 
CD4+ T cells could be selected. Finally, the HLA-DR+ events were identified with a 
pre-defined gate from a FMO control, in which a maximum of 1% of positive events 
were allowed in the double-positive quadrant. The plots are representative examples 
from one of the three included biological replicates. B) To compare their cellular 
phenotype, a flow cytometric evaluation of seven markers was performed at baseline 
and at day 6 for the responder HLA-DR T cells from the classic and TW MLC. 
Selected markers were also investigated for the responder control at day 6. Data is 
presented as mean  SEM. n = 3. C) A ratio of the expression of each of the seven 
markers was made between the classic MLC and the TW MLC, in order to visualize 
which markers were up- or down-regulated in each condition. CTLA-4: Cytotoxic 
T-lymphocyte associated protein 4 (CD152); PD-1 Programmed cell death 1 
(CD279); TNFRII: Tumor necrosis factor receptor II (CD120b). **, p  0.01 
Figure 4 Differential expression of several surface markers on HLA-DR+ and 
HLA-DR- responder T cells. The differential expression of the seven cell surface 
markers shown in Figure 3B was also investigated for the corresponding HLA-DR- 
responder T cell subset. These cells were identified from the top left quadrant of the 
last plot in Figure 3A. A) The correlation plots with adjunct histograms show the 
correlation between CTLA-4 and CD25 (top panel) and PD-1 and TNFRII (bottom 
panel) for CD3+ CD4+ HLA-DR+ responder T cells and the HLA-DR- equivalent. 
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All markers were enriched in the HLA-DR-presented subset in both types of MLCs. 
The plots are representative examples for the three biological replicates included. C) 
The histograms demonstrate how the expression of CD11a was increased in the 
CD3+ CD4+ HLA-DR+ responder T cells, when compared to the CD3+ CD4+ 
HLA-DR- subset. The histograms are representative for the three biological repli-
cates included.  
Figure 5 The phenotype of extracellular vesicles (EVs) from the MLCs display 
contact-dependent differences. The EV Array was applied to extensively pheno-
type the EVs from the cell supernatant from the MLCs. Antibodies targeting the 
listed markers were used for capturing of the EVs. The signal observed for each of 
the markers infers a simultaneous presence of CD9, CD63, and/or CD81, since a 
cocktail of antibodies against these three exosomal markers was used for detection. 
A) Summary of selected, investigated EV markers for two of the three included 
replicates. The heat map for the third replicate can be found in [31]. B) The relative 
distribution of selected EV markers for all MLCs and controls are visualized for the 
highly expressed markers (left plot) and for those with a lower expression (right 
plot). Data is presented as mean  SEM. C) A semi-quantitative EV Array analysis 
was performed for the EVs produced by non-irradiated and irradiated PBMCs after 6 
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Abstract 
In order to study the biological function and activity of extracellular vesicles (EVs), 
appropriate in vitro cell culturing platforms are necessary. The aim of this study 
was to describe an experimental system, where dynamic, vesicle-based communica-
tion between cells can be investigated. A commercially available cell-culturing 
system was applied to study contact-independent communication between cells, 
separating two cell populations by a membrane with a pore size of 0.4 m. Some of 
the factors determining the vesicle transport in this cell culturing system were in-
vestigated in a cell-free setup and analyzed using the Extracellular Vesicle (EV) 
Array and nanoparticle tracking analysis. Furthermore, the application of the cell-
culturing setup was demonstrated using human, primary cells. Here, the effects that 
contact-dependent and –independent cell communication had on the phenotype of 
EVs found in the cell supernatant were shown. Collectively, the investigations re-
vealed that the relative placement of the two cell populations in the presented cell 
culturing setup is important to the biological hypothesis, which is being investigat-
ed. These observations are relevant for short-time (<24h) as well as long-time stud-
ies (several days) of vesicle-based cell communication. Moreover, the introduced 
cell culturing setup and analytical strategy can be used to study contact-independent 








It is currently well accepted that extracellular vesicles (EVs) are released from a 
plethora of cell types in many biological systems (1). Furthermore, these vesicular 
entities can be used as a tool of intercellular communication. In line with this, EVs 
play an important role in many cellular processes in humans, both in physiological 
and pathophysiological scenarios (1-3). However, uncovering the specific biologi-
cal functions of EVs is still in its infancy. Many in vitro experiments carried out to 
answer these biological questions use two different approaches: i) EVs from one 
cell population/ condition are isolated and added to another cell population (4-7). 
Subsequently, the effect of the EVs on the second population is investigated. ii) The 
two cell populations are co-cultured but separated by a membrane with a pore size, 
which allows for the transport of vesicles of a certain size, as well as soluble factors 
(4, 8, 9). The effect of the co-culturing can thereafter be studied on either one or 
both cell populations. The latter setup represents the most dynamic of the two ap-
proaches to study vesicle-based communication, since it is based on co-culture. 
Consequently, it incorporates the continuous communication between the studied 
cells, with a consequent greater resemblance to the in vivo conditions.  
Experimental setup and aim 
The cell culturing setup described in the current study is based on the co-culture 
approach introduced above. The principle of this setup is depicted in Figure 1. Sev-
eral factors need to be taken into account, when designing such a study. A key fac-
tor, which this study investigates, is the importance of which cell population is 
placed in the upper and lower compartment, relative to the biological hypothesis 
being tested. This is relevant, since we are able to demonstrate that this placement 
affects the experimental outcome, both for short-time (<24h) and long-time studies 
(several days) of vesicle-based communication. Additionally, the subsequent analy-
sis of the EVs must be both reliable, reproducible, and provide as much information 
as possible. The aim of this report is to present a combined cell culturing and ana-
lytical setup, which allows for an easy and reproducible detection of differences in 
EV phenotypes caused by contact-dependent and –independent cellular communi-
cation.  
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Materials and Methods 
Co-culturing setup 
Specifications: The applied cell culturing system consists of a 24-well plate (Nunc, 
Thermo Scientific, Waltham, MA, USA) with Millicell Hanging Cell Culture 
Inserts (#PIHT 12R 48, Merck Millipore, Darmstadt, Germany) (Figure 1). The 
insert material is polystyrene, while the membrane in the bottom of the cell culture 
insert is made of polyethylene terephthalate (PET). It is tissue culture treated and 
gamma irradiated, thus providing a sterile device for cell culturing of both attach-
ment-dependent cells and cells in suspension. The insert is 16 mm in height with an 
outer diameter of 9 mm and an inner diameter of 6.5 mm. The membrane is 12 m 
thick and has an effective membrane area of 33 mm
2
. Moreover, the pore size of the 
membrane is 0.4 m and it has a pore density of 1 x 108 pores/cm2. The recom-
mended usage of the chosen insert includes study of cell proliferation and co-
cultures as well as in transport and permeability assays.  
Cell culturing: 800 l of cells/ culture medium was added to the lower compart-
ment of the cell culturing system. The insert was placed into the well (Figure 1) and 
the insert membrane was allowed to soak for a couple of minutes. 400 l of cells/ 
culture medium was added to the upper compartment and the culture plate with 
inserts was placed in a CO2 incubator. 
Transmembrane exchange of EVs 
Cell culture conditions and EV collection: Cell-free and EV-rich supernatant was 
obtained from the human colon cancer cell line LS180 (ATCC CL-187; ATCC, 
Manassas, VA, USA) cultured in growth medium containing RPMI 1640 (Gibco, 
Life Technologies, Carlsbad, CA, USA), 10% ultracentrifuged (100.000 xg, 24h, 
4C; Ti45 rotor, Beckman Coulter, Brea, USA), heat-inactivated fetal bovine serum 
(FBS) (Gibco), 100 U/mL penicillin, 10µg/mL streptomycin (Ampliqon, Odense, 
DK)). Upon collection of the EV-rich cell supernatant, the cell supernatant was 
centrifuged at 500 xg, 5 min, RT, to remove cells. To the cell-free supernatant, a 
protease inhibitor cocktail was added (EDTA-free, Roche, Basel, Switzerland, di-
luted 1:50 in PBS). Subsequently, the EV-rich cell supernatant was reduced in vol-
ume by using a 15 ml Amicon Ultra filter unit with a 100k MWCO (Merck Milli-
pore). The volume-reduced supernatant was washed twice with PBS prior to use. 
The final volume of the cell supernatant was approximately 1/20 of the original 
volume. 
Dilution series to investigate transmembrane exchange of EVs: The following dilu-
tions of the EV-rich cell supernatant from LS180 were included: 1:1 (undiluted), 
1:10, 1:50, 1:100, 1:500, and 1:1000. All dilutions were made with growth medium. 
To describe the exchange of EVs from the lower to the upper compartment, 800 l 
of cell supernatant was placed in the lower compartment of the cell culturing setup 
(Figure 1), as described previously. Subsequently, 400 l of growth medium was 
put in the upper compartment. To describe the transmembrane exchange from the 
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upper to the lower compartment, the opposite setup was made. Here, the growth 
medium was placed in the lower compartment, while the EV-rich supernatant was 
put in the upper compartment. Each dilution for each combination of the compart-
ments was made in duplicates. The culture plate holding the inserts was placed in a 
CO2-incubator (temperature: 37 C; CO2-concentration: 5%; relative humidity: 
90%) for 24h. After this, the content of each compartment was harvested into sepa-
rate tubes and stored at - 40 °C until semi-quantification of the vesicles by the EV 
Array (see section below).  
Contact-dependent and –independent mixed lymphocyte culture (MLC) 
Isolation of cells: Buffy coats were obtained from healthy blood donors at Aalborg 
University Hospital blood bank. Each blood donor had signed a written consent 
form, allowing for the use of his or her blood for research purposes. The procedure 
was approved by local ethics legislation. Isolation of peripheral blood mononuclear 
cells (PBMCs) was accomplished by using gradient centrifugation with 
Lymphoprep(Axis-Shield, Oslo, NO). The PBMCs were either used directly after 
the isolation or stored at -140 C in a storage medium (RPMI 1640, 40% heat-
inactivated FBS, 10% dimethyl sulfoxide (Merck Millipore), 100 U/mL penicil-
lin/10µg/mL streptomycin).  
Cell culture setup and EV collection: A 6-day allogeneic MLC was performed with 
PBMCs from two donors. The PBMCs from one donor were designated the stimu-
lator cells, which would induce a proliferative response in the PBMCs from the 
second donor, entitled the responder cells. Prior to the MLC, the stimulator cells 
were irradiated (1700 rad). For the contact-dependent MLC (classical), 5x10
4
 of 
each responder and stimulator cells were mixed in a 96-well plate (Nunc) in a total 
volume of 150 µL culture medium. For the contact-independent setup, stimulator 
cells and responder cells were separated by Millicell Hanging Cell Culture Insert. 
The upper chamber contained 2.5x10
5
 cells, while the lower chamber contained 
5x10
5
 cells. Control samples with monocultures of both stimulator and responder 
cells were also included. Here, 5x10
4
 of either responder or stimulator cells were 
seeded in a 96-well plate, as described above. The cells were placed in a CO2-
incubator (temperature: 37 C; CO2-concentration: 5%; relative humidity: 90%) for 
6 days. On day 6 of the MLCs, the cell culture supernatants were removed and 
centrifuged once at 500xg 10 min at RT to pellet cells. Protease inhibitor cocktail 
(EDTA-free, diluted 1:50 in PBS) was added to the cell-free supernatants prior to 
storage at -40 °C until vesicle phenotyping by the EV Array.  
EV Array analysis 
Production of microarrays: Microarray printing was performed on a SpotBot
®
 
Extreme Protein Edition Microarray Printer (Sunnyvale, ArrayIt, CA, US), as pre-
viously described (10).  
Antibodies/proteins for phenotyping of vesicles: For the phenotyping, a total of 10 
anti-human antibodies and one protein were used. They are listed in the following 
INVESTIGATING ASPECTS OF HLA-DR ANTIGENS ON T CELLS 
 
with the corresponding product number (#) or clone. From R&D Systems (Minne-
apolis, MN, USA): CD82 (#423524) and TNFRI (#DY225). From Biolegend: 
CD63 (MEM-259) and HLA-DR (L243). From LifeSpan BioSciences, Inc. (Seattle, 
WA, USA): CD9 (#LS-C35418) and CD81 (#LS-B7347). From Abcam (Cam-
bridge, MA, USA): Flotilin-1 (#Ab41927). From Haematologic Technologies, Inc. 
(Essex Juncton,VT, USA): Lactadherin (#BLAC-1200) (protein). From BD Biosci-
ences: CD3 (Hit3a). From Abbiotec (San Diego, CA, USA): CD11a (HI111). From 
eBioscience: ICAM-1 (R6.5). All antibodies/proteins for the phenotyping were 
printed in triplicates at 200 µg/mL diluted in PBS containing 5% glycerol. 
Antibodies for semi-quantification of vesicles: For the semi-quantification, only 
anti-CD9, anti-CD63, and anti-CD81 were printed on the micro-array slides, as 
previously described (11). In short, 18 repeated spots were printed with a cocktail 
of the three antibodies.  
Catching and visualization: The entire procedure was performed as described pre-
viously (11). In short, the printed slides were blocked, incubated with the EV-
containing sample, followed by detection of bound EVs with biotinylated anti-CD9, 
-CD63, and -CD81 and subsequently Cy5-labelled streptavidin.  
Data analysis: Creation of graphs and statistical calculations were carried out using 
GraphPad Prism (version 6.04, GraphPad Software, Inc., San Diego, CA, USA), 
SigmaPlot (version 11, Systat Software Inc, San Jose, CA, USA), and Excel (ver-
sion 2013, Microsoft, Redmond, WA, USA). Heat maps were produced using Gen-
esis (version 1.7.6, IGB TU Graz, Graz, Austria). For a given antibody spot, the 
signal intensity was calculated as the mean signal of triplicate spots (18 spots for 
semi-quantification) in relation to the sample signal of the negative spot (PBS) in 
triplicate. For each spot, the signal intensity was calculated by subtracting the mean 
of the background (no sample/blank, washing buffer) from the mean of the fore-
ground (spot signal). Before visualization and calculation of linearity, the antibody 
signal intensities were converted to log space by log2 transformation. The EV “re-
tention” percentage, used with the semi-quantitative data, was calculated as: (Signal 
in EV starting compartment/ total signal in upper and lower compartment) x 100. 
Nanoparticle Tracking Analysis (NTA) 
Instrument details: For EV size determination, NTA was performed with a 
NanoSight LM10-HS system equipped with a finely tuned 405 nm laser (NanoSight 
Ltd., Amesbury, UK), supplied with the Nanoparticle Tracking Analysis (NTA) 3.0 
0060 analytical software version, which was used for capturing and analysing the 
data. The camera type was EMCCD and the camera level was set to 11. 
Size determination: The NanoSight was calibrated with polystyrene latex 
microbeads 100 nm (Thermo Scientific, Fremont, USA) prior to analysis. Dulbec-




, filtered with a 0.22 
m filter prior to use (Lonza, Verviers, Belgium) was used to dilute the microbeads 
(1:1000 dilution) and the EV-containing cell supernatants (1:40 dilution). The sam-
ples were manually injected into the sample chamber and a temperature-measuring 
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device inserted directly into the sample chamber was applied to record the tempera-
ture of sample for each run. Samples were measured with a slide shutter of 600 and 
with a slider gain of 300 for 60 s. The applied dilutions yielded between 20 – 100 
particles/frame and each sample was measured in triplicate. Subsequently, the inte-
grated software automatically processed the data, yielding values such as the mean, 
the median, the mode particle size, the value of the highest point of the peak, and 
the corresponding standard deviations. The detection threshold was set to 3 and the 
blur setting was 9 x 9. 
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Results 
Transmembrane EV exchange between the two compartments of the cell cul-
turing setup 
Initially, the exchange characteristics of EVs between the two compartments of the 
cell culturing setup (Figure 1) were investigated using a cell-free setup. This was 
done to evaluate whether the experimental outcome is affected by the relative posi-
tion of the cells in the compartments. For this purpose, volume-reduced, EV-rich 
cell supernatant from the human colon cancer cell line LS180 was placed in one of 
the compartments and growth medium in the opposite compartment. Consequently, 
the transport of EVs from the upper to the lower compartment, and in the reciprocal 
direction, was studied. After 24h, the extent of transmembrane EV exchange was 
evaluated in each compartment by using the EV Array to semi-quantify the content 
of CD9-, CD63-, and CD81-containing EVs. The results from this analysis can be 
seen in Figure 2. Here, the EV “retention” percentage illustrated in Figure 2A des-
ignates how much of the EV Array signal detected in the EV starting compartment 
constitutes of the total signal from both compartments. Consequently, an EV reten-
tion percentage of 50% indicates that the EV Array signal was similar in the two 
compartments, while 100% indicates that no signal could be detected in the com-
partment opposite to the EV starting compartment. From Figure 2A it can be de-
duced that the transmembrane EV exchange is far greater from the upper to the 
lower compartment in the investigated time frame, as compared to the reciprocal 
direction. This difference already becomes noticeable with the 1: 10 dilution. Fur-
thermore, with the second dilution (1:50), practically no signal could be detected in 
the upper compartment, from the combination where the EVs initially were placed 
in the lower compartment. For the opposite combination, this tendency was ob-
served later, at the 1:500 dilution. After 24h, the signal in the compartment, where 
the EV-rich supernatant had initially been placed, was similar for both combina-
tions of the culturing setup (Figure 2B). Hence, the observed differences in the EV 
“retention” percentage could only be caused by the varying extent of 
transmembrane EV exchange for the two combinations.  
As an additional investigation, the size distribution of the EVs present in each com-
partment after the 24h of transmembrane exchange was determined by NTA. The 
analyzed samples included those from the 1:50 dilution presented in Figure 2, since 
there was a large difference in the two EV “retention” percentages for this particular 
dilution. The results from the NTA can be found in Table 2. After 24h, it appears 
from both the mean and mode values that smaller vesicles passed from the upper to 
the lower compartment, as compared to the opposite direction. This correlated well 
with the observed signal from the EV Array (Table 1), which in this setup targeted 
EVs enriched with CD9, CD63, and CD81; generally accepted exosomal markers, 
hence identifying EVs expected to have a size between 30-100 nm (1, 12). Even 
though the NTA also detected vesicles in the growth medium, the mode value indi-
cates that there is a different vesicle profile of the growth medium alone, when 
compared to the specific supernatants from the cell culturing setup. Moreover, the 
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EV Array signal obtained for the growth medium demonstrates how these vesicles 
do not have an impact on the specific signals from the array analysis. 
Demonstration of the applicability of the cell culturing setup and analysis plat-
form 
The aim of this study was to present an experimental system in which dynamic, 
vesicle-based cellular communication can be studied. To demonstrate this, contact-
dependent and –independent co-cultures of primary human peripheral blood mono-
nuclear cells (PBMCs) were prepared. In this co-culture, termed a mixed lympho-
cyte culture (MLC), one cell population is designated the stimulator cells. These 
cells induce an immunological response in responder cells, constituted by the se-
cond cell population. The classical MLC is contact-dependent; hence, the two cell 
populations are mixed and have physical contact. For the contact-independent 
MLC, both combinations of the two cell populations were included. Accordingly, in 
one combination, the responder cells were placed in the lower compartment, while 
the stimulator cells were placed in the upper compartment. In the second combina-
tion, the two cell populations were reversed. After 6 days, the EV Array was used to 
investigate the contact-dependent changes in the EV phenotypes from the cell cul-
tures. The results of this are depicted in Figure 3, showing a summary of the pres-
ence/ absence of 11 protein markers on EVs from the cell supernatants. As can be 
seen, there were several general features as well as contact-dependent differences in 
the EV phenotypes. For the general EV markers, CD9, CD81, and CD82 were pre-
sent on EVs from all cellular setups. In particular, CD81 and CD82 were enriched 
in the contact-independent co-cultures. In contrast, flotilin-1 was found to the great-
est extent in the contact-dependent MLC. Finally, tumor necrosis factor receptor 1 
(TNFRI) was detected in the co-cultures and not in the monoculture controls. For 
the more cell-specific markers, there were pronounced differences, depending on 
the cellular contact but also interestingly on the relative placement of the two cell 
populations in the contact-independent co-cultures. As such, CD3 was highly en-
riched on EVs from the contact-dependent MLC, while CD11a was found in almost 
all cell cultures. HLA-DR was found mostly on EVs in the compartments holding 
the stimulator cells, however, to a higher degree when these cells were placed in the 
upper compartment. Moreover, the signal obtained for ICAM-1 for the responder 
cells placed in the upper compartment was three times that of the corresponding 
signal for the responder cells in the lower compartment.  
As a final notion, the reproducibility of the presented cell culturing setup and analy-
sis platform was evaluated. Accordingly, the contact-dependent and –independent 
MLCs were repeated several weeks apart, using cells from the same individuals. In 
Figure 4, the results of three selected markers are presented for the two technical 
replicates. It can be seen, that for CD9 and CD81, the detected EV signals predomi-
nantly correlated from replicate to replicate, with 12 of the 14 %CV values ranging 
from 1.7%-15.6% (Figure 4). The last two %CV values for CD9 and CD81 were 
30% and 36.9% and they are both calculated from the stimulator cells in the lower 
compartment. For CD63, five of the seven %CV values could not be determined as 
one or both EV Array signals from the two technical replicates were below the 
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lower limit of detection (LOD). The last two %CV values for CD63 were 6.9 and 
100.7. For the latter sample, the detected log2 signals were very close to the lower 




In the research field of EVs, much effort is put into deciphering the biological func-
tions of these vesicular entities. Consequently, useful experimental and analytical 
platforms are of great interest. In this technical report, we present a cell culturing 
setup for the study of dynamic, contact-independent cell communication, focusing 
on the EVs involved. As depicted in Figure 1, this setup includes two compart-
ments, where a membrane with 0.4 m pores separates the cells. Initially, we want-
ed to investigate whether the transmembrane exchange of EVs were similar from 
both compartments. With the results presented in Figure 2, it is shown that for short 
time studies (<24h), the exchange of EVs is greatest from the upper to the lower 
compartment, than in the opposite direction. This observation is relevant because 
there are many studies, which investigate selected features of contact-independent 
cellular communication that have applied short incubation times (4, 8, 9, 12, 13). 
Moreover, these studies do not account for their choice of the relative placement of 
the cells in the two compartments, which our study indicates is highly relevant. Our 
study also suggests that this is important since for short times studies it may be 
advantageous to place the primary EV donor cells in the upper compartments, while 
the primary recipient cells should be placed in the lower compartment. Here, we 
have also demonstrated that the exchange of EVs between the two compartments 
must be subject to both diffusion and sedimentation, however, without determining 
the relative contribution of each of these two factors. In line with this, it would be 
logical to assume that the transport of EVs across the membrane depends on the 
concentration of EVs, which again depends on the rate of production and degree of 
uptake by the recipient cells. Hence, there are several factors affecting the more 
dynamic system of a co-culture than indicated by the “theoretical” EV transport 
described in Figure 2 and Table 1. One may therefore expect that the effects of the 
relative placement of two cell populations in the cell culturing setup could become 
less pronounced with long-time studies, i.e. over several days. Nonetheless, it 
would still be highly relevant to include both combinations of the compartments in 
a contact-independent cell culturing system to identify any major variations in the 
experimental outcome.  
To demonstrate the applicability of the presented cell culturing setup and analytical 
strategy, contact-dependent and –independent co-cultures of human PBMCs were 
made. The aim was to investigate the resulting differences in the EV phenotypes 
from the two co-cultures using the EV Array. Furthermore, the effects that the rela-
tive placement of the two cell populations in the co-culture would have on the EV 
phenotype were also evaluated. For the 11 protein markers included in the EV 
phenotyping, there were clear contact-dependent differences after 6 days of co-
culture (Figure 3). However, perhaps even more interesting was the observation of 
EV phenotype differences associated to the relative placement of the two cell popu-
lations in either the upper or lower compartment. Based on the results from the cell-
free setup (Figure 2 and Table 1), it would be reasonable to place the cell popula-
tion, which was expected to exert the major stimulatory function in the upper com-
partment, while the target cells can be placed in the lower compartment. This is 
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indeed supported by the fact that the EV phenotype changed for both stimulator and 
responder cells according to their position in the cell culturing setup. It seemed that 
these differences were more pronounced for the cell-specific markers (Figure 3, 
rightmost heat maps) than for the more general EV markers (Figure 3, leftmost heat 
maps). Even though the biological relevance of these observations were not investi-
gated in more detail, it is not inconceivable that these observed differences could be 
important to the functional consequences of the EV-based communication between 
the involved cell populations. Consequently, this stresses the point that it may not 
be trivial how the cell populations are placed relative to each other, both for short-
time and long-time studies of contact-independent cell communication.  
The reproducibility of the cell-based experiments was evaluated by repeating the 
MLCs and the subsequent analysis after several weeks, using cells from the same 
individuals. As presented in Figure 4, obtained %CV values for CD9 and CD81 
ranged from 1.7-36.7. However, 12 of these 14 samples had a %CV below 16, 
whereas the two highest values are calculated for the same sample, the stimulator 
cells in the lower compartment, pointing to an isolated trend for this sample. It has 
been established that the EV Array yields %CV values below 10, when working 
with plasma samples (10) and for immunoassays, %CV values below 25 have been 
proposed as an acceptable limit (14). However, this limit can be expanded if an 
experimental rationale for this is present (14), which may be the case when both 
technical and biological variations exist, as for this study. Nonetheless, one of the 
%CV values for CD63 differed somewhat more, amounting to 100.7 (Figure 4, 
italics). The log2 intensities from the relevant samples, forming the basis of the 
%CV calculation, were 0.13 and 0.75. Hence, the standard deviation was very large 
compared to the mean of the two intensity values, with a consequent large impact 
on the calculated %CV. This is an inherent issue for small intensities close to the 
lower LOD, which is difficult to completely circumvent. A third technical replicate 
may serve to improve the %CV. However, several other results from our work point 
to the fact that CD63 is a poor marker for EVs in general since it occurs in relative-
ly low amount, as compared to CD9 and CD81 (unpublished data and (11)). 
As part of the combined experimental setup presented here, the determination of the 
EV phenotype plays a major role. Using the EV Array to phenotype the vesicles 
provides the opportunity to gain much information about the system that is being 
studied. In the context of vesicle-based cell communication, the EV phenotype may 
be used for several purposes. First, the use of an extensive EV phenotype may aid 
in fine-tuning the biological hypothesis, which is being investigated. In this study, 
we targeted 11 protein markers. However, 60 analytes (here: antibodies) can cur-
rently be used simultaneously for each sample, when phenotyping EVs with the EV 
Array (10). Consequently, the EV phenotype may not only provide a large amount 
of information but can also be used to optimize the experimental design in an itera-
tive fashion. Currently, the designed EV Array does not provide direct information 
about which cells produce the EVs and their absolute quantity. However, by linking 
the extensive EV phenotype to a number of additional experimental outcomes, such 
as the cellular phenotype or the EV RNA cargo, delineating the biological functions 
of the EV-based communication becomes substantial and highly relevant. 
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Summary 
This technical report describes the use of a cell culturing setup and an analytical 
platform to study dynamic, contact-independent cellular communication facilitated 
by vesicles. From the report, a number of aspects can be summed up. First, for 
short-time studies (<24h), there was a greater exchange of EVs from the upper to 
the lower compartment of the cell culturing setup than in the opposite direction. For 
co-cultures, both short-time and long-time (several days) studies, it is recommended 
to evaluate both combinations of cells in the two compartments, to ensure that any 
effects of this are known. Our data suggests that it may be advantageous to place 
the primary EV producers in the upper compartment, while the principal vesicle 
recipient cells should be placed in the lower compartment. Finally, the collected 
experimental setup presented here provides a relevant and reproducible setup for in 
vitro studies of the functional consequences of EV-based cellular communication.  
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Figure 1 Principle of the culturing system for contact-independent cellular 
communication. In order to separate the two cell populations being studied, the use 
of cell culture inserts was applied. The insert was placed within a well of a standard 
culture plate (e.g. 6-well, 12-well, and 24-well plates), thus dividing the system into 
two compartments; an upper compartment (UC) and a lower compartment (LC). 
Multiple flanges at the top of the insert suspend it onto the edge of the culture plate 
well, which ensures that there is no direct contact between the insert and the well. A 
membrane is incorporated in the bottom of the insert, facilitating the cellular sepa-
ration. The pore size of the membrane can vary according to the experimental de-
sign. In this report, the membrane pores are 0.4 m in diameter, thus allowing for 
the passage of smaller vesicle subsets, such as exosomes (diameter 30-100 nm)[1], 
as well as soluble factors (indicated by the arrows).  
Figure 2 Transmembrane exchange of EVs between the two compartments of 
the cell culturing setup. The exchange of EVs from the upper to the lower com-
partment of the cell culturing setup, and vice versa, was evaluated. A) An EV-rich 
cell supernatant from the human cell line LS180 was placed in one of the two com-
partments, while growth medium was placed in the opposite compartment. This was 
done with six dilutions of the supernatant, as indicated on the x-axis. After 24h, the 
content of each compartment was harvested and the amount of CD9, CD63, and 
CD81-enriched vesicles was semi-quantified using the EV Array. The EV “reten-
tion” percentage on the y-axis indicates how much of the total signal from the EV 
Array was accounted for by the signal from the compartment, where the EV-rich 
supernatant was put initially. B) After 24h, the EV Array signal (y-axis) from the 
two compartments in which the EV-rich supernatant was placed initially are shown. 
Each bar represents the mean of duplicates from the EV Array. The dashed line 
indicates signal saturation of the EV Array signal. 
Figure 3 Detection of contact-dependent differences in EV phenotype. A con-
tact-dependent and a contact-independent reaction between peripheral blood mono-
nuclear cells from two different individuals were made. After 6 days of co-culture, 
the phenotypes of the produced EVs were evaluated using the EV Array to detect 
any contact-dependent differences. For non-specific reactions, monocultures of both 
stimulator (stim ctrl) and responder cells (resp ctrl) were included. Additionally, 
both combinations of responder and stimulator cells in the contact-independent 
MLC were included. As such, one combination included responder cells in the 
lower compartment (resp, LC) and stimulator cells in the upper compartment (stim, 
UC), while the other combination was reversed. Antibodies targeting the listed 
markers were used for capturing of the EVs. The signal observed for each of the 
markers infers a simultaneous presence of CD9, CD63, and/or CD81, since a cock-
tail of antibodies against these three exosomal markers was used for detection. For 
each type of MLC and controls, the mean value of two independent experiments  
INVESTIGATING ASPECTS OF HLA-DR ANTIGENS ON T CELLS 
 
was used to create the heat map. The colored bars under the heat maps indicate the 
log2 intensity values obtained from the EV Array, where 8 is the maximum. 
 
Figure 4 Reproducibility of the cell culturing setup and analytical platform. To 
demonstrate the reproducibility of the presented methodology, two independent 
experiments were performed of the contact-dependent and –independent mixed 
lymphocyte cultures (MLC)(one biological replicate). Displayed here are the results 
from three selected EV markers; CD9, CD63, and CD81 (also shown in Figure 3) 
from the EV Array analysis of the resulting cell supernatants. The corresponding 
%CV values are noted below each sample and were calculated based on the two 
technical replicates. The %CV values were not calculated for the samples with log2 
signal intensities below the lower limit of detection (marked by - ). 
 
Tables 
Table 1 Size distribution of the vesicles after 24h of transmembrane EV ex-
change. EV-rich cell supernatant was placed in either the upper (UC) or lower 
compartment (LC) of the cell culturing setup, while growth medium was placed in 
the opposite compartment. After 24h, the size of the EVs present in each compart-
ment was determined by Nanoparticle Tracking Analysis (NTA). The data present-
ed are from the 1:50 dilution shown in Figure 2. For each compartment, the signal 
from the EV Array is given along with the results from the NTA. The mean and the 
mode, and the corresponding standard deviations (SD), is given for triplicate meas-
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